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P. falciparum malaria remains one of the leading public health problems worldwide. The global
tally of malaria in 2018 was estimated at 228 million cases and 405, 000 deaths worldwide.
African countries disproportionately carry the global burden of malaria accounting for 93%
and 94% of cases and deaths, respectively. Even though most infected children recover from
P. falciparum malaria, a small subset (~1%) of cases progresses to severe disease and death.
Over the last decade, several genome-wide association studies (GWASs) have been conducted
in diverse malaria endemic populations to understand the natural host protective immunity
against severe malaria that can provide clues for the development of new vaccines and
therapeutics. However, beyond identifying association variants, conventional GWAS
approaches can’t inform the underpinning biological functions. To bridge this gap, we applied
various contemporary statistical genetic analytic approaches to malaria GWAS datasets of
diverse malaria endemic populations.
 First, we accessed malaria resistance GWAS datasets of three African populations 
(N=~11,000) including Kenya, Gambia and Malawi from European Genome Phenome Archive 
(EGA) through MalariaGEN consortium standard data accession procedures. We explored the 
challenges of GWAS approaches in the genetically diverse Africa populations and figured out 
how various advanced statistical genetic methods can be implemented to address these 
challenges. We investigated single nucleotide polymorphism (SNP) heritability (h2g) of malaria 
resistance in the Gambian populations and determined appropriate quality (QC) thresholds to 
accurately estimate the h2g in our dataset. Second, we estimated h2g in the three populations 
and partitioned the h2g into chromosomes, allele frequencies and annotations using the genetic 
relationship-matrix restricted maximum likelihood approaches. We further created African 
specific reference panel from African population datasets obtained from 1000 Genomes Project 
and African Genome Variation Project dataset and computed linkage disequilibrium (LD). We 
used LD information obtained from these reference panels to compute cell-type specific and 
none cell-type specific enrichments for GWAS-summary statistics meta-analyzed across the 
three populations. Our results showed for the first time that malaria resistance is polygenic trait 
with h2g of ~20% and that the causal variants are overrepresented around protein coding regions 
of the genome. We further showed that the h2g is disproportionately concentrated on three 
chromosomes (chr 5, 11 and 20), suggesting cost-effectiveness of targeting these chromosomes 
in future malaria genomic sequencing studies. 
iii 
Third, we systematically predicted plausible candidate genes and pathways from functional 
analysis of severe malaria resistance GWAS summary statistics (N = 17,000) meta-analyzed 
across eleven populations in malaria endemic regions in Africa, Asia and Oceania. We applied 
positional mapping, expression quantitative trait locus (eQTL), chromatin interaction mapping 
and gene-based association analyses to identify candidate severe malaria resistance genes. We 
performed network and pathway analyses to investigate their shared biological functions. We 
further applied rare variant analysis to raw GWAS datasets of three malaria endemic 
populations including Kenya, Malawi and Gambia and performed various population genetic 
structures of the identified genes in the three endemic populations and 20 world-wide ethnics. 
Our functional mapping analysis identified 57 genes located in the known malaria genomic 
loci while our gene-based GWAS analysis identified additional 125 genes across the genome. 
The identified genes were significantly enriched in malaria pathogenic pathways including 
multiple overlapping pathways in erythrocyte-related functions, blood coagulations, ion 
channels, adhesion molecules, membrane signaling elements and neuronal systems. 
Furthermore, our population genetic analysis revealed that the minor allele frequencies (MAF) 
of the SNPs residing in the identified genes are generally higher in the three malaria endemic 
populations compared to global populations. Overall, our results suggest that severe malaria 
resistance trait is attributed to multiple genes that are enriched in pathways linked to severe 
malaria pathogenesis. This highlights the possibility of harnessing new malaria therapeutics 
that can simultaneously target multiple malaria protective host molecular pathways.  
In conclusions, this project showed that malaria resistance trait is mainly a polygenic trait 
which is influenced by genes and pathways linked to blood stage lifecycle of P. falciparum. 
These findings constitute the foundations for future experimental studies that can potentially 
lead to translational medicine including development of new vaccines and therapeutics. 
However, ‘-omics’ studies including those implemented in this study, are limited to single data-
type analysis and lack adequate power to explain the complexity of molecular processes and 
usually lead to identification of correlations than causations.  Thus, beyond singe locus 
analysis, the future direction of malaria resistance requires a paradigm shift from single-omics 
to multi-stage and multi-dimensional integrative multi-omics studies that combines multiple 
data types from the human host, the parasite, and the environment. The current 
biotechnological and statistical advances may eventually lead to the feasibility of systems 
biology studies and revolutionize malaria research. 
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1. CHAPTER ONE: GENERAL INTRODUCTION 
 
 
“God be praised. At His command  
Seeking His secret deeds  
With tears and toiling breath 
I find thy cunning seeds 
O million-murdering death”  
 (Ronal Ross, 1902), Nobel prize winner in Medicine for the discovery of malaria parasite 
 
1.1. A glance in history of malaria, “king of diseases” 
 
Malaria is caused by infection with protozoan parasites belonging to the genus Plasmodium 
transmitted by female Anopheles. It is one the most important diseases of mankind which 
shaped the course of human history for centuries. Malaria has been documented as an epidemic 
with symptoms of typical fever and enlarged spleen in early civilized societies including Greek, 
Roman, Indian, Arabs, Egyptian and Chinese [1]. In old Europe, different forms of malarial 
disease were given different names including “benign tertian” (P. vivax), “quartan” (P. 
malariae), “subtertian, malignant” periodic fevers (P. falciparum).  “tertian and “quartan” 
refers to the relapsing fever episodes in every three and every four days, respectively. Similarly, 
“benign” and “malignant” refers to  mild disease and severe life threating disease 
manifestations, respectively [2]. In the ancient Indian scriptures, malaria was named as “king 
of diseases” referring to its epidemic nature and deadliest outcome [2]. 
Malaria is believed to be emerged out of Africa, in the  Ethiopian region and spread to the 
warmer parts of the rest of the world  in the past five million years [2,3]. From the valley of 
Nile, it spread continuously with human mobility to Mediterranean region, to Asia and to the 
north Europe assisted by agricultural developments [3]. With its global spread, malaria 
constituted one of the greatest challenges of early civilizations and often responsible for decline 
of kings and nations [2,3]. Even though controversial, Alexander the Great is said to have died 
of malaria [2,3]. One of the greatest King of Rome, Gregory the Great (c 540-604), who 
suffered from malaria described the epidemic fever occurred in Rome in 599 AD: “For every 
day I am weak and in pain and sigh, waiting for the remedy of death, assuredly among the 




man remains, who is fit for any office or ministry. However, from neighbouring towns I receive 
reports every day of the carnage of death” [1].  
Malaria was mainly conceived among early populations as the revelation of the supernatural 
demons that disseminate fevers to bring down kings, military lords and popes [4]. Thus, there 
had been enormous attempts to defeat malaria through supernatural practices and religious rites 
by different populations of the old world. The first scientific approach and detailed description 
of malaria was made by Hippocrates, the greatest scientist of the 5th century, who described 
malaria a dangerous fume (miasma) that originates from swamps and transported by winds [4].  
After  periods of several centuries, the discovery of bacteria by Antoni van Leeuwenhoek in 
1676 and the emergence of germ theory disproved the belief that malaria is caused by miasma 
rising from swamps [1]. In 1880, Charles Lous Alphonse Laveran discovered the malaria 
parasites in red blood cells of infected patients. The discovery was  first rejected by many 
eminent microbiologists of the time including Louis Pasteur; but  later accepted after proved 
by other scientists [4]. Levern was awarded the Nobel Prize for Medicine in 1907 for his work 
on malaria [5]. In 1897, Ronald Ross, a military surgeon in India discovered the fact that 
mosquitoes are the vectors of malaria parasites [4]. In the same year, three Italian researchers, 
Giovanni Battista Grassi, Amico Bignami and Giuseppe Bastianelli described the 
developmental stages of malaria parasites in the mosquito vectors [4].  
More than 4 millennia were required until malaria was fully demystified; the humanity 
struggled to face one of the most debilitating diseases of mankind which prevented any 
economic progress in vast regions of the earth for centuries [2]. After Second World War, 
malaria eradication was accomplished in Europe through implementation of mass drug 
treatment and residual insecticide spraying [6]. In 1960s, all these areas had been formally 
declared malaria free by the World Health Organization [7]. In the era of the global malaria 
eradication, there are still far more fights to defeat this scourge of mankind; particularly, in 







 “But all the evidence we possess would seem to indicate not that poverty is responsible for 
malaria but that malaria maintains poverty" Paul Russell in1994 
1.2. The current situation: Progress and challenges of malaria elimination 
Malaria is still one of the global health problems with 228 million cases and  about 405, 000 
deaths in 2018 [8]. African countries disproportionately carry the global burden of malaria 
accounting for 93% and 94% of cases and deaths, respectively [8]. Malaria has been considered 
as one of the poverty diseases as it affects the vulnerable populations with underdeveloped 
healthcare system and poor infrastructures. However, it can be argued that the malaria itself 
drives poverty not the vice versa. “But all the evidence we possess would seem to indicate not 
that poverty is responsible for malaria but that malaria maintains poverty" Paul Russell in1946 
[6]. Malaria impacts the economic growth of the endemic countries by weakening production 
and productivities, incurring costs of treatments, impeding trade and investments [9]. Besides, 
it has several indirect long-term  consequences in the affected children [9]. About 20% of 
children who recover from severe malaria develop neurological sequalae and sub-optimal 
neuronal development leading to low performance in school and inadequate self-awareness  
[9]. By controlling for other factors, it was estimated that a ten percent decrease in malaria 
incidence in an endemic country would correspond to 0.3 percent increase in economic growth 
[10]. 
After the failure of the malaria eradication campaign in 1970s; in fact, which didn’t include 
any of the African countries where the malaria burden is the greatest, a new hope of global 
malaria elimination become a real possibility in recent years [11]. The global malaria 
eradication program, accelerated by the WHO led Roll Back Malaria (RBM) partnership, is 
largely focusing on scaling up the coverage of the available intervention strategies [11]. These 
include distribution of long-lasting insecticide treated nets (LLINS); indoor residual insecticide 
spraying, intermittent treatment for pregnant women in high transmission settings and rapid 
diagnosis and effective treatments using artemisinin-based combination therapies (ACTs) [11]. 
This led to the significant decline of malaria burden in many parts of the endemic regions [12]. 
For instance, in between 2010 and 2015, the incidence of malaria and mortality rate among 
population at risk was globally decreased by 21% and 29%, respectively [13]. In the same 
period, the under 5 deaths due to malaria  fell down by 29 % globally [13]. The RBM 




least 90% in malaria case incidence , mortality rates, and elimination in at least 35 countries 
by 2030 [14]. 
Despite such an impressive progress towards global malaria elimination, there are wide arrays 
of barriers that affect the effectiveness and sustainability of the intervention strategies [15,16]. 
These include decreased funding, lack of political commitments in some countries, emergence 
of drug resistant parasites, emergence of insecticide resistant mosquitoes and lack of effective 
vaccine among others [15,16]. The massive use of insecticide led to the development of 
resistance to pyrethroids, the only class of compounds used in treating bed nets [17] while 
resistance to ACTs has been spread in Southeast Asia [18]. The greatest concern of the global 
malaria eradication program is the possible emergence and spread of the resistance parasite 
strains to sub-Saharan Africa. 
To overcome these challenges and maintain the current momentum, there is a pressing need of 
new intervention tools including  effective drugs and vaccines, rapid and accurate diagnostic 
tools, effective insecticides, improved surveillances and rapid responses among others [19]. 
Following the recent advances in molecular biology and bioinformatics, genetic and genomic 
studies of malaria parasites, mosquitoes and human host are increasingly becoming the critical 
component of malaria research [20,21]. The increased availabilities of big genomic dataset 
with improved capacity to analyze and interpretation have led to the practical applications of 
genomic methods in malaria eradications [21]. These include tracking transmission dynamics 
and genetic diversity of the parasites and mosquitos, detection of drug resistant parasites and 
vectors, understanding the impact of drug and insecticide selection on the genomes of malaria 
parasites and vectors among others [21].  
1.3.  The parasite: An overview of lifecycle   
Malaria is caused by infection with protozoan parasites belonging to the genus Plasmodium 
transmitted by female Anopheles [22]. Transmitted by different species of female mosquitoes,	
the genes Plasmodium infects birds, reptiles and mammals [22]. Out of roughly 200 recognized 
Plasmodium species, five are known to infect humans: Plasmodium falciparum (P.falciparum), 
P.vivax, P.malariae, P.ovale and P.knowsi. The life cycle of the genus Plasmodium is complex 
and alternate between vertebrate and invertebrate hosts (Fig 1). The humans and other 




reproduction takes place, is considered to be the definitive host [23].  I first describe the asexual 
life cycle in human host and extend to the sexual life cycle in mosquitoes. 
1.3.1. Asexual Life Cycle 
1.3.1.1. Pre-erythrocyte stage 
 Female anopheles probes its proboscis in to the host’s skin and deposit saliva to prevent the 
blood from coagulation during the blood meal [24]. In this process, infected mosquitoes 
inoculates the transmissive form the parasite, the sporozoites in to the skin [24]. From the skin 
of the infected individual, the sporozoites inter in to the blood circulation or up-taken by the 
lymphatic systems from which they invade liver [24]. The  sporozoites are highly mobile and 
invasive; they penetrate hepatic macrophages (Kupffer cells),  transverse the endothelium 
protection, scape the lysosomal protection and reach the liver parenchyma [25,26]. The 
invasion of hepatocytes involves surface proteins of sporozoite (thrombospondin domain on 
the circumsporozoite protein and on thrombospodin-related protein) and a host surface 
molecule, heparin sulphate proteoglycans [25,27]. Sporozoites develop in to the pre-
erythrocytic schizonts which take 4-15 days depending on the Plasmodium species [25].  
P.vivax and P.ovale, may not achieve maturation to a schizont immediately but remain dormant 
(hypnozoite) [28]. Hypnozoite may remain in the liver for weeks to many years before 
developing to pre-erythrocytic schizont and lead to relapsing of  malaria disease [28].  
Although P. falciparum is not considered to have a hypnozoite form, it may occasionally 
demonstrate dormancy [29].  
 In the hepatocytes, the parasite forms parasitophorous vacuole and differentiates in to 
trophozoites [26]. After maturation, the parasite buds off the hepatocytes in merozomes 
containing hundreds of thousands of merozoites [28]. The merosomes lodge in the pulmonary 
capillaries and slowly disintegrate within 48-72 hours releasing merozoites. The erythrocyte 
invasion is enhanced when blood flow is slow and the cells are tightly packed [28]. Detailed 







1.3.1.2.  Erythrocyte stage 
The erythrocyte stage also termed as blood stage parasites undergo three distinct developmental 
stages: the merozoite, ring, trophozoite and schizont stages [30]. Merozoite is oval shaped, 
small cell with approximately a length and a width of 1.6 µm and 1.0 µm, respectively and yet 
possess all special organelles (rhoptries, microneme and dense granules) needed to invade 
erythrocytes [30]. The invasion process requires release of essential molecular factors from the 
organelles including adhesive proteins, proteases and membrane-altering agents [31,32].  
Erythrocyte invasion is a complex, multistep process that involve initial binding, reorientation 
and erythrocyte deformation, junction formation and entry [33]. The primary recognition of 
erythrocytes and adherence can occur at any point on the surface of the merozoite and is of low 
affinity [30]. The initial interaction primary involves the parasite’s merozoite surface protein 
(MSPs) and host receptor erythrocyte glycoprotein band 3. Other parasite ligands and host 
receptors are believed to be involved in this process [30]. 
This is followed by reorientation events in which the apical end of the parasite is placed in 
contrast with surface of erythrocyte. After reorientation events, a moving tight junction is 
formed between the apical end of the parasite and surface of erythrocyte [34]. Aided by the 
tight junction, parasite enters in in to a parasite induced vacuole formed from erythrocyte 
membrane (PVM) [31]. The merozoites specifically infect erythrocytes within 30 seconds and  
requires multiple receptor-ligand interactions [27]. Unlike the P.vivax that utilizes Duffy 
antigens for erythrocyte invasions and restricted to young erythrocytes (reticulocytes), P. 
falciparum use alternative invasion pathways to infect erythrocytes of all ages [35]. These 
ligands belong to a family of protein called erythrocyte binding proteins (EBP) including Duffy 
binding like (EBA-175, EBA-140, EBA-181 and EBL1) and reticulocyte binding like homologs 
(PfRh2a, PfRh2b and PfRh4) families [36]. The majority of the ligands are functionally 
redundant which  increases the diversity [37]. Multiple erythrocyte receptors are involved in 
the invasion process including Glycophorin A, B and C, CD36, ICAM among others as 
reviewed elsewhere [38]. After successful invasion, the merozoites loses its organelles and 
develops to ‘a ring stage’. The term ‘ring’ refers to its disk-like structure under light 
microscope. The ring stage parasite feeds haemoglobin and develops in to trophozoites, a 
plumper like cell, which veraciously degrade more haemoglobin and uptakes the host cytosol 




1.3.2. Sexual life cycle  
In the human host, a small proportion of merozoites differentiate in to sexual forms 
(gametocytes) macrogametocyte (female) and microgametocyte (male) [40]. The development 
and maturation of gametocytes in P. falciparum is slower (12 days) compared to other 
Plasmodium species which takes only about 30-55 hours [40]. It has been postulated that stress 
factors trigger the parasite to switch to the sexual phase of development [41]. The sexual phase 
development involves five distinct stages (I-V) marked by expressions of various gametocyte-
stage specific proteins (Pfs16, PF14 744,  PF14 748, Pfg27) and more than 600 gametocyte-
sex specific proteins [41]. The ultrastructure of each developmental stage has been shown in 
[42].  
Mature gametocytes are large sized parasites which occupy almost the entire host erythrocyte 
before they egress [43]. Immediately after  ingestion by  mosquito, gametocytes  escape from 
their surrounding erythrocyte membrane to undergo gametogenesis [43]. The process of 
gametogenesis is believed  to be activated by  a drop of temperature and chemicals  in the 
mosquito host [43]. The male gametocyte multiply itself to multiple ex-flagellated gametes and 
fertilize the female gametes. The fertilized zygote develops to an invasive motile Ookinete that 
penetrate epithelial cell layer and exit the gut lumen [44]. In the midgut epithelium, the 
Ookinete transforms a cyst like structure called oocyst in which the parasite undergoes 
sporogonic replications and eventually transformed to the infective sporozoites and migrate to 
salivary glands. The detailed sexual life cycle in mosquito is reviewed in [45].  
1.4.  Pathogenesis of P. falciparum severe malaria 
1.4.1. Severe malaria: clinical syndrome 
Malaria is a complex disease with clinical manifestations ranging from asymptomatic to life-
threating severe cases [46]. In endemic populations, only a small fraction (1-2%) of cases 
progress to severe malaria (SM) [47]. Nevertheless, severe malaria is one of the commonest 
reasons for admission to hospital and is a major cause of hospital death in children aged 1-5 
years in endemic areas [48]. Severe malaria is defined as demonstration of asexual forms of 
the malaria parasites in the blood of a patient with a potentially fatal manifestation or 




 The major complications of SM include cerebral malaria (CM), pulmonary oedema, acute 
renal failure, severe malarial anaemia (SMA). Acidosis and hypoglycaemia are the most 
common metabolic complications which can rapidly develop and progress to death within few 
hours or days [49]. About eighty percent (80%) of the deaths associated with malaria are caused 
by CM [49,51]. 
CM is defined as coma with the presence of P. falciparum in the blood of a patient with no 
evidences of other cause of coma including  hypoglycaemia, meningitis, or a postictal state  
[49]. In endemic areas with intense transmission, CM is characterized a brief fever and 
generalized illness which rapidly develops to coma. The coma threshold in CM  is defined  as 
Blantyre coma score < 2 in children or Glasgow coma score < 11 in adults [49].  
Besides, it has been shown that  there is a direct link between CM and  malarial retinopathy 
(retinal whitening, vessel colour changes, white-centred haemorrhages) resulting from the 
sequestration of the infected RBC in microvasculature of the brain and associated pathologies 
[52]. Malarial retinopathy is often used as an in vivo surrogate marker of CM [53]. In the 
presence of the other criteria, malarial retinopathy dramatically improves the specificity of CM 
diagnosis from approximately 61% to 100% [54]. However, CM cases with viral co-infection 
may not manifest retinopathy. Brian swelling has also reported as one of the cardinal clinical 
manifestations of CM [53]. CM cases with brain swelling are likely to progress in to brain 
dysfunction and respiratory failure which leads to fatal outcome. Children with CM in the 
absence of  brain swelling were shown to have higher chance of survival [53]. About 10% of 
the survivors of CM develop permanent or transient disabilities [52].  
SMA is another complication of severe malaria, particularly in children and pregnant women 
[49]. SMA is defined as haemoglobin < 5 g/100 ml or haematocrit < 15% and other malaria 
related syndromes [49]. The causal mechanisms of SMA is attributable to several factors 
including erythrocyte lysis during the parasite replication, sequestrations, splenic removal of 
deformed iRBCs, suppression of haematopoiesis, immune mediated haemolysis and RBC 
eryptosis among others [55]. The destruction of  uninfected RBCs constitute about 90% of the 
total loss of RBCs  during SM [56].  
The clinical manifestations of CM and SMA anaemia appears to be different in that SM usually 
either leads to CM or SMA but not both at the same time. It has been suggested that the 
mismatch is due to the variations at which the iRBCs are removed from the circulation by 
spleen [57]. Effective splenic clearance of immature iRBCs decreases the rate of sequestration 
and hence protect against CM while excessive removal of un-infected RBCs may lead to SMA. 




and leads to rapid development of CM while it decreases the risk of SMA [57]. However, 
severe malaria cannot be fully explained by these clinical syndromes. Rather, it is constituted 
by a combination of multiple distinct pathophysiological processes that lead to complications 
and reduced oxygen delivery to tissues [37,55]. 
 
1.4.2. Pathogenesis of severe malaria: Molecular mechanisms 
1.4.2.1. Adhesion of infected erythrocytes to host tissues 
Although better insights have been gained in recent years, the molecular bases of SM 
pathogenesis remain obscure due to the complex nature of the parasite life cycle, host genetic 
factors and immune responses [37]. However, the pathologies observed during malaria 
infections are generally the consequence of erythrocytes infections by merozoites also known 
as blood stage life cycle of the parasite (Fig 1). P. falciparum infected red blood cells (RBCs) 
adhere to vascular endothelium [58]. This phenomenon, commonly called “sequestration” is 
believed to be the mechanism of avoidance from splenic clearance and host immunity [59]. 
Parasite adhesions phenotypes include binding to endothelial cells (cytoadherence) [60], 
binding with uninfected erythrocytes (rosetting) [61] and platelet-mediated clumping of the 
infected cells [62]. All adherence phenotypes are resulted from the structural alteration of the 
infected erythrocyte surface commonly called ‘knobs’[63]. Knob is an electron dense 
protrusion induced by P. falciparum derived array of proteins [63]. The major protein family 
that orchestrates the knob formation and the subsequent sequestrations is a P. falciparum 
erythrocyte membrane protein1 (PfEMP1) [63]. 
PfEMP1 is encoded by approximately 60 genes collectively known as var family [64,65]. The 
var genes are one of the multi-gene families that exhibit extremely variable gene expressions 
patterns which modify the antigenic and functional properties of infected erythrocytes during 
the mature stages of the intraerythrocytic cycle [66]. The var genes demonstrate mutually 
exclusive clonal gene expression mechanisms in which one PfEMP1 protein is expressed by 
any individual parasite and reserve the remaining repertoire [66]. The extracellular region of 
PfEMP1 contain variable adhesion domains including Duffy-binding like (DBL) domain and 
1-2 cysteine-rich inter domain region (CIDR) reviewed in [37].   
Studies have showed that there are three distinct var gene categories  named as A, B and C 
groups  on the basis of the conserved upstream region [67,68]. Among these groups, expression 
of group ‘A’ genes have stronger associations  with SM [68]. Subsequent studies showed that 




ends  are associated with the severity of malarial disease [69,70]. PfEMP1 demonstrate 
variations in binding specificity to different host receptors. Chondroitin sulphate A is the main 
receptor of  infected erythrocytes in placenta (pregnancy malaria) [71]. ICAM1 is the 
commonest receptor in the brain tissue (cerebral malaria) [72]. Complement recepter1 (CR1), 
heparin sulphate and blood group A and B receptors are shown to be associated with the 
rosetting  which lead to SMA as reviewed in [58].  
There have been several other host receptor molecules identified thus far including CD36, 
CD56, P-selectin, PECAM1, Thrombospondin, Fractalkine, gC1qR/HABP1/p3 among others 
[58]. While non-adherent RBCs are cleared by the spleen rapidly, the iRBCs remain protected 
in the site of their adhesion [37]. Sequestration disrupts blood flow, damages endothelial cells, 
promote inflammatory cells activation and may lead to severe disease [58]. However, the 
adhesion phenotypes are different based on the parasite strains and the involved host tissues 
and thus, not all adhesion lead to life-threatening disease. Different strains of parasites can bind 
to a combination of different receptors in different tissues and hence, the severity of the disease 
is heterogeneous [37]. The parasite may demonstrate different antigens in each asexual life 
cycle which results in a new adhesion phenotype [73]. Furthermore, the heterogeneity of 
adhesion phenotypes based on geographic regions and transmission intensity have been 
reported [58].   
1.4.2.2. Inflammatory responses 
Another important event during SM is the massive release of pro-inflammatory cytokines 
including interleukin (IL)-1, IL-6, tumour necrosis factor (TNF), lymphotoxins (LM), 
interferon gamma (IFNγ) and superoxide [74]. The early stages of pro-inflammatory cytokines 
production during the malaria infection plays protective roles. For instance, the pyrogenic 
cytokines such as IL-1β and TNF determines the cyclic paroxysms of malaria parasite. This 
may help to delay the growth of the parasite by affecting its temperature preferences [75]. 
However, in the later stages, over reaction of the inflammatory reaction is one of the critical 
factors that drive malaria pathologies including vascular dysfunctions and organ damages, 
suppression of erythropoiesis and enhance the expression of adhesion molecules [74].  
The release of pro-inflammatory cytokines is thought to be mediated  mainly by parasite-driven 
factors released during  erythrocyte invasion events,  rupture of iRBCs, rupture of schizonts 
and sequestration processes [52]. The parasite molecules expressed in iRBCs trigger innate 




triggers the cytokines production and is the major driving factor of the cytokine storm during 
the malaria episodes [51]. In addition to this, the erythrocyte invasion events that involve 
interactions of the parasite glycosylphosphatidylinositol (GPI)-anchored Merozoite Surface 
Proteins (MSP-1 and -2) and host receptors is  one of the  inducers  of TNF-α [76]. TNF-α in 
turn induces the epithelial expression  of ICAM-1 in the brain which facilitates sequestration 
of iRBCs [76]. The release of TNF-α stimulates the induction of IFNγR1 from natural killer 
cells [77].  Polymorphisms of IFNγR1 gene have been reported to confer resistance against 
CM in Gambian populations [78]. It has been shown that LM which also share the same 
receptor, is principal mediator of murine CM instead of  IFNγ [79].  
The asexual reproduction of the parasite (schizogony) remarkably increases histone content in 
its cell which eventually accumulate in the cite of parasite sequestration and stimulate the 
production of IL-8 and other inflammatory mediators [80]. A recent study further implicated 
that the parasite histone contributes to the thrombosis and brain swelling and associated 
pathology during CM [81]. Another important parasite-driven protein which induces pro-
inflammatory cytokine is a histidine-rich protein 2 (HRP2) [82]. HRP2 is produced by the 
parasite in the iRBCs [83] and accumulates in the site of sequestration in the brain where it 
induces inflammasome and causes vascular leakage and associated pathologies [82]. It has 
been shown that HRP2 level in the plasma correlates with the progression of  CM [84].  
Furthermore, the parasite genome which is known to be rich in CpG motifs, is one of the major 
inducers of innate immunity [85]. It has been shown that the parasite DNA bounded by the by-
product of digested haemoglobin (hemozoin) in iRBC triggers the release of a proinflammatory 
cytokines [86]. Similarly, an invitro study has shown that colocalized DNA with hemozoin 
induce other systemic inflammation such as NLRP3 and AIM2 inflammasomes during malaria 
infection [87].  
In addition to the parasite factors, the host-driven components contribute to the induction of 
pro-inflammatory cytokines and thereby determine the disease severity. A classic example of 
the host-driven factor is the release of extracellular vesicles (EVs) from iRBCs.  EVs, also 
termed as micro vesicles, are small vesicles containing various molecules including proteins, 
RNA, and even organelles [88]. The EVs are involved in various biological activities such as 
transferring genetic information between cells [88]. 	Studies  have shown that EVs are able to 
activate innate immunity both in mice and humans and  are linked to the malaria disease 




cellular communications within the parasite populations and externally with the  host immune 
system [89,90]. A recent study implicated that iRBC-driven EVs contain several important 
molecules including parasite proteins, DNAs and  regulatory microRNAs [91]  and form a 
functional RISC complex with human protein called Ago2. This complex shown to have the 
capacity of silencing  endothelial gene expressions and leads to vascular disfunctions [91]. 
Likewise, Platelet-driven EVs can effectively link with iRBCs and various endothelial cells 
and play critical role in malaria pathogenesis [92].	
Another important host-driven factor that is capable of eliciting inflammatory reaction is a free 
heme released to extracellular environment after parasite-induced haemolysis [93]. The 
oxidation of free haemoglobin leads to the production of reactive oxygen species including 
superoxide anions (O2), hydroxyl radicals (OH), and hydrogen peroxide (H2O2) [39]. These 
degradation products mediate oxidative stress and induce inflammations resulting in tissue 
damage, increase expression of adhesion molecules, vascular leakages and infiltration of 
leukocytes [93]. However, the toxic effects are shown to neutralized by the action of heme-
oxygenase 1 enzyme which degrades heme in to none toxic products including iron (Fe), 
biliverdin and carbon monoxide (CO) [94].		
 
1.4.2.3. Dysregulation of coagulation cascades 
In addition to sequestration of iRBCs and inflammatory responses, dysregulation of 
coagulation cascades is one of the key factors that drive the pathogenesis of SM. Several studies 
have reported the presence of thrombi  and haemorrhages in different tissues of infected 
children  including in brain, kidney, lungs and retina [95,96]. The  activation of  coagulation 
cascade is thought to be resulted from malaria-related pathological events such as the release 
of pro-inflammatory cytokines, endothelial damages,  activation of platelets and binding of 
coagulation-based receptor with iRBCs [97]. Activated endothelium during CM has been 
shown to induce elevated secretion of von Willebrand factor (vWF), a large protein derived 
from endothelial surface and megakaryocytes and stored in  Weibel–Palade bodies (WPBs)  
[98]. The abnormal accumulation of vWF  induces  platelet-mediated clumping of iRBCs in 
the brain microvasculature  [98,99].  
In addition to  vWF,  elevated secretions of tissue factor (TF) has been shown to play a critical 
role in  initiating blood coagulation during SM [100]. The secretion of TF is enhanced by the 




infections [97]. The free Hb released from parasite-induced haemolysis during SM quenches 
the NO from the circulation [101]. The resulting decrease in  endothelial bioavailability of  NO  
leads to impaired neuronal signalling, oxidant damage and vascular dysfunction [102,103]. 
Platelets are  another important factor  which  promote blood coagulations  during SM [92]. 
Activated by the inflammatory cytokines, platelets  accummulate of at the site of adhesion and  
promote blood coagulation activities [104,105]. It has been shown that interactions between 
the platelets and endothelial cells play vital role  in  disruptions of  blood-brain barrier (BBB) 
and associated complications during  CM [106].  Taken together, the molecular mechanisms 
of SM pathogenesis involve combinations of sequestrations, inflammatory responses and 
dysregulation of haemostasis. These molecular events are not mutually exclusive and are 







Figure 1: Pathogenesis of malaria. a) Different stages of asexual and sexual life cycle in 
mosquito and human host b) The pathogenesis and development of Malaria disease. Adapted 


















1.5.  Antimalarial agents and drug resistance 
Antimalarials are the primary weapons in fighting against malarial disease since early times 
[107].  However, there are still limited number of existing antimalarials drugs on the markets. 	
Here I discuss the most prominent antimalarial drugs and emergence and spread of drug 
resistance.	 
1.5.1.  Quinine and Antifolate drugs  
The bark of Cinchona trees known to contain several alkaloids was used as remedy for febrile 
illness among malaria endemic populations in Southeast Asia [108].  Quinine, one of the 
alkaloids was discovered in 1820 became the major drug until World War II when supplies of 
the drug from Southeast Asia was interrupted [108]. The discovery of quinine is considered the 
most successful medical discovery of the 17th century. Later efforts to prepare alternative 
synthetic antimalarial drugs led to the discovery of Chloroquine (CQ) in 1930s. Chloroquine 
became the most widely used synthetic antimalarial during the 1960s and 1970s [109]. Other 
common quinine-related compounds include amodiaquine (ADQ), primaquine, piperaquine 
(PIP) and mefloquine. Antimalarial antifolates have been central for prophylaxis and treatment 
of malaria [110] . Sulfadoxine-pyrimethamine was first introduced for treatment of malaria in 
Africa during the early 1980s for cases when chloroquine treatment failed, and has since 
become the first-line treatment in many countries. These drugs are usually administered as 
various combinations of dihydro-folate-reductase inhibitors (proguanil, chlorproguanil, 
pyrimethamine, and trimethoprim) and sulfa drugs (dapsone, sulfalene, sulfamethoxazole, 
sulfadoxine, and others) [110]. The combination includes sulfadoxine/pyrimethamine 
(Fansidar), sulfalene-pyrimethamine (metakelfin), and sulfamethoxazole-trimethoprim (co-
trimoxazole).  The antifolates act by inhibiting parasite enzymes necessary for folate 







1.5.2. Artemisinin compounds 
	
Artemisinin (Qinghaosu ) was first isolated in 1971 by Tu Youyou from the plant Artemisia 
annua [111]. Tu Youyou received a Nobel Prize in Physiology and Medicine for her 
contribution in discovering Artemisinin [111] .These drugs  demonstrated a  very rapid 
clearance of the parasite from the circulation than any available antimalarials [110]. However, 
artemisinin has a very short elimination half-life and can’t be used as malaria prophylaxis. 
Therefore, artemisinin is usually paired with other long acting drugs (Artemisinin-based 
combination therapy (ACT)) to allow parasite killing and protects against reinfection. 
Artemisinin-based combination therapy (ACT) is currently the mainstay of treatment for 
uncomplicated falciparum malaria in all malaria endemic regions (WHO). Commonly used 
ACT drugs includes: Artemether-Lumefantrine, Artesunate-Amodiaquine, Artesunate-
Mefloquine, Dihydroartemisinin piperaquine and Sulphadoxine-Pyrimethamine [110]. 
 
1.5.3. Antimalarial drug resistance 
Malaria treatment failure due to drug resistance is a recent phenomenon despite the long history 
of antimalarial use in endemic populations [109]. According WHO Antimalarial drug 
resistance is defined as “The ability of a parasite strain to survive and/or multiply despite the 
administration and absorption of a drug given in doses equal to or higher than those usually 
recommended but within tolerance of the subject” [110].  Factors that contribute to antimalarial 
drug resistance include widespread availability of low-quality medicines, non-compliance, 
incorrect use or suboptimum dose of drugs, nutritional status among others [110] .  
1.5.4. Resistance to Chloroquine and sulfadoxine–pyrimethamine 
QC resistant forms of Plasmodium falciparum malaria first appeared in Thailand in 1957 [109].  
In 1970s, the emergence and widespread of QC resistance was reported in sub-Saharan Africa 
and South America which led to enormous human loss [112]. The spread of CQ resistance was 
a major factor for the failure of the first malaria eradication campaign in the middle of the 20th 
century [112]. QC is no longer effective against P. falciparum, but it still used for the treatment 
of P. vivax in regions where resistance has not developed [112]. QC acts by preventing 
detoxification of hematin within the parasite digestive vacuole [112].  Resistance to CQ is 




transporter (pfcrt) protein encoded by the pfcrt gene on chromosome 7 [113]. pfcrt gene is 
believed to function as a transporter and is involved in the drug flux [114].  
Sulfadoxine-pyrimethamine (SP) targets dihydrofolate reductase (PfDHFR) and 
dihydropteroate synthase (PfDHPS) which are enzymes in the folate biosynthetic pathway 
[115]. Accumulations of point mutations in these genes lead to resistance to SP; The more 
mutations accumulate in these genes, the greater the amount of resistance that is conferred to 
the parasite[116]. A similar pattern was observed with DHPS, with highly resistant lineages 
emerging in Southeast Asia and South America, and then spreading from Southeast Asia to 
Africa [116].    
1.5.5. Resistance to Artemisinin 
Artemisinin resistance is a major threat to global public health, with the most severe potential 
effects in sub-Saharan Africa where the malaria burden is the highest [117]. Resistance to 
Artemisinin (ART-R), characterized by delayed clearance of parasitaemia has emerged in 
South East Asia [118]. Resistance to Artemisinin has been associated with a mutation in a kelch 
protein located on P. falciparum chromosome 13 (K13 propeller) [119]. The K13-propeller 
mutation acts as a key causal determinant of artemisinin resistance has widespread distribution 
in the Greater Mekong subregion (GMS), which consists of Cambodia, Thailand, Vietnam, 
Myanmar and Laos [120].  
In Africa, several mutations in K13 propeller mutations that have been observed at low levels 
[121]. However, these mutations are different from the Mutation in SEA   and not associated 
with delayed clearance of parasites [121]. However, a recent study in Rwanda reported the 
existence of Pfkelch13 561H, one of the K13 mutations in SEA and its clonal expansion.  The 
authors further validated as a mediator of ART-R in vitro [122].  The findings of this study 
have substantial implications for public health in confirming the de novo emergence and clonal 
expansion of an ART-R Pfkelch13 R561H lineage in Rwanda which can potentially 
compromise the success of malaria control in Africa [122]. Therefore, it is imperative to 
undertake continuous genetic surveillance and monitoring of antimalarial drug resistance in 
endemic regions. Furthermore, alternative antimalarial drugs are urgently needed to realize the 






1.6. Malaria vaccine strategies:  progress and limitations 
	
 
The field of malaria vaccine has faced many challenges including the genetic and biological 
complexities of the Plasmodium parasite, presence of multiple, antigenically distinct life cycle 
stages in the mammalian host, the involvement of mosquito vectors and the prevalence of 
malaria in the in resource constraint populations among others [123] .	The WHO set a malaria 
vaccine development roadmap to be met by 2030: these include (1) developing vaccines with 
protective efficacy of at least 75% against clinical malaria and, (2) vaccines that reduce 
transmission of the parasite to reduce the incidence of human malaria infection [123] . Several 
strategies have been implemented to develop vaccine that can be used in mass vaccination 
programs to facilitate the global malaria eradication efforts [124]. These including pre-
erythrocytic, blood-stage and mosquito-sexual stage of development [125].  Here I discuss the 
recent progresses in malaria vaccine developments and their limitations. 
1.6.1. Pre-erythrocytic vaccines 
The Pre-erythrocyte (PEV) vaccine approach aim to target the malaria parasite during its 
sporozoite and liver stage of development and hence avert the progression to the blood-stage 
[125]. PEVs are designed to induce (1) antibodies against surface antigens that clear 
sporozoites from skin or bloodstream or block their invasion of hepatocytes, or (2) T cell 
responses that attack infected hepatocytes [125]. The two most successful Pre-erythrocyte 
vaccine thus far include whole organism sporozoite vaccine and a recombinant protein in 
adjuvant vaccine called RTS, S vaccine. 
1.6.1.1. RTS, S  
RTS, S, is the first human parasite vaccine passed the highest level of the WHO regulatory 
scrutiny in 2015 [125].  It is composed of the major surface antigen of sporozoites (CSP): 
fragment comprising central repeat (hence “R”) and C- terminal regions (containing T cell 
epitopes, hence “T”) fused to hepatitis B surface antigen (“S”). RTS is expressed in yeast that 
also carry hepatitis B “S” expression cassettes, and thus synthesize S and hence given the name 
RTS, S [126].  Recommended by the WHO, RTS, S/AS01E pilot implementation programs 




standard public health mechanisms [126].  However, the protection offered by RTS, S/AS01 
vaccine is modest and wanes over time [126].   R21 is an improved version of the RTS, S/AS01 
vaccine designed by incorporating a higher proportion of Pf CSP C-terminus bound to HBsAg 
N-terminus without the three-fold molar excess of HBsAg found in RTS, S/AS01. This 
enhanced B cell activation led to stronger anti-CSP humoral immune responses was 
immunogenic even at very low doses in mice and   has been under evaluation in Phase 1/2a 
clinical trials [127]  
1.6.1.2. Whole Sporozoite Vaccines  
This approach was introduced in 1970s and has been formulated in different ways including 
radiation-attenuated Sporozoite (Spz), genetically-attenuated parasite and Spz administered 
together with antimalarials [125].  Implementing these vaccines has been practically difficult 
because of the challenges including the requirement of liquid nitrogen cold chain, intravenous 
inoculation, difficulty to scale-up of the vaccine manufacture [125].  In effort to address these 
challenges, Sanaria company introduced a technology that is capable of harvesting PfSPZ from 
the salivary glands of aseptic mosquitoes infected by cultured laboratory parasites, followed 
by purification, vialing, and cryopreservation in liquid nitrogen vapor phase in 2010 [125].   
A recent study in Mali showed that the PfSPZ vaccine is well-tolerated and have 29% efficacy 
against heterologous strains [128]. Many studies have been aimed at improving attenuated Spz 
vaccines, focusing on efforts at producing a large repertoire of immunogens, evaluating the 
impact of a particular regime, dosage and inoculation route, thereby enabling an effective 
cellular and humoral immune response to be achieved[129]. Future improvements are needed 
to broaden efficacy against heterogeneous parasites. 	
1.6.2. Blood-stage vaccines  
Blood-stage malaria vaccines (BSV) are attractive in that they target the disease-causing stage 
of the parasite development [125]. It has long been shown that passive transfer of IgG purified 
from semi-immune African adults were able to clear parasitaemia from African children and 
later in Thai adults [124]. Several studies have been conducted to produce effective BSV 
vaccines the majority of which target the merozoite surface protein (MSPs), apical membrane 
antigen1 (AMA1) and P. falciparum reticulocyte-binding protein homolog 5 (PfRH5)   [130]. 




impair parasite invasion and infection in laboratory environment or experimental animals. 
However, the results showed scant evidence of protection against controlled human infection 
or against naturally occurring infection [125].  Among BSV candidates, only GMZ2 (consisting 
of conserved domains of GLURP and MSP3) showed statistically significant  (14%) efficacy 
in Africa [131]. 
 The challenges of developing effective anti-merozoite vaccines include (1) the very short time  
when merozoites are accessible to antibodies, (2) antigenic polymorphism, (3) redundant 
invasion pathways, and (4) the large number of parasites that need to be targeted [125].  
 
1.6.3. Transmission-blocking vaccines  
Transmission-blocking vaccine (TBVs) target the sexual stage of malaria parasite in 
mosquitoes host and hence block transmission of malaria[132].  Effective TBVs would ideally 
be used to protect the immediate neighborhood of the vaccinated individuals if high population 
coverage is achieved [125]. 
 The leading candidates are grouped as gamete surface proteins first expressed by gametocytes 
in human blood such as Pfs230 and Pfs48/45 of P. falciparum (BVS1 et al), and zygote surface 
proteins expressed only post-fertilization in the mosquito host such as Pfs25 and Pfs28 [133]. 
However, because these vaccines do not prevent infection in vaccinated individuals they are 
an unattractive financial venture for vaccine companies and thus far, demonstrated only modest 
efficacy [134]. The challenges of TBV development include achieving sufficient adaptive 
responses that maintain high levels of antibodies over time, widespread coverage to accomplish 














“The corpuscles of anaemic heterozygotes are smaller than normal, and more resistant to 
hypertonic solutions. It is at least conceivable that they are more resistant to attacks by the 
protozoa which cause malaria, a disease prevalent in Italy, Sicily and Greece, where the 
gene is frequent” (Haldane, 1949). 
 
1.7.  Human genetic polymorphisms and severe malaria: From few genes to whole 
genome 
A comprehensive understanding of the genetic basis of  severe malaria resistance can 
potentially inform the development of treatments and vaccines [135] . A classic example is 
the success achieved in the development of candidate vaccine for P. vivax, the predominant 
causative agent of malaria in South America and Asia [136]. The fact that this parasite is 
remarkably rare in sub-Saharan Africa had long been a puzzle for scientists [137]. After a 
series of studies, it was  revealed that most Africans lack the Duffy blood group, an essential 
receptor for erythrocyte invasion by P. vivax [137]. Later, the discovery of causative SNP in 
the chemokine receptor (DARC) gene and subsequent molecular analysis of this genomic 
region led to the development of candidate vaccine [138]. Continuing efforts have been made 
to make useful genetic discoveries for P. falciparum for the last several decades [135]. 
P. falciparum malaria is one of the best-known strong evolutionary selective forces acted on 
the human genome [139]. Malaria parasites have been infecting humans for at least 5000-
10,000 years following the emergence and expansions of agriculture [139]. The discovery 
of major erythrocyte disorders (hemoglobinopathies) in a higher frequency in some 
populations puzzled the geneticists of 20th Century [140]. The majority of the scientists of 
the time associated this phenomenon with human mutations as a consequence of Second 
World War [141]. However, J.B.S.Haldane, one of the most distinguished founders of 
population genetics, was unsatisfied with this argument and suggested that  “The corpuscles 
of anaemic heterozygotes are smaller than normal, and more resistant to hypertonic 
solutions. It is at least conceivable that they are more resistant to attacks by the protozoa 
which cause malaria, a disease prevalent in Italy, Sicily and Greece, where the gene is 
frequent” [142]. This insight soon became the so called “Malaria hypothesis” that propose 
inherited red cell disorders including thalassaemia and sickle cells are the results of  natural 




respect to the high frequency of thalassaemia genes, it turned out to be true for sickle cell 
trait and other hemoglobinopathies [143].  
Hemoglobinopathies are caused by structural and functional defects of human haemoglobin 
and are distributed in malaria endemic countries or in areas where malaria was prevalent 
[141]. Human haemoglobin is a tetrameric globular protein consisting of two α and two β 
polypeptide chains each having an oxygen-binding heme [144]. The α-chain (HBA) has 141 
amino acids and the β chain (HBB) has 146 amino acids [144]. The genes that code for α 
chain are located in the telomeric region of the short arm of chromosome 16 (16 p 13.3), 
whereas the genes encoding for the β chain are located on the short arm of chromosome 
11(11p.15.5) [144]. Among several structural Hb variants discovered so far, only three HbC 
(β 6Glu→Lys), HbS (β 6Glu→Val), and HbE (β 26Glu→Lys) reached polymorphic 
frequencies; suggesting that mutants at other sites of HBB locus and all sites at HBA loci, 
are either neutral or detrimental in malaria endemic environments [145].  
The majority of hemoglobinopathies are related to “loss of function” resulting in reduced 
expression or altered gene products [145]. As a result, inherited red blood cell disorders are 
among the most common genetic diseases in humans (more than 300,000 children are born 
each year with a severe inherited haemoglobin disorders) [145]. Furthermore, it has also been 
suggested that immunological, inflammatory and other chronic diseases prevalent today may 
be attributed to the pleiotropic effects of mutations that confer malaria resistance [146]. 
Therefore, population genetic studies of malaria resistance have huge implications in human 
health and evolutions. It is now generally agreed that P. falciparum malaria caused a number 
of host-protective polymorphisms at high frequencies because of its ability to kill before 
reproductive age [147].  Next, I discuss the well-known variants. I will discuss the novel 
variants identified by GWASs in Chapter 2. 
 
1.7.1. Haemoglobin S (HbS) 
 
Sickle cell trait has been recognized as the most prominent human genetic factor that confer 
protection against the lethal form of malaria [141]. It is caused by a SNP (rs334) in the coding 
region of HBB on chromosome 11p15.4 which results in substitution of Glutamic acid with 
Valine at amino-acid residue 6 of the β -globin chain [143]. Unlike homozygous (SS) 
individuals who suffer from a severe haemolytic syndrome, heterozygous (AS) are healthy and 




Haplotype studies suggested that the mutation of HbS independently arose in different 
populations at least one in Africa and one outside Africa [148]. Within Africa, the presence of 
the same mutation on different haplotype in different populations may suggest that the 
independent mutation likely arose more than once in this continent [149,150]. However, it is 
also possible that haplotype diversity can be caused by the differences in gene background 
conversion and recombination in different populations [149]. AS has shown to have a protection 
of approximately 90% against SM [151]. HbS is widespread all over malaria endemic areas 
and common in sub-Saharan Africa with a prevalence reaching 15-20% [140].	
 
1.7.2. Hemoglobin C (HbC) and Hemoglobin E (HbE) 
 
HbC is caused by change in b-globin molecule at the same amino-acid position as for HbS, but 
the change from Glutamic acid to Lysine rather than to Valine [152]. While homozygous form 
(CC) causes mild symptom of chronic haemolytic anaemia, the heterozygous (AC) is 
asymptomatic [153]. Both heterozygous (AC) and homozygous (CC) form confer protection 
against SM [154]. This may suggest that HbC could eventually reaches fixation in malaria 
environment with better fitness compared to HbS [154]. However, the current distribution of 
HbC is mainly limited to west Africa compared to the wider distribution of  HbS [155].  HbE 
is caused by substitution of Lysine with Glutamic acid in codon 26 [156]. This structural variant 
is common in South East Asia; reaching up to 70% in northern Thailand and Cambodia [140]. 
Linkage disequilibrium analyses suggest that HbE variant was emerged recently and come 
under intense selection in South East Asia [157]. The heterozygous state (AE) confers 
protection against SM [157]. 
1.7.3. Thalassemia 
 
α-thalassemia  has two major varieties  including  α0-thalassaemia, in which both of the linked 
HBA genes are deleted, and α+-thalassemia in which one of the pairs of linked genes (HBA1 
and HBA2) on chromosome 16 is deleted or inactivated by a point mutation [140]. The 
homozygous state is represented by --/-- and–α-α for α0-thalassaemia and α+ thalassaemia, 
respectively [140]. While α+ thalassemia cause a mild hypochromic anaemia in their 
homozygous state, homozygous  form of the  α0 (--/--) is a lethal disease resulting in stillborn 




distribution in past or present including sub-Saharan Africa and the Mediterranean region, the 
Middle East, the Indian subcontinent  and south East Asia [140]. Homozygous state and 
heterozygous state of α+-thalassemia confers an estimated protective level of 63% and 83%, 
respectively [151].  
β-thalassemia is caused by the reduction or loss of functional protein in HBB gene on 
chromosome 11 [158].  More than 200 mutations have been reported; the large majorities are 
point mutations in functionally important regions of β-globin genes [158]. The frequency of β-
thalassemia variants ranges from 5-20% in global population [140]. The severity of the disease 
varies depending on the nature of β-thalassemia allele, but at its most extreme form can 
resemble sickle-cell anaemia [159]. Individuals with β-thalassemia major (homozygous for the 
loss of production of β-chain) have profound anaemia and if not treated with blood transfusion, 
die in their first year of life [160]. But heterozygous individuals (β-thalassemia minor) have 
only mild anaemia [160]. β-thalassaemia trait has been reported to play protective role against 
SM [161].  
 
1.7.4. Proposed protective mechanisms hemoglobinopathies 
 
 
The molecular mechanisms that confer  protection against severe malaria  remains 
incompletely understood [151]. Nevertheless, it has been showed that the protection is 
attributable to genetic, molecular and immunological factors in which the parasite growth is 
impaired or its removal is enhanced [162]. Studies showed that ring-stage parasite don’t grow 
under low oxygen tension in HbS red cells [163,164]; suggesting that hemoglobinopathies 
interfere with intra-erythrocyte growth of the parasite. Another interesting invitro study 
implicated miRNA for the parasite growth inhibition in RBCs [165]. The authors observed 
translocation and fusion of several host miRNAs with parasite’s mRNA transcripts in in RBCs 
collected from AS and SS individuals. The fusion of the miRNAs was shown to inhibit the 
translation of enzymes that are important for the parasite development [165].  
In addition to interference with the parasite invasion and intraerythrocytic development, 
hemoglobinopathies have shown to neutralize the pathogenic pathways of the SM [151]. For 
instance, HbS and α+-thalassemia impair cytoadhesion and rosetting which  are the major 
mechanisms of pathogenesis [61]. HbC and HbS have been shown to reduce parasite induced 
remodelling of iRBCs and thereby reduce adhesion properties of the iRBCs [166]. It has also 




parasitized RBCs in HbAS individuals [167]. Sickling RBCs are rapidly removed from the 
circulation by immune system and hence minimize the chance of developing complications 
that lead to severe malarial disease [167]. The detailed proposed mechanisms of protections 
were described in [151]. 
 
 
1.7.5. Enzymopathies: Glocose-6-phosphate Dehydrogenase (G6PD) and Pyruvate 
kinase  
 
G6PD is an important enzyme that catalyses the first reaction in the pentose phosphate 
pathways [168]. It is a key enzyme to produce reduced glutathione and control oxidative stress 
in cell [168]. G6PD deficiency is one of the most common inherited disorders affecting around 
400 million people worldwide with a global prevalence of 4.9% [169]. The G6PD gene is 
located on the telomeric region of the long arm of X-chromosome (Xq28) close to the genes 
for haemophilia and colour blindness and is 18kb long consisting of 13 exons [168]. The region 
that encodes G6PD gene is one of the most polymorphic loci in human genome in which about 
140 different variants have been identified [168,170]. 
The global prevalence of G6PD deficiency is geographically correlated with areas inhabited 
by populations historically exposed to malaria including Africa, Mediterranean, South East 
Asia and Latin America [170]. In Africa, the most frequent variant is a mutant allele A- caused 
by nucleotide changes either at A376 (Asn to Asp) or changes at G202A (Val to Met) [170].  
It has been estimated that G6PD A- allele arose within the past 3,840-11,760 years and spread 
with expansion of malaria [170]. Some studies reported that both hemizygous males and 
homozygous females are protective against SM [170].  However, a relatively more 
comprehensive study showed that G6PD deficiency protects hemizygote males but not 
heterozygous females from SM [171].   
Deficiency of pyruvate kinase, a rate limiting glycolytic enzyme,  has also been implicated in 
conferring protection against malaria [149]. The enzyme is encoded by PKLR located on 
chromosome 1 (1q22) and abundantly expressed in RBCs and Liver [172]. Mutations in the 
isoform which is exclusively present in RBCs  causes an autosomal recessive inherited  
pyruvate kinase deficiency which results in a nonspherocytic haemolytic anaemia [172].  
Genetic studies in mouse models [173] and invitro analysis in humans [174] suggested that the 






1.7.6. Erythrocyte membrane polymorphisms: ABO blood group, Ovalocytosis and 
Glycophorins  
The histo-blood group ABO consists of three carbohydrate antigens A, B and H [175]. A, B 
and AB express glycosyl-transferase that adds either N-acetylgalactosamine to form the A 
antigen, galactose to form the B antigen, or leaves the H (O) antigen unmodified [176]. The 
ABO gene is located on chromosome 9q34, and the A and B alleles are co-dominant against 
the recessive O allele [175,177]. Similar to hemoglobinopathies, loss of functional allele in 
ABO gene (allele O) provides survival advantage while group A confers disadvantage and 
group B has intermediate effect against SM [178]. The prevalence of group O  higher in malaria 
endemic regions compared to group A [178].  
Ovalocytosis is an autosomal dominant hereditary condition that affects erythrocyte membrane 
rigidity and shape [179]. The term ‘ovalo’ is referring to the oval shape of erythrocytes of 
affected individuals [179]. Ovalocytosis is caused by a 27 bp deletion in SLC4A1	gene on 
17q21.31 which encode ‘band 3’ protein [180]. ‘band 3’ is a major  transporter of anions across 
the erythrocyte membrane and also involves in  maintaining integrity of the erythrocyte 
membrane [180]. Ovalocytosis is highly prevalent in parts of South-East Asia and its 
distribution coincides with malaria endemicity. Ovalocytic erythrocyte partially resists 
invasions by  both P. vivax and P. falciparum and confers protections against malaria [181]. It 
has also been reported that Ovalosytosis confers protection against CM [182].  
Another erythrocyte membrane component implicated in malaria resistance are Glycophorins 
gene cluster including GYPA, GYPB and GYPC [183]. Glycophorins constitute the 
sialoglycoproteins of erythrocyte membrane which determine different blood group antigens 
and are recognized as receptors of P. falciparum merozoites [184,185]. GYPA and GYPB acts 
as a receptor for P. falciparum erythrocyte-binding antigen 175 (EBA 175)  and erythrocyte-
binding ligand 1 (EBL-1), respectively  and determine MNS blood groups [184,185]. GYPC 
determines Gerbich blood group and serves as receptor for the P. falciparum erythrocyte-
binding antigen 140 (EBA140) [186]. Glycophorin variants have been shown confer malaria 









1.7.7. Haptoglobin (Hp)  
Haptoglobin (Hp) is an acute phase glycoprotein present in human plasma encoded by a gene 
on 16q22 [187]. There  are three  genetic variants of Hp in humans including Hp1, Hp2 and 
Hp2-1 [187]. Hb is functions as the main scavenger of toxic free hemoglobin (Hb) resulting 
from intravascular haemolysis. Hp binds to extravascular Hb  and forms Hp-Hb complex which 
is removed by a CD163, a receptor, abundantly expressed on macrophages [188]. In SM, Hp 
forms stable complexes with extracellular Hb  that is released from parasite driven-lysis of 
RBCs and thereby curtail the haemoglobin-induced oxidative tissue damage [189].  However, 
the protective role of different Hp genotypes on SM  remains controversial as reviewed in 
[149].  
1.7.8. Polymorphisms in adhesion molecules: CD36, ICAM1and CR1 
 
P. falciparum differs from other species in that the infected red blood cells (RBCs) adhere to 
vascular endothelium and disappear from the blood circulation for the entire life cycle to avoid  
splenic clearance and host immunity [58]. CD36 is one of the major host receptors to CIDRa2-
6 domain of the parasite’s PfEMP1 [190]. CD36   is a membrane glycoprotein encoded by a 
gene on chromosome 7q21.11 and present on platelets, mononuclear phagocytes, adipocytes, 
hepatocytes, myocytes [191]. It is a cell surface receptor which plays a role angiogenesis and 
phagocytosis [191]. It has been shown a missense mutation of the gene encoding of CD36  
confers  protection against SM by reducing parasite sequestration [192]. 
ICAM1 is an inducible glycoprotein belonging to immunoglobulin superfamily and is encoded 
by gene on chromosome 19p13.2 [193].  It another receptor for PfEMP1 which is widely 
expressed in brain tissue (CM)  [72]. A polymorphism caused by A-to-T transversion at 
nucleotide 179 of N-terminal domain of ICAM1 ( also called ICAM1 Kilifi) has shown to 
be linked to have a high frequency in malaria endemic populations [194]. ICAM1 Kilifi has 
been associated with increased susceptibility to SM in Kenyan population. The same mutation 
has been reported to be associated with resistance against SM in Gabon population [195]. 
However,  another study conducted Malawi, Kenya and Gambian populations reported that 




CR1 is an immune-regulatory protein encoded by a gene located on chromosome 1q32.2 and 
is involved in complement	activation	and	clearance	of	immune	complexes	[197]. CR1 is 
abundantly expressed in RBCs and leukocytes  and has been shown to be associated with  
rosetting, one of the major factors that lead to sequestration  and associated pathologies during 
SM [58]. Deficiency of CR1 has been shown to be common in malaria endemic populations in 
Melanesian populations [198]. The same study demonstrated that CR1 deficient individuals are 
protected against SM [198]. Further studies have reported that polymorphisms in CR1 genes 
confer protection in Kenyan [199] and west African populations [200]. 
 
1.7.9. Polymorphisms in immune response genes: HLA, IFNγ  
 
Human Leukocyte Antigen (HLA) is encoded by the Major Histocompatibility Complex 
(MHC) which is the most polymorphic genes known in human genome. The diversity of MHC 
is believed to be driven by selection pressure from infectious pathogens and known to be 
associated with the risk of several infectious diseases [201]. HLA variants such as HLA class I 
antigen (HLA-Bw53) and HLA class II (DRB1*1302-DQB1*0501) were reported to common 
in African populations and confer some degree of protection against severe malaria [202]. HLA 
class I antigen is expressed by liver cells and hence, T cells (CTL) responses might more 
efficiently act against the liver stage of malaria parasite in individuals with HLA-Bw53 [202]. 
Whereas, individuals with DRB1*1302-DQB1*0501 variant might possess efficient antigen 
presentation mechanism that can lead to rapid clearance of blood stage parasite [202].  
Massive release of pro-inflammatory cytokines is one of the factors that lead to malaria 
pathogenesis.   IFNγ is encoded by a gene on 12q15 and plays a regulatory roles in development 
and functions of immune system[203]. It is one of the major cytokines, abundantly during 
malaria infection caused be  deficiency caused by  a polymorphism at promoter region of this 
gene ( IFNγ 183G/ T) has been associated with protection against CM in Malian 
populations[204].  Moreover, polymorphisms in transcription factor interferon regulatory 
factor 1 (IRF-1) which regulates IFNγ production is shown to confer protective role against 
SM [205]. Similarly, polymorphisms of IFNγR1 gene have been reported to confer resistance 
against CM in Gambian populations [78].  Several other immune variants were reported to be 






1.8.  Approaches to study human genetic resistance and susceptibility to severe 
malaria   
1.8.1. Candidate gene association studies 
Candidate gene association study approaches is one of the best known genetic epidemiological 
methods used to establish relationship between genes and diseases [206]. It is a knowledge 
based, hypothesis-driven  approach which enables to test associations between a specific 
genomic regions and the phenotype of interest [206]. Candidate gene association study 
approaches include cohort studies and case control studies. In cohort studies, individuals who 
have and do not have specific alleles or genotypes grouped in separate cohorts and followed 
prospectively to determine whether exposure affects the risk of developing diseases. The 
comparison is made by calculating relative risk between the groups. In case-control studies, 
the study individuals are grouped based on disease status and examined for exposure 
retrospectively. The case-control study approaches compare the frequencies of genetic markers 
in cases and controls. The comparison is usually presented by calculating the odds ratio 
between the cases and controls [206].  
Candidate gene association study approaches have been successfully applied to malaria  
susceptibility/resistance studies for more than two decades and  identified a number of genes 
[141,147,149]. However, several conflicting findings were reported from different studies 
[149]. Some variants that were reported to be  associated with protection against SM in one 
population were found neutral in another populations [141]. In some instances, variants that 
were associated with the protection against SM in initial population were found to be associated 
with increased risk in the second population when replication was attempted [149]. 
Consequently, only few of the associations were replicated in different populations. For 
instance, in a multi-center case-control association study conducted in malaria endemic 
countries, forty percent of the previously reported loci (22 out of 55) were failed to replicate 
[207]. 
The major limitations of this approach is that the candidate genes are selected based on prior 
knowledge of biology and epidemiology of malaria; specifically, the observation of balancing 
selections of inherited red cell disorders[147]. As a result, the majority of the identified risk 
loci are erythrocyte variants that cause red blood cell diseases as reviewed elsewhere [141]. 
Erythrocyte variants can easily be detected compared to the phenotypic consequences of 




compared to a sickling red cell [147]. Thus, other potential genes that influence malaria 
resistance/susceptibility might be missed. Another limitation of the conventional candidate 
gene approach is that, it can’t accommodate polygenic genetic architecture in which multiple 
variants with small effects add up to control the phenotypic variance[207].  
 
1.8.2. Family based linkage studies 
 
Linkage study approaches aim to identify genetic associated loci using families or set of 
families that display sufficient phenotypic variations  for the disease/trait under investigation 
[208]. The co-segregations of the genomic region that contain causal variant/variants within 
the family are assessed by set of selected polymorphic markers. Linkage study approaches can 
be used to generate hypothesis because, it enables identifying the genomic regions of 
association without the need of previous knowledge about the link between the certain genomic 
regions and the disease of interest [208]. The result of linkage analysis is usually reported as a 
logarithm of the odds (LOD) score. 
Linkage studies have been applied in malaria as a classical approach to identify genes that are 
co-segregating in families [209]. Several genomic loci including 1p36, 2p25,4q13,5q31-q33, 
6p25,9q34,10p15.3, 10p14, 12q21-q22,13q13,20p12 and 20q11 were reported to be associated 
with malaria infection and severity in different African populations [209–214]). However, the 
majority of the findings were discordant and failed to be replicated in different populations.  
This is mainly due to the fact that the sample sizes in linkage studies are generally small and 
the variants assayed are limited to several hundred to thousands of markers which lacks the 
resolution power to detect genes with small effect sizes [215]. Moreover, the markers are 
usually heterogeneous in populations with different genetic backgrounds; implying that 
association signals can be dissolved during the analysis and leads to false negative results.  
 
1.8.3. Genome-wide association studies (GWAS) and Post-GWAS 
Genome wide association studies (GWAS) approach has been proven to be a powerful tool for 
investigating the genetic basis of common diseases [135]. This approach overcomes the 
majority of the fore-mentioned challenges in candidate gene and linkage studies and provided 
unprecedented successes in genetic studies of a wide range of complex-traits and common 
diseases [135,215]. The fundamental rationale of GWAS is a ‘common disease common 




variants in populations [216]. GWAS makes use of commercial ‘SNP chips’ that are designed 
to capture the majority of the common variations in human genome. The representative SNPs 
(tag SNPs) in genotyping array are selected based on the linkage disequilibrium (LD), the 
correlation between neighbouring SNPs in populations because of past evolutionary history 
[216]. Following the availability of comprehensive reference data and SNP catalogue, denser 
commercial ‘SNP chips’ become available for GWAS; some of which currently contains up to 
2,000,000 SNPs [217]. This further facilitated the application of GWAS in a wide range of 
genetic studies of complex-traits and diseases [217].  
The application of GWAS approach to malaria research was motivated by two main reasons: 
(1) Malaria has been a strong selective force in the recent human evolution; 2) Only a small 
proportion of heritability of malaria resistance trait is explained by the well-known variants 
[135,218]. The Malaria Genomic Epidemiology Network (MAlariaGEN) [20], a global 
partnership of malaria researchers, has been established to conduct multi-centre-scale genetic-
association studies of  malaria resistance and susceptibility. The consortium addressed the 
major practical and ethical obstacles including recruiting large number of patients, 
implementation of data management and sharing systems, proper classification of severe 
malaria phenotype, standardization of sampling and sample processing systems across the 
study sites [20].  
This led to the successful implementation of several GWASs in malaria endemic regions 
[150,219–223]. Importantly, a central repository of genotypic and phenotypic data was 
established which researchers can access up on acceptance of their proposals and signing of a 
legally binding data access agreement (www.malariagen.net/resourse/2) to facilitate further 
scientific discoveries [224]. In addition to GWASs, recent advances in post-GWAS including 
capturing polygenicity, risk prediction, detecting new risk loci, imputing un-typed associated 
variants and fine-mapping causal variants from GWAS summary statistics and LD information 
based on population specific reference panel are also playing an increasingly critical role in 
complex disease studies [217]. However, the severe malaria resistance GWASs have been 
suffering from several challenges.  I will discuss the progress and pitfalls of the application of 






1.9.  Motivations of the project 
 
The global malaria eradication efforts have been implemented  in malaria endemic areas using 
conventional strategies including  distribution of long-lasting insecticide treated nets (LLINS), 
indoor residual insecticide spraying, intermittent treatment for pregnant women in high 
transmission settings [11]. This led to the significant decline of malaria burden in many parts 
of the endemic regions [12]. Despite the successes gained, the progress towards global malaria 
elimination is currently challenged by emergence of drug resistant parasites, insecticide 
resistant mosquitoes and lack of effective vaccine [12]. In effort to devise host-directed 
intervention strategies such as therapeutics and vaccine, several GWASs have been 
implemented in the last decade and shed new light to the genetic bases of malaria resistance. 
Even though the GWASs enabled better understanding of the genetic basis of the complex 
disease/trait, the method suffers from the following shortcomings:1) the weak performance in 
genetically diverse populations;  2) the lack of translation of associated loci into suitable 
biological hypotheses 3) the well-known problem of missing heritability;  4) the lack of 
understanding of how multiple modestly associated loci within genes interact to influence a 
phenotype; 5) inefficiency in distinguishing between inflation from bias (cryptic relatedness 
and population stratification) and  true signal from polygenicity; 6) the imperfection of 
asymptotic distribution of current mixed model association or logistic regression in the specific 
case of low-frequency variants. These shortcomings were clearly reflected in previous severe 
malaria resistance GWASs [150,219,220,223].  
For instance, in one of the studies, HbS locus, a well-known variant conferring resistance to 
severe malaria demonstrated a weak signal (p values ~ 10-7); partly because of the weak LD 
between causal variants and the SNPs that were genotyped, suggesting that several other 
signals with modest effect sizes were missed. On the other hand, several genomic regions 
containing variants with evidences of associations were identified. For instance, in malaria 
GWAS studies  conducted in eleven populations,  34 regions of the genome that contain 
variants with evidence of associations with severe malaria were identified [219]. Earlier 
GWAS in Ghanaian population also identified 40 genomic regions containing 102 SNPs with 




study [225]. However, the majorities of the variants fail to pass the stringent significance 
GWAS threshold (p=5x10-8) required to report genuine associations.  
This raises several questions including 1) What is the genetic architecture of malaria 
protection? 2) What is the contribution of polygenic effects and their distributions across cell-
types, chromosomes, functional groups and molecular pathways? 3) What is the extent and 
pattern of epistasis and pleiotropy at genome wide scale which are known to influence malaria 
resistance trait among others. This information has a huge potential to allow us understand the 
underpinning biology and hence paves ways to design alternative therapeutics and vaccine 
candidates. Another obstacle is that the genetic determinants of malaria resistance trait and 
their effect sizes have been shown to vary between different African populations in previous 
GWAS studies. This could be because of several reasons including differing environmental 
factors, differing patterns of linkage disequilibrium (LD) and differences in allelic architecture 
due to the population diversity in Africa. Furthermore, the biological and functional 
information of the identified variants have not been well elucidated at gene and pathway levels. 
In attempt to address the fore-mentioned challenges, advanced statistical approaches that can  
improve power of association studies have been recently developed and implemented in 
complex disease studies [226–229]. In addition to this, recent advances in post-GWAS methods 
enabled applications of  gene-based GWASs, functional studies, protein-protein interactions, 
and polygenic analysis on publicly available GWAS-summary statistics without the need of 
individual genotype datasets  [230–234]. However, the majority of these approaches have not 
been implemented in malaria resistance GWAS datasets. Given the availability of malaria 
resistance GWAS datasets and improved public reference panels, it is now an intriguing time 
to investigate the genetic basis and underpinning biological functions of malaria resistance 
trait. We therefore, aimed to implement contemporary statistical genetic analytic approaches 








1.10.   Objectives of the thesis 
 
1. To explore the challenges of GWAS approaches in severe malaria datasets and figure 
out how various advanced statistical genetic methods can be implemented to address 
these challenges.  
2. To estimate the SNP heritability of malaria resistance in African population and partition 
in to chromosomes, allele frequencies and annotations  
3. To prepare African specific reference panel from public datasets to enable LD-based 
enrichment analysis from summary statistics 
4. To identify candidate malaria resistance genes and pathways  
5. To compare population genetic structure of candidate malaria resistance gene in malaria 
endemic populations and global populations 






















1.11.  Outlines of the thesis  
 
In CHAPTER 1 of this thesis, we presented a general introduction as described above. In 
CHAPTER 2, we discussed progresses and challenges of the conventional GWAS approaches 
in African populations in general and in malaria resistance GWAS datasets in particular. We 
presented alternative strategies that can potentially be applied to the GWAS datasets and 
provide better insights to the genetic basis of severe malaria resistance. In CHAPTER 3, we 
presented the results from comprehensive heritability analyses of severe malaria resistance in 
three African populations including Kenya, Gambia and Malawi. As part of enrichment 
analysis, we prepared African specific reference panel obtained from African populations 
datasets in 1000 Genomes Project and African Genome Variation Project reference datasets 
and computed LD for the panels.  In CHAPTER 4, we presented the results obtained from 
various functional analyses performed on malaria resistance GWAS dataset of 17,000 
individuals meta-analysed across eleven populations in Africa, Asia and Oceania.  We further 
presented the findings obtained from population structure analyses and rare variant analysis 
performed on raw genotype GWAS datasets (N = ~11,000) of Kenya, Gambia and Malawi 
populations. In CHAPTER 5, we summarized all the findings and discussed the future works 




















1.12. Overall contributions of thesis project in malaria field  
 
In this work, by noticing the fact that performance of conventional GWASs is relatively weak 
in African populations in general and in malaria resistance GWAS datasets in particular, we 
figured	out	how advanced statistical genetic analytic approaches can be applied improve the 
power of these studies. We showed that the statistical genetic methods that have been 
developed for homogeneous populations such as Europeans can be applied to the genetically 
diverse African dataset when population specific reference panels are used and stringent quality 
control strategies are implemented. The reference panel we prepared as part of our analyses 
can potentially be used for other LD-based studies in African populations.  
We showed for that malaria resistance is polygenic trait with SNP-heritability (h2g) of ~20% 
and that the causal variants are overrepresented around protein coding regions of the genome. 
By applying several gene-based, pathway-level and network-level functional analyses to severe 
malaria resistance GWAS summary statistics (N=17,000) meta-analysed across eleven 
populations in malaria endemic regions in Africa, Asia and Oceania, we systematically 
identified 57 genes located in the known malaria genomic loci and additional 125 genes across 
the genome.  
We showed that identified genes were significantly enriched in malaria pathogenic pathways 
including multiple overlapping pathways in erythrocyte-related functions, blood coagulations, 
ion channels, adhesion molecules, membrane signalling elements and neuronal systems. 
Overall, our works showed that severe malaria resistance trait is attributed to multiple genes 
that are enriched in pathways linked to severe malaria pathogenesis. These findings laid the 
foundations of future experimental studies which can potentially lead to translational medicine 













2. CHAPTER TWO: GENOME-WIDE ASSOCIATION STUDIES OF SEVERE 
P. FALCIPARUM MALARIA SUSCEPTIBILITY: PROGRESS, PITFALLS 
AND PROSPECTS 
  Summary 
 
In this chapter, we assessed the progress of severe malaria resistance GWASs, presented the 
biology of the novel variants identified by the previous GWASs studies and proposed the 
mechanisms of protections of these variants against severe malaria. We extended our 
discussion to the challenges that compromise the power of the GWASs including the genetic 
diversity in African populations, small sample sizes, allelic heterogeneity of malaria and 
inherent limitations of the GWAS approaches. In view of providing alternative strategies 
that can potentially address these challenges, we reviewed the current progress in GWAS 
and post-GWAS approaches including polygenic analysis, fine-mapping, protein-protein 
interactions, gene-based and pathway-level analyses. We estimated SNP-heritability of 
severe malaria at 20.1% in Gambian populations and showed how advanced statistical 
methods can potentially be implemented in the current malaria resistance datasets to provide 
useful functional insights. We further advocated for making paradigm shift from single-
omics to ‘multi-step’ and ‘multi-dimensional’ integrative studies which can integrate multi-
layer genetic information from human host and the parasite together with the impacts of 
environment factors. The future systems biology level studies will eventually revolutionize 
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P. falciparum malaria susceptibility:
progress, pitfalls and prospects
Delesa Damena1*, Awany Denis1, Lemu Golassa2 and Emile R. Chimusa1
Abstract
Background: P. falciparum malaria has been recognized as one of the prominent evolutionary selective forces of
human genome that led to the emergence of multiple host protective alleles. A comprehensive understanding of
the genetic bases of severe malaria susceptibility and resistance can potentially pave ways to the development of
new therapeutics and vaccines. Genome-wide association studies (GWASs) have recently been implemented in
malaria endemic areas and identified a number of novel association genetic variants. However, there are several
open questions around heritability, epistatic interactions, genetic correlations and associated molecular pathways
among others. Here, we assess the progress and pitfalls of severe malaria susceptibility GWASs and discuss
the biology of the novel variants.
Results: We obtained all severe malaria susceptibility GWASs published thus far and accessed GWAS dataset of
Gambian populations from European Phenome Genome Archive (EGA) through the MalariaGen consortium
standard data access protocols. We noticed that, while some of the well-known variants including HbS and ABO
blood group were replicated across endemic populations, only few novel variants were convincingly identified and
their biological functions remain to be understood. We estimated SNP-heritability of severe malaria at 20.1% in
Gambian populations and showed how advanced statistical genetic analytic methods can potentially be
implemented in malaria susceptibility studies to provide useful functional insights.
Conclusions: The ultimate goal of malaria susceptibility study is to discover a novel causal biological pathway that
provide protections against severe malaria; a fundamental step towards translational medicine such as development
of vaccine and new therapeutics. Beyond singe locus analysis, the future direction of malaria susceptibility requires
a paradigm shift from single -omics to multi-stage and multi-dimensional integrative functional studies that
combines multiple data types from the human host, the parasite, the mosquitoes and the environment. The current
biotechnological and statistical advances may eventually lead to the feasibility of systems biology studies and
revolutionize malaria research.
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Plasmodium falciparum, the causative agent of severe
malaria, has been infecting humans for at least 5000-10,000
years following the advent and expansions of agriculture [1–
3]. Malaria still poses a huge social, economic and health
problems in several low-income countries, particularly in sub
Saharan Africa [4, 5]. P. falciparum infects millions and kills
hundreds of thousands of African children each year. How-
ever, this constitutes only a small proportion (1%) of the
populations in endemic areas in which the infections pro-
gress to severe malaria such as profound anemia or cerebral
malaria [6, 7].
Comprehensive understanding of the genetic basis of re-
sistance and susceptibility to severe malaria is crucial to
understand the molecular mechanisms of host-parasite inter-
actions that can inform the development of effective thera-
peutics, vaccination, diagnostics and risk prediction strategies
[8, 9]. To this end, GWASs have recently been implemented
in malaria endemic areas and replicated some of the well-
known variants including HbS and ABO blood group [10–
13]. Despite the fact that malaria is expected to drive several
protective alleles to high frequencies that can be captured by
GWAS approach, it is unclear why only limited number of
novel variants were identified of which a small fraction was
replicated across endemic populations. Some of the contrib-
uting factors for this discrepancy might include small sample
sizes, the genetic diversity of the malaria endemic popula-
tions and allelic heterogeneity of malaria protective al-
leles among others. On the other hand, several association
signals distributed across the genome that didn’t pass GWAS
significance threshold were observed in these studies [10–
13]; suggesting the possible existence of polygenic effects.
This raises several key questions including 1) What is the
genetic architecture of malaria susceptibility/resistance? 2)
What is the heritability of malaria susceptibility and its distri-
bution across the genome? and 3) What is the extent and
pattern of epistasis and pleiotropy at genome wide scale?
Here we review the current status of malaria susceptibility
GWASs and provide guidance to future research directions.
We begin by assessing the progress and pitfalls of severe
malaria susceptibility GWASs and discuss the biology of the
novel variants. We then provide an overview of the recent
progresses in post-GWAS approaches and discuss how these
methods can be implemented in severe malaria susceptibility
studies to better understand the underlying biology. We con-
clude by discussing on research areas where further works
are needed in light of the global malaria eradication efforts.
Results
Severe P. falciparum malaria susceptibility GWASs:
progress and pitfalls
In malaria endemic areas where repeated P. falciparum
infection is very common, the majority of children
recover from malaria. However, a small proportion of
infections progress to the severe form of the disease
such as severe anaemia, cerebral malaria, acidosis and
respiratory distress [7]. Cerebral malaria is the common-
est cause of death characterized by rapid onset of gener-
alized convulsion followed by coma (a Blantyre coma
score of less than 3 in the presence of P. falciparum
parasitaemia). Severe anaemia is defined as a haemato-
crit of < 15% or haemoglobin < 5 g/dl in the presence of
P. falciparum parasitaemia [14]. Although the clinical
outcome of malaria is determined by several factors in-
cluding infection rate, parasite genetics and the environ-
ment, the host-genetics factor contribute about 25% of
P. falciparum malaria severity. However only small pro-
portions (~ 2%) of heritability is explained by the well-
known variants such as sickle-cell anaemia and !-thalas-
saemia [7]. The conventional approaches such as candi-
date gene-based studies [15–17] and the family based
linkage studies [18, 19] have been implemented at least
for the last three decades and identified several associ-
ation variants. Unfortunately, the majority of the find-
ings were discordant and failed to replicate in different
populations [1].
GWAS in malaria susceptibility study was motivated to
address the acute limitations of the conventional
approaches and provide better understandings of the
underpinning genetics at genome wide scale. To this ef-
fect, a global partnership of malaria researchers, named as
Malaria Genomic Epidemiology Network (MalariaGEN)
was established in 2008 [20]. MalariaGEN has successfully
conducted multi-center-scale GWASs [10–13] and re-
ported some interesting findings which we will discuss in
later sections. However, the GWAS approach has several
limitations including 1) weak performances in genetically
diverse populations [8], lack of translation of associated
loci into suitable biological hypotheses [21], 3) the well-
known problem of missing heritability [22], 4) the lack of
understanding of how multiple modestly associated loci
within genes interact to influence a phenotype [23], 5) in-
efficiency in distinguishing between inflation from bias
(cryptic relatedness and population stratification) and true
signal from polygenicity [24], 6) the imperfection of
asymptotic distribution of current mixed model associ-
ation in the case of low-frequency variants [25]. The
discussion on limitations of GWAS approache is beyond
the scope of this review. Here we focus on the major
challenges of malaria susceptibility GWASs and highlight
the recent positive progresses.
Genetic diversity of African population
Owing to the fact that Africa is the origin of modern
humans, there is high level of genetic diversity and weak
linkage disequilibrium (LD) in Africans compared to non-
African populations [26–28]. These distinct genetic
characteristics created major setbacks to GWASs in
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African populations primarily because of lack of represen-
tative dense genotype chips and reference panels [8]. It
was estimated that a GWAS of 0.6 million SNPs based on
HapMap phase 1 dataset in European population has an
equivalent power to the chips with 1.5 million SNPs in
African populations [29].
This might have affected the power of previous malaria
GWASs. For instance, in the first malaria GWAS [10],
HbS locus, a well-known variant conferring resistance to
severe malaria demonstrated a weak signal (p-values
~ 1x10-7) because of the weak LD between causal variants
and the SNPs that were genotyped. After which authors
sequenced the locus, undertook multipoint imputation,
used proper reference panel and dramatically improved
the signal to p-value ~1x10-14. However, coverages of the
genotyping chips have been enormously improved to be
able to capture the genetic diversities among global popu-
lations following the recent technological advances and
availability of diverse reference data sets [27, 30–32]. For
instance, Omni microarrays based GWASs were proven
to have considerable power in African populations [27].
Such developments have also facilitated imputation-
based studies in African populations. For instance,
Band et al. [9] showed the feasibility of multi-point
imputation based meta-analysis in for malaria GWASs
using HapMap3 haplotype panel. Another study
showed a substantial improvement of imputation ac-
curacy by using the more diversified AGVP WGS ref-
erence panel [27]. We believe that the reference
dataset will grow further and accelerate genomic re-
search by including wide range of haplotype diversity
in African populations.
Sample size
In GWAS, a stringent p-value (0.5x10-8) is usually
needed to declare evidences of genuine associations to
minimize false discovery rate that can arise from mul-
tiple testing [33]. Thus, very large sample size is required
to achieve genome-wide significance threshold particu-
larly for loci with modest effect sizes. The required sam-
ple size is even much higher for studies in population of
African ancestry because of the higher genetic diversity.
In contrast, the current sample sizes of GWASs in Afri-
can populations including those of malaria susceptibility
are generally small compared to non-Africans [34] which
might have affected the power of the studies. Therefore,
more powered studies in African population might lead
to the discovery of novel association variants.
Allelic heterogeneity of malaria protective variants
Allelic heterogeneity defined as the presence of multiple
causal variants in the same locus is one of the challenges
of GWA and fine mapping studies [35]. The presence of
multiple causal variants with variable effect sizes and LD
structures limits the power of GWASs. In such cases,
fine-mapping methods will also have lower accuracy to
pinpoint true causal variants among several possible can-
didates [35]. Allelic heterogeneity has been described for
the well-known loci affecting malaria susceptibility,
which is reflected by their geographical distribution
within malaria-endemic regions [36].
Several distinct variants are known to exist at the loci
causing inherited hemoglobinopathies [36]. Allele frequen-
cies, LD structure and effect sizes of these variants differ in
sub-populations within endemic areas [37]. For instance,
the sickle cell allele, HbS, is known to have different haplo-
type structure and effect sizes in different regions of sub-Sa-
haran Africa [27]. HbC allele is common in some parts of
west Africa such as Burkina Faso, Ghana, Togo and Benin
while absent in other west African countries such as
Cameroon and Chad [38]. In the same region, several alter-
native alleles with differing effect sizes are known to exist at
the locus causing G6PD deficiency [36, 39]. Although
population specific studies can minimize such challenges,
the current MalariaGEN datasets are comprised of several
populations each with small sample size; making it difficult
to undertake powered GWASs for specific geographic
areas.
Genetic architecture of malaria susceptibility and resistance
The performance of GWASs is dependent on the genetic
architecture of the diseases and traits under investiga-
tion. For the majority of complex diseases and traits, the
GWAS variants identified thus far, only explain a very
small proportion of heritability; a phenomenon com-
monly termed as ‘missing’ heritability [22] . There have
been different explanations for the ‘missing’ heritability
including common disease rare variant hypothesis [40],
none-additive components, primary epistasis [41, 42]
and polygenic genetic architecture [21].
One of the challenges of malaria GWASs is that we
don’t know much about the genetic architecture of mal-
aria protection trait. First, as one of the prominent evo-
lutionary selective forces, the majority of malaria
protective alleles might have evolved under positive se-
lection and might potentially be balanced by other forces
[43]. In this case, the protective variants are expected to
have large effect sizes with high allele frequencies that
can be detected by the conventional GWAS approaches;
provided that proper reference panel and genotyping
platforms are used [43]. Second, similar to the genetic
architecture of other infectious diseases [44], malaria
protection trait might largely be attributed to few rare
variants of large effect sizes. In this case, the GWASs are
underpowered as rare variants might not be in LD with
common variants. Third, malaria protection trait might
be mainly under polygenic and epistatic control [1, 7,
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45] which the conventional GWAS approach can’t
capture.
Biology of the novel variants identified by severe P.
falciparum malaria GWASs
Severe malaria GWASs have replicated some of the well-
known variants such as HbS and ABO blood groups and
few novel variants related to red blood cell membrane
biology which reinforce the importance of erythrocyte var-
iants for protection against severe malaria. Besides, the
GWASs have identified notable novel association vari-
ants in immune and other pathways that may directly or
indirectly influence the disease outcome. The epidemi-
ology and biology of the well-known variants were
reviewed else-where [1]. Below we characterize the novel
malaria susceptibility genetic variants identified by
GWASs. We first discuss the biology of two variants such
as cluster of the glycophorin genes (GYPA/B/E) and
ATP2B4 that were well-replicated across malaria endemic
populations. We then extend our discussion to other
novel variants.
ATP2B4
The association of variants in ATP2B4 gene with severe
malaria susceptibility was reported by Timmann et al.
[11] in Ghanaian populations and replicated in subse-
quent studies in other populations [12, 46]. SNPs in this
locus were also linked with reduction of mean corpuscu-
lar hemoglobin concentration (MCHC) level [47].
ATP2B4 encodes a ubiquitous plasma membrane cal-
cium-transporting protein (PMCA4b) [48]. PMCA4b is
widely expressed in different tissues and is the main
transporter of Ca2+ in erythrocyte membrane [48].
A recent study showed that the GWAS SNPs are local-
ized in a previously unrecognized ATP2B4 haplotype
named as ‘haplotype-1' and individuals with this haplo-
type exhibit a reduced PMCA4b expression level [49]. In
this study, it was also shown that the reduction of
PMCA4b expression significantly decreases the calcium
extrusion in RBCs. Consistent with this, a study con-
ducted by Lessard et al. and colleagues elegantly charac-
terized the ATP2B4 locus using a combination of
transcriptomic, epigenomic and gene-editing study ap-
proaches [50]. The authors first undertook knock out
experiment and demonstrated that ATP2B4 knocked-out
mice express an elevated level of MCHC. Then, they
conducted expression quantitative trait locus (eQTL)
mapping studies using UK biobank dataset and
showed strong associations between ATP2B4 erythro-
blast specific variants and RBC related traits including
MCHC level, decreased RBC distribution and in-
creased hemoglobin levels.
Further analysis of DNase I hypersensitivity sites
(DHSs) at ATP2B4 and eQTL mapping showed that the
GWAS SNPs are mapped to an erythroid specific enhan-
cer element. Deletion of this enhancer from human
erythroid cell line using CRISPR-Cas9 system showed a
dose dependent reduction of ATP2B4 expression level.
Bi-allelic deletion of the enhancer resulted in eighty
three percent reduction of ATP2B4 expression level
compared to the wild type while mono-allelic deletion
resulted in moderate reduction of the ATP2B4 expres-
sion level [50].
To determine the effects of the regulatory variants at
ATP2B4 gene on calcium homeostasis, Lessard et al.
measured the calcium concentration in unedited and
edited (ATP2B4 enhancer deleted) HUDEP-2 cells. The
edited cells demonstrated higher intracellular calcium
level compared to wild cells indicating that ATP2B4 ex-
pression is essential for plasma membrane calcium
pump. The disturbance of intracellular Ca2+ homeostasis
might play an important role in impairing the invasion,
development and reproduction of malaria parasite in
RBCs [51, 52]. Therefore, ATP2B4 region can potentially
be targeted for development of vaccine and therapeutics.
Cluster of the 3 glycophorin genes (GYPA/B/E)
The largest multi-center malaria susceptibility GWAS
which included eleven populations was conducted by
Band et al. [12]. In this study, 34 genomic regions con-
taining potential susceptibility loci for severe malaria
were identified. Among which, a strong signal was ob-
served at locus between FREM3 gene and cluster of 3
glycophorin genes (GYPA/B/E) on Chromosome 4. A
haplotype (at SNP rs184895969) within this region was
reported to reduce the risk of developing severe malaria
by about 40% and is common in Kenyan populations
with allele frequency reaching 10% [12].
A subsequent study in the same populations identified
a large number of copy number variants which are char-
acterized by deletion, duplications and hybrid structures
in GYPA and GYPB genes [53]. Of which a distinct vari-
ant called DUP4 was reported to reduce the risk of se-
vere malaria by about 40% in eastern African (Kenya)
populations. Further characterization showed that, this
variant is composed of complex GYPB-A hybrid and en-
code Dantu antigen in MNS blood group system [53].
The association of this region with severe malaria was
supported by another recent case control study in Tan-
zanian populations [54]. The glycophorin gene cluster,
GYPA and GYPB encode the MNS blood group system
and are known to be receptors for P. falciparum during
RBC invasion [55]. GYPA and GYPB serve as an erythro-
cyte membrane receptor for EBA-175 and EBL-1 pro-
teins of the parasite respectively [56]. This genomic
region is also known to be under an ancient selective
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pressure resulted from host-pathogen arm races between
P.falciparum and humans [57] . Further functional ana-
lysis is required to better understand how these variants
affect the invasion and/or development of the parasites
in erythrocytes and convey protection against severe
malaria.
SCO1 and DDC
Notable association signals were identified by the first
malaria susceptibility GWAS conducted in Gambian
population [10]. The first lead SNP (rs6503319) is lo-
cated close to SCO1 (synthesis of cytochrome c oxidase)
gene on chromosome 17p13. SCO1 is a multi-functional
signaling protein which plays an essential role in mito-
chondrial cytochrome c oxidase (COX) copper delivery
pathways [58]. COX catalyzes electron transfer from re-
duced cytochrome c to oxygen and is abundantly
expressed in muscles, brain and liver [58]. Deficiency of
COX caused by mutations in SCO1 gene can lead to re-
spiratory distress and severe metabolic acidosis [59]
which are also the major complications during cerebral
malaria [60]. Further studies are needed to understand
how the variants in SCO1 gene are associated with the
pathological pathways of cerebral malaria.
The second notable association signal identified in this
study was Dihydroxypheny-alanine decarboxylase (DDC)
on Chromosome 7p12.2. A recent study in Tanzanian
populations replicated the association of DDC variants
with cerebral malaria [54]. DDC gene encodes Aromatic-
L-amino-acid decarboxlase enzyme which is involved in
biosynthesis of neurotransmitters such as dopamine and
serotonin [61]. DDC is an essential enzyme for brain and
nervous developments and its deficiency is associated
with reduced cognitive functions [61]. DDC is involved
in cellular immunity and contributes in protection
against parasitic disease in invertebrates [62]. Further-
more, mutations in DDC gene was reported to be associ-
ated with refractoriness of Anopheles gambiae mosquito
against P.falciparum parasites [63]
MARVELD3
In addition to the ATP2B4, Timmann et al. [11] identi-
fied an association SNP (rs2334880) on chromosome
16p 22.2 which is linked to MARVELD3. However, this
association has not been replicated in other studies.
MARVELD3 is one of the components of tight junction
proteins in several epithelial and endothelial tissues and
is expressed as two alternative spliced variants [64].
These proteins are involved in assembly, development,
maintenances and regulations of tight junction. Tight
junctions play a major role in intracellular adhesions and
involved in sub-cellular signaling mechanisms [64].
IL-12 receptors and IL-23 receptors
The most recent malaria susceptibility GWAS was con-
ducted in Tanzanian population [13]. In this study, not-
able associations signals were identified in immune
pathways including in interleukin receptors (IL-23R and
IL-12RBR2), in ketch-like proteins (KLHL3) and Human
Leucocyte Antigen (HLA) regions. Interleukin-12 is
formed from a hetrodimer of IL12B (ILp40 subunit) and
IL-12A (ILp35 subunit) [65]. IL-12 plays a vital role in
stimulating cell-mediated immune responses against
intra-cellular pathogens through binding to high affinity
IL-12RB1 and IL-12RBR2 receptor complexes. It pro-
motes the development of T-helper cells (Th1) and en-
hances the production of INF-!, both of which are
known to mediate the clearance of intracellular patho-
gens [65]. In malaria, IL-12 has been implicated in medi-
ating the protective immunity both in experimental
animals and in humans [66] . IL-23 is an important pro-
inflammatory cytokine that shares p40 subunits with
IL12 [67]. It induces the differentiation of naive CD4 T-
cells to IL-17 which plays key roles in pathogenesis of
autoimmune diseases [68].
HLA is encoded by the Major Histocompatibility
Complex (MHC), the most polymorphic genes known
in human genome. The diversity of MHC is believed to
be driven by selection pressure from infectious patho-
gens and known to be associated with the risk of sev-
eral infectious diseases [69]. HLA variants such as HLA
class I antigen (HLA-Bw53) and HLA class II variant
(DRB1*1302-DQB1*0501) were reported to confer pro-
tections against severe malaria in Gambian populations
[69]. HLA class I antigen is expressed by liver cells sug-
gesting that T cells (CTL) responses might efficiently
act against the liver stage of malaria parasite in individ-
uals with HLA-Bw53 [69]. On the other hand, individ-
uals with DRB1*1302-DQB1*0501 variant might possess
efficient antigen presentation mechanism that can lead
to rapid clearance of blood stage parasites [69].
Variants in immune pathways are of great interest be-
cause of their potential to inform the development of ef-
fective malaria vaccines [1]. The current study is
interesting in that several putative variants in immune
pathways were identified. However, the power of this
study is limited because of relatively smaller sample size
and weak significance threshold used to interpret the
findings. Therefore, further studies with higher detective
power are needed to consolidate the findings (Table 1).
Polygenic genetic architecture and epistasis: Presenting
the absent in the current severe malaria GWASs
Polygenic genetic architecture
Polygenic view of genetic architecture is gaining ground
in genetic epidemiological studies and widely implicated
for the ‘missing’ of heritability in GWAS analysis [70] .
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The rationale behind polygenic inheritance is that com-
plex-traits/diseases are influenced by multiple variants
with modest effects that are too small to pass the strin-
gent genome wide significance threshold [71]. In stand-
ard GWAS analysis, ‘Genomic control’ (GC) method is
applied as a quality-control measure to minimize spuri-
ous associations that can be caused by population struc-
tures such as population stratification and cryptic
relatedness.
However, a slight inflation of the test statistics (true but
weak signals) which cannot be corrected by GC was ini-
tially observed across the genome in a Schizophrenia
GWAS [72]. Subsequently, this observation has been sup-
ported by other studies [73] and led to the development of
a number of statistical tools aiming to capture polygenic
signals at genome-wide scale including 1) polygenic scor-
ing method implemented in PLINK software [74] ; 2)
Mixed Linear Models (MLM) such as: GCTA [73], BOLT-
LMM [75] , Bayes-R [76] and LDAK [77, 78], PCGC [79]
3) linkage-disequilibrium (LD) score regression method
[80] among others.
Polygenic contributions in malaria susceptibility and
resistance
Co-evolution of host-pathogen model predicts that
multiple host loci are involved in resistance/suscepti-
bility to infectious diseases due to the complex
interactions between the multi-locus parasite geno-
type and the corresponding defense from the host-
genome [42, 81]. Indeed, malaria might have left
multiple genetic variants; the majority of which have
effects too small to be detected by the standard
GWASs. The existence of polygenic inheritance in
malaria protection was predicted by several authors
Table 1 Summary of the novel severe malaria susceptibility and resistance association variants identified by GWASs






















Nearest gene name Chr Position SNP ID
(Ref/Alt)
MOI OR p-value OR P-value OR P-value OR P-value
ATP2B4 01 203658471 rs 4951377 (A/G) DO – – – – – 3.1x10!9 – –
203654024 rs 10900585(T/G) AD – – 0.61 1.9 ! 10!10 – – – –
203660781 rs4951074(G/A) AD – – 0.62 1.3 ! 10!9 – – – –
IL23R, IL12RB 01 67,731,614 rs6682413(!) RE – – – – – – 0.48 8 ! 10!7
GYP A/B/E and FREM3 04 143777125 rs184895969(A/C) DO – – – – 0.67 9.5 ! 10!11 - -
C4orf17 04 100429757 rs73832816(!) REC – – – – – – 0.29 3.8 ! 10! 7
AF146191.4–004 (lincRNA) 04 90717704 rs114169033(!) AD - - - - - - 3.32 6.7 ! 10!7
AC108142.1 (antisense) 04 82822332 rs1878468 HET - - - - - - 0.383 9.0 ! 10!7
Intergenic 05 43,909,343 rs113449872(!) HET – – – – – 0.35 2.2 ! 10!8
KLHL3, MYOT 05 37,011,761 rs2967790(!) AD – – – – – – 0.60 5.9 ! 10!7
TREML4 06 41,205,690 rs9296359 (!) HET – – – – – – 4.08 1.2 ! 10!7
DDC 07 50,623,201 rs10249420(C/G) AD 0.69 6.8 ! 10!5 – – – – – –
rs1451375(!) DO 0.75 6.1x10!6 – – – – – –
Intergenic 07 53,676,837 rs17624383(!) AD – – – – – – – 5.6 ! 10!7
CSMD1 08 4754838 rs73505850(!) AD – – – – – 4.79 5.9 ! 10! 7
LINC00944 12 127237620 rs11335470 (!) HET – – – – – – 0.40 2.5 ! 10!7
Intergenic 11 130,417,522 rs3133394 AD 0.5 9.4X10!7
FAM155A 13 108228013 rs144312179(!) AD – – – – – – 0.2 6.2 ! 10!7
MARVELD3 16 71,653,637 rs2334880 (T/C) AD – – 1.19 1.9 ! 10!6 – – – –
SOC1 17 10,573,909 rs65033119(!) AD 1.21 7.2 ! 10!7 – – – – – –
Intergenic (LINC00670) 17 12,399,526 rs149085856(!) AD – – – – – – 3.87 2.1x10!7
ZNF536 19 1,069,639 rs8109875(!) REC – – – – – – 0.5 5.7 ! 10!7
MIO Mode of inheritance, AD Additive, HET Heterozygous, DO Dominant, REC Recessive, OR Odd-ratio, Ref Reference allele, Alt Alternative allele, Pop Population
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[1, 7] and supported by the GWASs. For instance,
the largest malaria susceptibility GWAS so far, iden-
tified 34 regions of the genome containing variants
with evidence of associations [12]. Earlier GWAS in
Ghanaian population identified 40 genomic regions
containing 102 SNPs with evidences of association in
the discovery phase of the study [11]. The recent
GWAS in Tanzanian populations [13] identified 2322
SNPs at several regions across the genome.
Thus, implementation of polygenic analytic methods
in malaria studies may potentially shed more light to the
underlying biology. For instance, heritability can be esti-
mated and partitioned in to different cell-types and
functional groups and molecular pathways which enable
to localize causal variants. Furthermore, these ap-
proaches can be extended to explore the genetic correla-
tions between susceptibility to malaria and
susceptibility to other infectious diseases. The existence
of shared genetic basis between infectious diseases sus-
ceptibility/protection is well-documented [82]. However,
the extent and pattern of these correlations have not
been systematically investigated at genome-wide scale;
partly because of inadequate GWAS data for infectious
diseases. Such studies can potentially provide clues to
common molecular processes between resistance/sus-
ceptibility to infectious diseases that will have practical
importance including designing multi-purpose vaccine
and genetic risk prediction strategies.
Heritability of severe malaria in Gambian population
To figure out how polygenic analysis can be implemented
in malaria susceptibility, we accessed the Gambian malaria
susceptibility GWAS dataset from European Phenome
Genome Archive (EGA) through data application proced-
ure and estimated heritability of malaria susceptibility using
MLM approaches. The Gambian GWAS data is the
largest MalariaGen dataset obtained from a single
country comprised of 4920 samples (2429 cases and
2491controls) and 1.6 million SNPs that passed
GWAS quality control (QC). We first excluded the
known malaria susceptibility associated loci and per-
formed stepwise extra QC filtering. Specifically, we fo-
cused on sample relatedness, SNP missingness
proportion and SNP differential missing proportion
which are well-known to affect the accuracy of herit-
ability estimation [78]. We then estimated the herit-
ability using GCTA model for different QC thresholds
by including 10 principal components (PCs) as fixed
effects to account for population structure. As ex-
pected, the estimation was unstable when less strin-
gent QC thresholds is applied (varying from 37.8 to
20.1%) as shown in Table 2. However, when more
stringent QC (Relatedness threshold (5%), SNP differ-
ential missingness proportion (p < 1 ! 10 ! 3) and
SNPs missing proportion of (p > 0.02)) was applied,
the estimation became stable (~ 20.1%, SE = .05). Nei-
ther the inclusion of more PCs (15, 20) as fixed ef-
fects nor SNP phasing further brought down the
estimate. Using the same stringent QC threshold, the
estimation was approximately the same for Mandinka
ethnic group (~ 24.3%, SE = 0.6). We couldn’t estimate
for other ethnic groups because of smaller sample
sizes. Furthermore, the use of PCGC model which is
designed for case/control approximately showed the
same estimate (19.8%, SE = .07).
Although our heritability estimation is fairly stable
when stringent QC is implemented, care should be taken
in interpreting these results: First, all polygenic methods
perform better in less structured data obtained from
homogenous populations than the MalariaGen dataset
which is comprised of diverse populations spanning
most of the Malaria endemic belt in Africa. Second, the
methods are designed and perform well in highly poly-
genic traits/diseases in which effects of each variant is






















Gambia – 5% – 1% 10 4920 1627656 37.8(.05).
5% 5% 1 ! 10!10 1% 10 4128 1627656 30.5(.05)
5% 5% 1x10! 5 1% 10 4128 1607610 28.7(.05)
5% 5% 1 ! 10!3 1% 10 4128 1570344 25.1(.05)
5% 2% 1 ! 10! 3 1% 10 4128 1486554 20.1(.05) 19.8(.07)
5% 2% 1 ! 10!3 1% 15 4128 1486554 22.5(.05)
5% 2% 1x10!3 1% 20 4128 1486554 19.5(.05)
Phased – – 1% 10 4128 1627656 20.4(.06)
Mandinka 5% 2% 1x10!3 1% 10 1281 1486554 24.2(0.6)
GCTA Genome Complex Trait Analysis, PCGC Phenotype Correlation Genotype Correlation regression
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mostly modest. In contrast, a considerable proportion of
malaria protection trait might be attributed to rare vari-
ants of large effect sizes that might not be in LD with
common variants and can’t not be ‘tagged’ by SNPs chip
which means that the contributions of such variants will
not be accounted for. Third, subtle population structure
that cannot be corrected by conventional methods such
as unmatched case/control can potentially create sys-
tematic biases to the estimates.
Epistasis
Epistasis is becoming one of the hot research topics in
genetic epidemiological studies in the last few years be-
cause of the fact that none additive genetic variations
are shown to have significant influence on the phenotype
of complex traits/diseases than previously expected [83].
The available statistical approaches and software pack-
ages for detection of epistasis at genome-wide scale were
reviewed elsewhere [83, 84]. These approaches have
been applied in genetic studies of complex diseases such
as lupus erythematosus [85], anklosing spondlylitis [86],
psiorosis [87] and unraveled previously unknown epista-
sis interactions between risk loci which explained a sig-
nificant proportion of ‘missing’ heritability of the
respective diseases.
Epistasis between malaria risk loci have been well docu-
mented and implicated as one of the possible reasons for
lack of replication of susceptibility variants in different
populations and the ‘missing’ heritability. For instance,
sickle-cell trait (HbS) and ! thalassaemia were shown to
demonstrate negative epistatic interactions such that the
protection against severe malaria offered by HbS is re-
duced when co-inherited with !+ thalassaemia [88].
A case-control study in Kenyan population also reported
that !+ thalassaemia modulates the effects of Haptoglobin
(Hp) variants in predicting the risk of severe malaria [89].
In this study, it was shown that the combination of !+
thalassaemia and Hp2–1 variant synergistically increase
the protection against severe malaria by about 37%. How-
ever, the protective effect is decreased to 13% when ! +
thalassaemia is inherited with Hp1–1 and further dimin-
ished to neutral (zero) when inherited with Hp2–2. Simi-
larly, in a multi-center case control study, the existence of
negative epistasis interaction between HbC and ATP2B al-
leles was reported [15].
Another recent case control study of severe malaria
in Kenya reported the existence of negative epistasis
between a compliment receptor called S12 and
!+thalassaemia in which the protective effect of S12
higher in children with normal !-globin [90]. The ex-
tent and pattern of epistatic interaction at genome-
wide scale is yet to be explored. In malaria suscepti-
bility GWAS, the priority has been given to a single
locus analysis to identify novel risk loci. We expect
that, the next step of malaria susceptibility GWAS
will include the investigations of epistasis at genome-
wide scale.
From GWAS to biology: multi-step and multi-dimensional
analyses
Fine-mapping and pathway analyses
The ultimate goal of genetic susceptibility studies is to
identify causal variants and understand the underlying
biological pathways which can lead to translated medicine
such as effective vaccines and therapeutics. However,
translating GWAS signals in to biological themes remains
an open problem because of the confounding effects from
LD between association SNPs, limited knowledge of gene
functions and localization of the majority of GWASs hits
in none protein coding regulatory regions (regulatory
SNPs) [91–93]. In attempt to address this challenge, sev-
eral fine mapping strategies have been developed and im-
plemented [94]. One such strategy is trans-ethnic fine
mapping in which the natural variability of haplotype
structure across ethnically diverse populations is used to
narrow down candidate causative variants [95]. The
smaller LD and diversity of haplotype structure in African
population makes it relatively easier to identify the causal
SNPs and target gene/genes through fine mapping ap-
proaches [8]. However, the fact that malaria protective al-
leles are heterogeneous across populations might
challenge the application of trans-ethnic fine-mapping ap-
proaches in malaria susceptibility studies.
Alternatively, several fine mapping statistical tools
have recently been developed following the advances in
annotation data bases and improved reference panels.
These include Bayesian approach, heuristic approach
and penalized regression methods [96]. The principles,
applications, strength and weakness of these methods is
reviewed elsewhere [94, 96]. These methods are increas-
ingly playing crucial role in the efforts being made to
pinpoint causal variants of complex diseases/traits. For
instance, Galarneau et al. [97] identified novel independ-
ent association signals by fine-mapping three loci that
are known to influence fetal hemoglobin (HbF) levels.
The authors sequenced the three loci (BCL11A, "-globin
and HBS1L-MYB), undertook dense genotyping, per-
formed step-wise conditional analysis and revealed pre-
viously un-recognized SNPs that explain additional
genetic variation. Similarly, a recent fine mapping study
of HLA region identified several susceptibility loci for
multiple infectious diseases [82]. More sophisticated
studies that combine statistical and functional fine-map-
ping strategies have recently been implemented and pro-
vided mechanistic insights to the genetic basis of
complex diseases [98].
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In addition to fine mapping approaches, pathway and
interaction analysis can be another avenue for exploring
molecular basis of Malaria susceptibility/resistance. Instead
of emphasizing on single-variant analysis, these approaches
test the coordinated effects of several variants at systems
level using biological information from annotation data
basis [99]. Pathway analysis improve study power by inte-
grating cumulative effects of weak association signals and
provide functional information by identifying associated
sets of genes/proteins [100]. By implementing the pathway
analysis approaches, several studies have gained new in-
sights in understanding the genetic basis of complex dis-
eases [101–103]. The available statistical tools for pathway
and interaction analysis is reviewed in [104]. We therefore,
advocate for the implementation of fine mapping and path-
way analytic methods in malaria susceptibility studies to
shed more light in to the underlying biology.
Epigenomics and Epigenome wide association studies
Epigenetics refers to heritable phenotype changes that
do not involve alterations in the DNA sequences such as
methylation, post-translational histone modification, his-
tone variation, chromatin remodelling and non-coding
RNAs [105]. Epigenetic impacts have recently been im-
plicated in malaria susceptibility and resistance [106,
107]. For instance, in a recent study, strong transcrip-
tional response was detected in monocytes of P. falcip-
arum infected individuals from Fulani, an ethnic group
that is less susceptible to malaria [107]. The authors sug-
gested that, this response is likely regulated by genome
wide chromatin alterations. The discussion on the pos-
sible mechanisms of epigenetic impacts on malaria sus-
ceptibility and resistance is beyond the scope of this
paper and is reviewed in [108].
However, the majorities of epigenetic studies including
those of malaria susceptibility and resistance have been
limited to either small sample sizes or inadequate gen-
ome coverage and thus, lack adequate power to decipher
the epigenetic impacts on complex diseases [105]. In ef-
fort to address this challenge, investigators recently de-
veloped a large-scale, systematic epigenomic equivalents
of GWAS called epigenome-wide association studies
(EWAS) that attempts to uncover epigenetic variants
underlying common diseases/phenotype using genome-
wide technologies such as Illumina 450 K array [109].
EWA approach recently gains a considerable attention
partly due to the fact that the majorities of the GWAS
SNPs are mapped to none coding regions of the genome
implying that the variant SNPs cause changes in gene
expression levels rather than causing changes in protein
function [109]. Thus, combining both genetic (GWA)
and epigenetic (EWA) approaches in parallel may prove
a fruitful approach for understanding mechanisms of
disease risk [109]. Undoubtedly, application of such
approaches may shed new light into mechanisms of mal-
aria susceptibility and protection.
Multi-omics approaches
Today, there are significant advances in high throughput
technologies that can generate big ‘-omic’ data from all
spectrum of molecular biology [91]. The ‘-omics’ studies
(Genomics, Epigenomics, Transcriptomics, Proteomics,
Metabolomics) are crucial to understand the underpin-
ning biology of complex diseases. In severe malaria,
‘-omics’ studies have provided important clues about the
molecular events that lead to either complications or re-
covery from diseases. For instance, following the discov-
ery of glycophorin regions by the GWAS, a whole
genome sequencing-based study [53] was conducted to
characterize variants in this region and identified a novel
distinct copy number variant called DUP4 which reduces
the risk of severe malaria by about 33% . In addition to
this, a genome-wide gene expression study was con-
ducted in Kenyan children and reported increased ex-
pression of genes related to neutrophil activation during
malaria infections [110]. The authors also observed dif-
ferential expression of heme- and erythrocytes-related
genes in acute malaria patients which reaffirms the im-
portance of erythrocyte-related genes in malaria suscep-
tibility and resistance.
In another host-parasite interaction study, the import-
ance of miRNA in inhibiting parasite growth in erythro-
cyte was reported [111]. The authors observed
translocation of several host RBC miRNAs in to P.
falciparum parasites, as well as fusion of these human
miRNAs with parasite mRNA transcripts to inhibit the
translation of enzymes that are vital for the parasite de-
velopment. Specifically, two micro-RNAs, miRNA-451
and let-7i, were highly enriched in HbAS and HbSS
erythrocytes and these miRNAS along with miR-223
were shown to attenuate the growth of parasite [111].
However, ‘-omics’ studies are limited to single data-
type analysis and lack adequate power to explain the
complexity of molecular processes and usually lead to
identification of correlations than causations [112].
Thus, integrating and analysing multiple ‘-omics’ data
enables better understanding of the molecular processes
and interactions that give rise to complex diseases/traits.
For example, leveraging host microbiome relative abun-
dance data as a second (quantitative) trait, and perform-
ing a joint analysis of bivariate phenotypes can increase
statistical power by maximizing phenotypic information
and inform how the interaction between host genotype
with microbiome impacts the phenotype.
Multi-omics approaches aim to integrate big ‘-omics’
data, undertake ‘multi-step’ and ‘multidimensional’ ana-
lysis for elucidating complex biological problems [112] .
Driven by the massive abundance of ‘-omics’ data from
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wide ranges of biological molecules, multi-omics strategy
have recently provided unprecedented successes in com-
plex diseases/trait studies. The current state of art of
multi-omics approach and available statistical methods
is recently reviewed in Hasin et al. [112]
Malaria susceptibility and resistance is influenced by
several host, parasite and environmental factors as
depicted in Fig. 1. The protective alleles have inde-
pendently evolved in different populations being
shaped by the co-evolution and interaction between
the human genome, the parasite and the environment
[1]. Thus far, single ‘-omics’ data analysis enabled us
to understand some of the factors that are associated
with the malaria protective traits. To progress beyond
associations and pinpoint the causal pathways, it may
require to implement carefully designed, coordinated
multi-omics studies that involve human host, the
parasite, the environment and possibly mosquito. The
current advents of high-throughput technologies in
generating massive ‘-omics’ data and their continu-
ously decreasing cost complemented with the avail-
ability of statistical tools which able to simultaneously
capture millions of data points will lead to the
implementations of multi-omics approaches in malaria
susceptibility studies.
Conclusions and perspectives
The ultimate goal of malaria susceptibility study is to
discover a novel causal biological pathway that provide
protections against severe malaria; a fundamental step
towards translational medicine such as development of
vaccine and new therapeutics that can facilitate the glo-
bal malaria eradication efforts. To achieve this goal, vari-
ous study approaches have been implemented at least
for the last three decades and successfully identified sev-
eral association variants.
Recently, a number of GWASs have been implemented
in malaria endemic areas to better understand the
underlying biology. While some of the well-known vari-
ants were replicated, only few novel variants were con-
vincingly identified and their biological functions
remains to be understood. Several limiting factors in-
cluding genetic diversity of population in malaria en-
demic areas, allelic heterogeneity of protective variants,
small sample sizes, lack of proper reference panel and
Fig. 1 Schematic representation of the integrative analyses. Systems biology approach which incorporate multiple layers of information from host
(multi-omics), the environment and parasite genetic factors can potentially lead to the discovery of malaria protective pathways
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proper genotyping chips might have negatively impacted
the malaria GWASs.
Another challenge is that we don’t know much
about the genetic architecture of malaria protective
trait. There are at least two scenarios in which
GWAS approach might fail; First, malaria protective
trait might largely be attributed to rare variants of
large effect sizes that might not be in LD with com-
mon variants and can’t be captured by the GWAS
approach. Second, malaria might have left multiple
genetic variants distributed across human genome;
the majority of which have effects too small to be
detected by the standard GWASs [1, 7]. Theoretic-
ally, the large sample sizes, dense genotyping chips
or whole genome sequencing, use of appropriate ref-
erence panels and effective genotype imputation can
address the majority of the challenges. However,
given the resource constraints; especially, in Africa
where malaria problem is the greatest, this will likely
take several years to achieve.
On the other hand, the recent advances in statistical
techniques is enabling to extract useful information
from the present-day GWAS sample sizes. For ex-
ample, a number of statistical approaches have been
developed to capture polygenicity in complex diseases.
We showed how these methods can potentially be
implemented in malaria susceptibility studies and pro-
vide useful insights. We believe that further studies
with larger sample sizes can elucidate the polygenic
effects in malaria protective trait by extending the
analysis to genome partitioning, risk prediction and
genetic correlations.
Beyond singe locus analysis, multi-step and multi-
locus analyses including pathway analysis, fine mapping
and interaction analysis can potentially be implemented
in malaria susceptibility GWASs to gain new insights to
the underpinning biology. For instance, pathway analysis
can provide important information by analyzing the co-
ordinated effects of several variants at systems level
using biological information from annotation databases.
Methods that combine statistical and functional fine-
mapping strategies can potentially be implemented to
pinpoint the causal variants from the GWAS association
signals.
Most importantly, the future direction of malaria sus-
ceptibility requires a paradigm shift from single ‘-omics’
to multi-stage and multi-dimensional integrative func-
tional studies that combines multiple data types from
the human host, the parasite, the mosquitoes and the
environment. The current biotechnological advances, an
ever-increasing annotation data bases and availability of
advanced analytical techniques, will eventually lead to
feasibility of systems biology studies and revolutionize
malaria research.
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In this chapter, we investigated the polygenic effects of severe malaria trait in three African 
populations including Gambia, Kenya and Malawi. We estimated SNP-heritability (h2g) of 
severe malaria resistance from genotype GWAS dataset and determined its distribution across 
the genome including allele frequency spectrum, chromosomes and genomic annotations. In 
addition to the direct estimation from the raw genotype, we performed various functional 
enrichment analysis from GWAS-summary statistics meta-analysed across the three 
populations using stratified linkage disequilibrium score regression (LDSC) method. The 
LDSC approach require population specific reference panel to produce reliable results making 
it difficult to apply in African populations which have been poorly represented in public 
reference domain. 
 In effort to address this challenge, we prepared African population specific reference panel 
and computed the LD scores. By using LD information from the prepared panel, we estimated 
the univariate h2g and partitioned it in to cell-specific and nonspecific functional categories. 
We estimated the h2g estimated at 0.21 (se = 0.05, P = 2.7 × 10−5), 0.20 (se = 0.05, P = 7.5 × 
10−5) and 0.17 (se = 0.05, P = 7.2 × 10−4) in Gambian, Kenyan and Malawi populations, 
respectively. A comparable range of h2g [0.21 (se = 0.02, P < 1 × 10−5)] was estimated from 
GWAS-summary statistics meta-analysed across the three populations.  We showed for the that 
the h2g of malaria resistance is largely ascribed by common SNPs and the causal variants are 
overrepresented in protein coding regions of the genome. Our African population specific 
reference panel can potentially be used in other LD-based analyses involving African 
populations.  Our current SNP-heritability estimates were roughly close to a report from a 
previous family-based study. This might be due to the fact that the previous study 
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Abstract
Background: Estimating single nucleotide polymorphism (SNP)-heritability (h2g) of severe malaria resistance and its
distribution across the genome might shed new light in to the underlying biology. Method: We investigated h2g of severe
malaria resistance from a genome-wide association study (GWAS) dataset (sample size = 11 657). We estimated the h2g and
partitioned in to chromosomes, allele frequencies and annotations using the genetic relationship-matrix restricted
maximum likelihood approach. We further examined non-cell type-specific and cell type-specific enrichments from
GWAS-summary statistics. Results: The h2g of severe malaria resistance was estimated at 0.21 (se = 0.05, P = 2.7 " 10#5), 0.20
(se = 0.05, P = 7.5 " 10#5) and 0.17 (se = 0.05, P = 7.2 " 10#4) in Gambian, Kenyan and Malawi populations, respectively. A
comparable range of h2g [0.21 (se = 0.02, P < 1 " 10#5)] was estimated from GWAS-summary statistics meta-analysed across
the three populations. Partitioning analysis from raw genotype data showed significant enrichment of h2g in genic SNPs
while summary statistics analysis suggests evidences of enrichment in multiple categories. Supporting the polygenic
inheritance, the h2g of severe malaria resistance is distributed across the chromosomes and allelic frequency spectrum.
However, the h2g is disproportionately concentrated on three chromosomes (chr 5, 11 and 20), suggesting cost-effectiveness
of targeting these chromosomes in future malaria genomic sequencing studies. Conclusion: We report for the first time that
the heritability of malaria resistance is largely ascribed by common SNPs and the causal variants are overrepresented in
protein coding regions of the genome. Further studies with larger sample sizes are needed to better understand the
underpinning genetics of severe malaria resistance.
Introduction
In spite of the global eradication efforts, malaria remains a
major global public health problem with 219 million cases and
435 000 deaths in 2017 (1). Plasmodium falciparum malaria results
in diverse clinical manifestations ranging from asymptomatic
parasitaemia to severe malaria (2). Such a wide variation of
clinical outcome is attributed to several factors including genetic
factors of the host, virulence of parasite and environmental
factors (2). Family studies reported that the host genetic factors
(heritability) contributes !25% of the variations observed in
clinical severity of malaria in endemic populations (3). Thus,
understanding the molecular basis of the natural immunity
against severe malaria will speed up the development of an
efficient malaria vaccine.
Driven by the wide availability of genome-wide single
nucleotide polymorphism (SNP) arrays, the focus of genetic
studies has been shifted from the traditional candidate gene and
family-based linkage studies to GWASs. However, only a small
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significant SNPs. This led to a problem commonly termed as
‘missing heritability’ (4). In effort to address this problem, several
statistical methods that aim at quantifying SNP-heritability
without identifying the causal variants were developed (5–7).
Packages such as the genome-wide complex trait analysis
(GCTA) implement genetic relationship-matrix restricted maxi-
mum likelihood (GREML) method in which all SNPs of unrelated
subjects are simultaneously analysed in a linear mixed model
framework to estimate the proportion of phenotypic variations
explained by genotypic variation (5). Apart from GREML
approaches, Golan et al. (7) recently introduced a regression
method called phenotype-correlation-genotype-correlation
(PCGC) for estimation of heritability from case-control datasets.
PCGC is a Haseman–Elston regression model in which a
normalized phenotype is regressed on the genetic covariances
of all unique pair of samples. The slope of the regression is
used as an estimator of h2g. Application of these methods
provided new insights in to the genetic architecture of complex
diseases including autism, schizophrenia, Parkinson’s disease,
type 2 diabetes, hypertension among others (8–13). Alternative
contemporary statistical methods that enable estimation of h2g
from publicly available GWAS-summary statistics without the
need of individual genotype data are also widely available (14–16)
and gained popularity due to their privacy advantages and
computational costs.
Because only unrelated individuals are included, the h2g anal-
ysis offers a greater flexibility of study designs that enable us
to conduct powered studies. The use of only unrelated indi-
viduals also minimizes the biases from shared environments,
one of the greatest challenges in pedigree studies (5). Further-
more, h2g analytic methods allow partitioning of the cumulative
heritability in to different functional categories and biological
pathways and thus, provide more insights in to the underpinning
biology (6,17).
Even though a number of severe malaria GWASs have
recently been implemented in endemic areas in Africa and
reported few novel association variants (18–21), little is known
about the h2g and its distribution across the genome. Here we
present results from a comprehensive h2g study of severe malaria
resistance in three African populations including Gambia,
Kenya and Malawi. We estimated h2g and partitioned in to
chromosomes, different minor allele frequency (MAF) bins,
functional categories and cell types. We found that the h2g is
disproportionately concentrated on three chromosomes (chr
5, 11 and 20) and enriched in the coding region of genome.
Overall, our results suggest that malaria resistance is mainly
under polygenic control.
Results
SNP-heritability estimates from genotype datasets
We estimated h2g at different quality control (QC) levels to deter-
mine the appropriate threshold (see Materials and Methods).
As expected, the estimates were inflated at less stringent QC
thresholds (Supplementary Material, Fig. S1). However, applying
stringent QC protocols including relatedness threshold (5%),
SNP differential missingness proportion (P ! 1 " 10#3) and SNPs
missing proportion (P > 0.02) yielded a more stable ranges
of h2g values that were not affected by the inclusion of
additional principal components (15, 20, 50) as covariates. At
the stringent QC threshold, the h2g of severe malaria resistance
was 0.21 (se = 0.05, P = 2.7 " 10#5), 0.20 (se = 0.05, P = 7.5 " 10#5)
and 0.17 (se = 0.05, P = 7.2 " 10#4) in Gambian, Kenyan and
Malawi populations, respectively (Table 1). These estimates
were approximately similar in Kenya ethnic groups such as
Chonye (0.20, se = 0.07, P = 5.1 " 10#3) and Giriama (0.19, se = 0.07,
P = 7.3 " 10#3). However, the estimate was slightly inflated in
Mandinka ethnic group of Gambia (0.24, se = 0.06, P = 5.1 " 10#5).
We did not estimate h2g for other ethnic groups because of
inadequate sample sizes. Furthermore, the PCGC model yielded
broadly similar results including 0.20, (se = 0.06, P = 9.7 " 10#4),
0.16 (se = 0.06, P = 8 " 10#3) and 0.23 (se = 0.07, P = 1.3 " 10#3) in
Gambia, Kenya and Malawi populations, respectively.
Proportion of SNP-heritability attributable to GWAS loci. To quan-
tify the effects of the known variants, we estimated the h2g with-
out removing the severe malaria GWAS loci from the datasets
(see Materials and Methods). This resulted in slight increment
of the h2g estimate in Gambian [0.27 (se = 0.05, P = 1 " 10#5)]
and Kenyan [0.26 (se = 0.05, P < 1 " 10#5)] populations. Repeating
the GREML analysis by including rs334 as an additional covari-
ate decreased the estimate to [0.24 (se = 0.05, P < 1 " 10#5)] and
[0.23 (se = 5%, P < 1 " 10#5)] in Gambian and Kenyan populations,
respectively. This suggests that the h2g attributable to the GWAS
significant loci and HbS locus is approximately 0.07 and 0.03,
respectively.
Partitioning SNP-heritability by chromosomes, minor allele frequen-
cies and functional annotations. We observed no significant
differences in h2g estimate obtained from separate analysis
(0.24, se = 0.05, P < 1 " 10#5) and the joint analysis (0.22, se = 0.05,
P = 1 " 10#5) (Supplementary Material, Fig. S2), suggesting that
the population structure was adequately controlled. Moreover,
we observed significant correlations between chromosomal
length and h2g per chromosome (Adj r2 = 0.38, P = 0.001) (Fig. 1).
However, the estimates of three chromosomes (chr 5, 11 and
20) and three other chromosomes (chr 7, 8 and 15) fell above
and below the expected h2g at 95% CI, respectively. Notably,
chr5 contained a considerable proportion ($0.035) of the h2g
(Supplementary Material, Table S1).
We performed MAF stratified analysis to estimate the
relative contribution of variants with various allele frequencies
(Fig. 2). However, we did not find significant differences
between the proportion of h2g attributed to different MAF
bins [standards errors overlapped at 95% confidence interval
(CI)]. Moreover, the total sum of our h2g estimate per bin [0.27
(se = 0.08, P = 5.3 " 10#5)] was not significantly different from the
univariate estimate. We further estimated the h2g explained by
genic SNPs and the intergenic SNPs at 0.165 (se = 0.05) and 0.062
(se = 0.05), respectively (Table 2). On average, a SNP residing in
genic region was enriched 2.9" compared to a SNP residing in an
intergenic region of the genome. This is statistically significant
at 95% CI.
Functional enrichment from GWAS-summary statistics
After imputation of severe malaria GWAS-summary statistics
and QC filtering, we obtained a total of 20 million high qual-
ity SNPs (see Materials and Methods). Using this dataset, we
estimated the liability scale h2g at 0.21 (se = 0.02, P < 1 " 10#5).
Partitioning the h2g in to 24 main genomic annotations (base-
line model) showed evidences of enrichment in multiple cat-
egories including 5%UTR (11"), digital genomic footprint (DGF;
10"), enhancer (9"), coding (6"), H3K4me1 (4.9"), TSS (5"), tran-
















170 Human Molecular Genetics, 2020, Vol. 29, No. 1
Table 1. h2g of severe malaria resistance determined by GCTA and PCGC methods
Population SNPs (n) Samples (n) h2 g-GCTA (%) h2 g-PCGC (%)
Gambia 1 513 822 4128 0.20(se = 0.05) 0.20(se = 0.05)
Kenya 1 579 227 2062 0.20(se = 0.05) 0.16 (se = 0.05)
Malawi 1 502 462 2418 0.17(se = 0.05) 0.23(se = 0.06)
Mandinka 1 513 822 1281 0.24 (se = 0.06) ne!
Chonye 1 579 227 637 0.20(se = 0.06) ne!
Giriama 1 579 227 1173 0.19 (se = 0.06) ne!
ne!: Model did not fit because of small sample size and there was no reliable estimation SNP: single nucleotide polymorphisms, h2g-GCTA: h2g estimated using GCTA
method, h2g PCGC: h2g estimated using PCGC method
Figure 1. h2g per chromosome(y-axis) plotted against chromosome length (x-axis). The blue line represents the h2g estimates regressed against chromosome length.
The grey shaded areas represent the 95% CI around the slope of the regression model.





SNPs(n) h2g h2g per SNP
Genic 727 996 0.165(se = 0.05) 2.3 " 10#5
Inter-genic 785 826 0.062(se = 0.05) 7.9 " 10#6
(4") as shown in Figure 3. However, none of the enrichments
was statistically significant after correction for multiple testing.
Further cell-type specific and cell group analysis did not show
significant enrichments.
Discussions
In this study, we estimated the h2g and functional enrichment
of malaria resistance in three African populations and their
meta-analysis. After excluding the severe malaria resistance
GWAS loci, we performed GREML analysis at different QC
levels to determine the appropriate threshold; indeed, the
estimates were inflated upward at less stringent QC levels and
became stable at more stringent QC levels. These estimates
were broadly similar across the three study populations.
Except a slight inflation observed in Mandinka ethnic group
which might have been underpowered because of small
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Figure 2. h2g partitioned in to different allele frequency spectrum. We created six MAF-bins and estimated the proportion of h2g attributed to each bin. The proportion
of h2g attributed to each bin is shown in red bar and the proportion of SNPs per bin is shown by the blue bar. Error bars represent the 95% CI of the estimate.
ethnic groups. Approximately a similar range of h2g of severe
malaria resistance was recently reported (22). This might
suggest that substantial human genetic factors that influence
malaria disease severity have been maintained across endemic
populations. Consistent with our findings, a previous family-
based study reported a similar range of heritability of severe
malaria resistance in two different endemic populations in
Kenya (4).
In contrast to the findings from other complex disease stud-
ies in which h2g is much smaller than family-based heritability
values (23), our current h2g estimates were roughly close to a
report from a previous family-based study (4). This might be due
to the fact that the previous study underestimated the heritabil-
ity estimates: First, only additive genetic effects (narrow-sense
heritability) was calculated i.e. the contributions of nonadditive
effects including epistasis, dominance and gene-gene interac-
tions were not taken in to account. Second, the authors indicated
that their paternity assessment was prone to misclassification,
which might have underestimated the actual narrow-heritability
estimate (4).
In the current study, including GWAS significant SNPs in
the GREML analysis resulted in an increment of the h2g esti-
mates by ! 0.07 in the study populations, suggesting that the h2g
attributable to the known malaria resistance GWAS loci (h2g-GWAS)
is generally small. This is consistent with the hypothesis that
the vast proportion of heritability of complex traits/diseases
is explained by SNPs with effect sizes too small to attain the
stringent genome wide significance threshold (P < 5 " 10#8) at
the current sample sizes (24). Repeating the analysis by including
rs334 as an additional covariate brought down these estimates
by ! 0.03, suggesting that more than a third of the h2g-GWAS is
attributable to the HbS locus. This might be explained by the
fact that the HbS locus has relatively larger effect sizes in the
endemic populations (18).
To gain better insights in to the genetic architecture of severe
malaria resistance, we partitioned the h2g in to different chro-
mosomes, allele frequency spectrum and annotations. Separate
GREML analysis and joint analysis yielded broadly similar h2g
estimates, suggesting that population structure is adequately
controlled. The rationale is that. However, the joint analysis in
which genomic relatedness matrix (GRMs) of all chromosomes
are simultaneously fitted in to a single GREML model, can effec-
tively control the upward biases that can be created by correlated
SNPs on different chromosomes (29).
Supporting the polygenic view of genetic architecture, we
found a correlation between h2g per chromosome and chro-
mosomal lengths (Adj r2 = 0.39, P = 0.001). However, the h2g is
disproportionately concentrated on three chromosomes (chr 5,
11 and 20), suggesting that these chromosomes might contain
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Figure 3. Enrichment estimates of h2g for the 24 main annotations. Error bars represent jackknife standard errors around the estimates of enrichment.
targeting these chromosomes using more powered studies (e.g.
DNA sequencing) might be a cost-effective approach to discover
new severe malaria resistance loci. Previous family-based stud-
ies reported that a region on chr5 (5q31–q33) is associated with
susceptibility to mild malaria (25,26).
MAF-stratified analysis didn’t reveal significant differences
between the proportion of h2g attributed to different MAF bins.
This might assert that h2g of severe malaria resistance is broadly
uniform across the allele frequency spectrum and is not over-
represented by rare alleles. Partitioning by annotation revealed
that the h2g of severe malaria resistance is significantly enriched
in SNPs residing in protein coding regions of the genome, sug-
gesting that further studies focusing on coding regions (e.g.
exome sequencing and/or exome array genotyping) might lead
to the discovery novel variants.
In addition to the direct estimation of h2g from raw genotype
datasets, we performed functional enrichment analysis from
GWAS-summary statistics using stratified linkage disequilib-
rium score regression (LDSC) approach (14). To improve the
performance of the analysis, we created a reference panel that
is more specific to our study populations by merging the African
population datasets obtained from 1000 Genomes Project and
African Genome Variation Project (27). Using this panel, we cre-
ated annotation files and estimated h2g of severe malaria resis-
tance from GWAS-summary statistics meta-analysed across the
study populations.
Our liability scale h2g estimate [0.21 (se = 0.02, P < 1 ! 10"5)]
was comparable to the direct estimates from raw genotype
datasets. However, our functional enrichment analyses did not
reveal significant results. One of the downsides of stratified
LDSC method is that it requires very large sample sizes to
detect significant enrichments (14). Of note, the coding genes
and the surrounding categories were among the top annotations
in our base line model. This further highlights the importance of
protein coding regions of the genome in influencing the malaria
disease severity.
Finally, our study had a number of caveats that might
directly or indirectly affect the accuracy of estimating the true
genetic heritability. First, the controls used in this study were
not screened for mild malaria that might potentially bias the
accuracy of h2g estimates. Second, assumptions of the models
implemented for the analyses might not adequately explain the
true genetic architecture of severe malaria resistance. Third, all
the models implemented here do not measure the variances
attributable to environmental factors. Fourth, the study is
underpowered for the functional enrichment anlyses.
Conclusions
In conclusion, our study showed for the first time that heri-
tability of severe malaria resistance is largely explained by com-
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in protein coding regions of the genome. Consistent with the
polygenic genetic architecture, we observed that the h2g of severe
malaria resistance is distributed across chromosomes and allele
frequency spectrum. However, the h2g is disproportionately con-
centrated on three chromosomes (chr 5, 11 and 20), suggesting
the cost-effectiveness of targeting these chromosomes in future
malaria genomic sequencing studies. In this study, we created
annotation files using population specific reference panel and
showed that stratified LDSC analysis can provide reliable SNP-
heritability estimates in African populations. Further studies
with larger sample sizes are needed to understand the unpin-
ning genetics and biology of severe malaria resistance trait.
Materials and Methods
Description of the study datasets
GWAS datasets of three African populations including Gam-
bia, Kenya and Malawi were obtained from European Phenome
Genome Archive (EGA) through the MalariaGen consortium stan-
dard data access protocols (28,29). The datasets contain infor-
mation about a total of 11 657 samples including 4921 sam-
ples from Gambia (2491 cases and 2430 controls), 3752 samples
from Malawi (3752 cases and 3220 controls) and 2984 samples
from Kenya (1506 cases and 1478 controls). Cases were obtained
from children who were admitted to Hospitals and fulfilled
WHO case definition for severe malaria (29) and controls were
obtained from the general population (18–21). All the samples
were genotyped on Illumina Omni 2.5 M array. Information about
phenotypes, imputation and QC was also provided.
Quality control
The basic QC protocols including plate effects, sample related-
ness, Hardy–Weinberg equilibrium, heterozygosity, missingness
and differential missingness were done as described elsewhere
(18,30). Taking in to consideration that small artifacts can
have substantial cumulative effects in h2g analysis (31), we
applied further stringent QC filtering steps. Briefly, we aligned
the quality filtered VCF files to forward stand of the human
reference sequence (GRCh3) using the illumina supplied files
(www.well.ox.ac.uk/!wrayner/strand) and removed all SNPs
with position and strand mismatches. We further removed SNPs
with MAF below 0.01, deviate from Hardy–Weinberg at P-value
below 0.01 using PLINK software (32). We then implemented
step-wise QC filtering based on SNPs missingness proportion,
differential missingness and sample relatedness as described
in (6).
Estimating heritability from genotype data
We applied GCTA (5) and PCGC (7) models to estimate the
h2g of severe malaria resistance from raw genotype datasets.
Briefly, we excluded the region of extended inversion (7 238 552–
12 442 658) on chromosome 8p23 (33), the major histocompati-
bility complex (MHC) region (25 000 000–40,000,000) on chr 6 and
the known severe malaria resistance loci including the ATP2B4
region on chr1:203 154 024–204 154 024, cluster of glycophorin
(GYPA/B/E) region on chr4:143 000 000–146 000 000, ABO blood
group region on chr9:135 630 000–136 630 000, and the sickle cell
(HbS) region on chr11:2 500 000–6 500 000 to avoid potential biases
from large effects.
We constructed GRMs from pruned high quality independent
autosomal SNPs using GCTA software (5) and obtained list of
samples with relatedness threshold >5%. We then computed
GRMs using all the autosomal SNPs for each cohort and
excluded one of any pair of samples with relatedness threshold
>5% as recommended elsewhere (6). The final sample of
unrelated individuals was 4128, 2062 and 2418 for Gambia,
Kenya and Malawi, respectively. The distribution of off-
diagonal element of the GRMs for each population is shown
in Supplementary Material, Fig. S3.
We used population prevalence of 1% of severe malaria as
previously described in (29) and included the top 10 PCs as
fixed effects in the GREML analysis. We then transformed the
estimates to liability scale as described in Lee et al. (34). Using
the same GRMs, we estimated the h2g using PCGC model as
outlined in Golan et al. (12). We also computed separate GRMs
and estimated h2g for major ethnic groups in Gambia (Mandinka)
and Kenya (Girimia and Chonye). Furthermore, we created GRMs
in the presence of the GWAS significant SNPs and performed
GREML analysis to quantify the effects of malaria resistance
GWAS loci. We repeated the analysis by including rs334 as addi-
tional covariate to estimate the h2g attributable to HbS.
Partitioning SNP-heritability from genotype data. Using Gambian
dataset (largest sample size), we partitioned h2g by chromo-
somes, MAF bins and annotations. For the partitioning analy-
ses, we excluded the severe malaria resistance GWAS loci to
minimize the potential biases from SNPs with large effects. To
investigate the biases that might be created by population struc-
ture, we performed separate and joint GREML analysis using all
autosomal chromosomes. We first computed GRMs for individ-
ual autosomal chromosome and estimated h2g attributed to each
chromosome by separate GREML in which one chromosome is
fitted to the model at a time. We then performed a joint analysis
in which GRMs of all autosomal chromosomes are simultane-
ously fitted in to a single GREML analysis and compared the
results obtained from both analyses.
In addition to this, we partitioned the h2g in to different
allele frequencies and annotations. Briefly, we created five MAF
bins including > 0.01–0.05, > 0.05–0.1, > 0.1–0.2, > 0.2–0.3, > 0.3–
04, > 0.4–0.5, computed separate GRMs for each bin and per-
formed joint GREML analysis. For partitioning by annotation,
we mapped all the autosomal SNPs to the human reference
panel hg19 in UCSC genome database (http://genome.ucsc.edu)
using QCTOOLV2 (https://www.well.ox.ac.uk/!gav/qctool) and
obtained a list of genic and intergenic variants. Genic variants
included those SNPs mapped to genomic regions within 10 kilo-
bases (kb) upstream and downstream of a protein coding gene.
Intergenic variants included all the SNPs mapped to genomic
regions outside 10 kb of a protein coding gene. We constructed
separate GRMs and estimated h2g attributable to each category
using the joint analysis implemented in GCTA software (5).
Functional enrichment analysis of SNP-heritability
from GWAS-summary statistics
African-specific reference panel. Partitioning h2g in to cell-types
and functional categories using stratified LDSC approach has
recently been shedding new lights in to the genetic architecture
of several complex diseases (14,35,36). The method is based on
the fact that a given category of SNPs is enriched for h2g if
SNPs with high LD to that category have higher !2 statistics
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stratified LDSC analysis require population specific reference
panel and very large sample sizes to produce reliable results (14).
Consequently, the current European 1000G haplotype reference
panel that is used as a default in LDSC software (14,35) might not
well represent our study populations.
To address this challenge, we created a reference panel
that matches with our study populations. Briefly, we merged
African population datasets obtained from 1000 Genomes
Project and African Genome Variation Project (27) based on
overlapped variants and removed structural variants and
ambiguous SNPs using plink tool (32). This resulted in a
combined dataset of sample size (n = 4975). After excluding the
admixed populations including Americans of African Ancestry
and African Caribbean, we clustered the dataset in to East
African and west African sub-regions using smart pca software
(37) as shown in Supplementary Material, Fig. S4. We removed
SNPs with MAF < 1%, missingness > 0.05 and HWE in controls
(alpha level 0.0001), and retained a total of 22 473 268 SNPs
(sample size = 2112) and 18 919 068 SNPs (sample size = 380) in
east African and west African sub-regions, respectively. We
finally calculated the MAF of the panel for later partitioning
analysis. Owing to the fact that our study populations are
comprised of both east African (Malawi and Kenya) and west
Africa (Gambian) populations, we used the entire dataset as a
reference panel for functional enrichment analysis.
Baseline model and functional annotations. We created baseline
model and cell type specific annotations for our reference panel
as described in (14). The baseline-LD model included 24 main
annotations that are not cell type-specific including coding,
UTRs (3!UTR and 5!UTR), promoter and intronic regions obtained
from UCSC genome browser and processed by Gusev et al. (12),
the histone marks (H3) such as: acetylation of histone at lysine
9 (H3K9ac), monomethylation (H3K4me1) and trimethylation
(H3K4me3) of H3 at lysine 4 obtained from Trynka et al. (38),
acetylation of H3 at lysine 27(H3K27ac) version one processed by
Hnisz et al. (39) and version two Psychiatric Genomics Consor-
tium, combined chromHMM and Segway predictions obtained
from Hoffman et al. (40), regions that are conserved in mammals
(41,42), super enhancers (39), FANTOM5 enhancers (43), TFBS and
DGF post-processed by Gusev et al (12). Around each partition, we
added 500 bp windows as separate categories to prevent biases
that might arise from adjacent annotations.
The 24 main annotations together with the additional win-
dows and a category containing all SNPs yielded 53 overlapping
baseline model. Next, we created 220 cell type-specific annota-
tions for the four histone marks: H3K4me1, H3K4me3, H3K9ac
and H3K27ac (14) using our reference panel and computed LD
score for each annotation. We then combined the 120 cell spe-
cific annotations in to 10 cell groups including adrenal and
pancreas, central nervous system, cardiovascular, connective
and bone, gastrointestinal, immune and hematopoietic, kidney,
liver, skeletal muscle and other as described in (14). For each of
the 10 categories, we computed the corresponding LD scores.
Stratified LDSC analysis. We obtained meta-analysed GWAS-
summary statistics of the three populations (n = 15 122 094 SNPs)
from the previous GWAS (18). We performed imputation on this
dataset using ImpG software (44). Briefly, we removed SNPs
that mismatch with 1000G phase three markers, computed z-
score from the association statistics and performed the impu-
tation using ImGv.1.1 under default settings. We used all the 661
individuals labeled as ‘AFRICAN’ haplotypes in phase 1 of 1000
Genome Project version-3 calls (45). We removed all imputed
SNPs with a predicted accuracy less than 0.9 and SNPs with
MAF < 0.01. After QC filtering, we performed stratified LD score
regression analysis using our reference panels as described in
(14). Briefly, we converted the summary statistics to LDSC for-
mat, filtered SNPs with imputation accuracy greater than nine
and MAF >1%, removed structural variants, ambiguous SNPs, the
MHC region and significant SNPs. We then performed non-cell
type- and cell type- specific analyses as described in (14).
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Supplementary Figure 1. SNP-heritability of severe malaria susceptibility and resistance at 
different QC-threshold from less stringent to more stringent (from left to right) determined 
GCTA. Error bars represent the 95% CI of the estimates. QC1: GWAS QC-filtered data, 
QC2:QC1+ samples with 5% relatedness removed, QC3: QC2+ SNPs with differential missing 
rates 1x10 -3 removed, QC4:QC3+ SNPs with missingness proportion 2 x 10-2 removed, QC5: 









Supplementary Figure 2. SNP-heritability estimate per chromosome(y-axis) plotted against 
chromosome length(x-axis). The red line and blue line represent regressed SNP-heritability 
estimates obtained from joint GREML and separate analysis respectively. The 95% confidence 
interval around the slope of the regression model is represented by the grey shaded areas. 
 
 
Supplementary Figure 3. Distribution of off-diagonal elements of the Genetic Relatedness 
Matrix (GRM) after removing closely related individuals (pairwise relatedness threshold >5%). 
As expected, the distribution was centred at zero suggesting that there was no close relatedness 
in all the datasets. 
 65 
 
Supplementary Figure 4. We clustered our reference panel (quality filtered) in to geographic 
sub-regions in Africa using smart pca software. The left cluster represents east African 
population panel composed of 2112 samples and 22,473,268 SNPs. The right cluster represents 







Supplementary Table1. h2g of severe malaria resistance per chromosome estimated by 














Chromosome Chromosomal   length (Mb) h2g 
1 249.3 0.019960 
2 243.2 0.017271 
3 198.0 0.014731 
4 191.2 0.010840 
5 180.9 0.03500 
6 171.1 0.016039 
7 159.1 0.000021 
8 146.4 0.002449 
9 141.2 0.003458 
10 135.5 0.011938 
11 135.0 0.028226 
12 133.9 0.006632 
13 115.2 0.01 
14 107.3 0.01 
15 102.5 0.001 
16 90.4 0.006277 
17 81.2 0.004484 
19 78.1 0.001521 
20 59.1 0.002942 
21 63.0 0.016854 
22 48.1 0.000001 
Total   
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4. CHAPTER FOUR:  FUNCTIONAL ANALYSIS OF GENOME-WIDE DATASET 
FROM 17,000 INDIVIDUALS IDENTIFIES MULTIPLE CANDIDATE MALARIA 




 In this chapter, we applied various statistical functional analytic methods to the GWAS 
summary statistics (N=17,000) dataset of severe malaria resistance meta-analysed across 
eleven populations in malaria endemic regions in Africa, Oceania and Asia and identified 
plausible malaria resistance candidate genes and pathways. We performed population genetic 
structure of candidate malaria resistance gene in three malaria endemic populations (Gambia, 
Kenya and Malawi) and global populations consisting of 20 ethnic groups. We further applied 
gene burden and rare variant analysis on the genotype GWAS dataset of the three malaria 
endemic populations and identified rare variants that are associated with malaria resistance 
trait. Our functional mapping analysis identified 57 genes located in the known malaria 
genomic loci while our gene-based GWAS analysis identified additional 125 genes across the 
genome. The identified genes were significantly enriched in malaria pathogenic pathways 
including multiple overlapping pathways in erythrocyte-related functions, blood coagulations, 
ion channels, adhesion molecules, membrane signalling elements and neuronal systems. 
Overall, our results suggest that severe malaria resistance trait is attributed to multiple genes 
that are enriched in overlapping pathways linked to severe malaria pathogenesis; highlighting, 
the possibility of harnessing new malaria therapeutics that can simultaneously target multiple 
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Recent genome-wide association studies (GWASs) of severe malaria have identified several 
association variants. However, much about the underlying biological functions are yet to be 
discovered. Here, we systematically predicted plausible candidate genes and pathways from 
functional analysis of severe malaria resistance GWAS summary statistics(N=17,000) meta-
analyzed across eleven populations in malaria endemic regions. We applied positional mapping, 
expression quantitative trait locus (eQTL), chromatin interaction mapping and gene-based 
association analyses to identify candidate severe malaria resistance genes. We performed network 
and pathway analyses to investigate their shared biological functions. We further applied rare 
variant analysis to raw GWAS datasets (N=11,000) of three malaria endemic populations including 
Kenya, Malawi and Gambia and performed various population genetic structures of the identified 
genes in the three populations and global populations. 
Our functional mapping analysis identified 57 genes located in the known malaria genomic loci 
while our gene-based GWAS analysis identified additional 125 genes across the genome. The 
identified genes were significantly enriched in malaria pathogenic pathways including multiple 
overlapping pathways in erythrocyte-related functions, blood coagulations, ion channels, adhesion 
molecules, membrane signaling elements and neuronal systems. Our population genetic analysis 
revealed that the minor allele frequencies (MAF) of the single nucleotide polymorphisms (SNPs) 
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residing in the identified genes are generally higher in the three malaria endemic populations 
compared to global populations. Overall, our results suggest that severe malaria resistance trait is 
attributed to multiple genes; highlighting the possibility of harnessing new malaria therapeutics 
that can simultaneously target multiple malaria protective host molecular pathways. 
Introduction 
Malaria is still one of the global health problems with approximately 228 million cases and 405, 
000 deaths in 2018 (1). African countries disproportionately carry the global burden of malaria 
accounting for 93% and 94% of cases and deaths, respectively (1). P. falciparum malaria is still 
one of the leading causes of child mortality in endemic regions, particularly in sub-Saharan Africa. 
According to the World Health Organization (WHO), malaria killed about 285,000 under five 
children in 2016 (2). About 10-20% of children who recover from severe malaria develop 
neurological sequalae and sub-optimal neuronal development (3). Severe malaria (SM) is defined 
as demonstration of asexual forms of the malaria parasites in the blood of a patient with a 
potentially fatal manifestation or complication of malaria in whom other diagnosis have been 
excluded (4). The  SM complications include rapid progression to severe malarial anaemia (SMA), 
hypoglycaemia, cerebral malaria(CM), acidosis and death (4). 
The global malaria eradication program, accelerated by the WHO led Roll Back Malaria (RBM) 
partnership, is largely focusing on scaling up the coverage of the available intervention strategies 
such as the distribution of long-lasting insecticide treated nets (LLINS), indoor residual insecticide 
spraying, intermittent treatment for pregnant women in high transmission settings and rapid 
diagnosis and effective treatments using artemisinin-based combination therapies (ACTs) (5). This 
led to the significant decline of malaria burden in many parts of the endemic regions. Despite the 
successes gained in reducing the global burden of malaria, the progress towards global malaria 
elimination is challenged by wide arrays of problems including decreased funding, lack of political 
commitments in some countries, emergence of drug resistant parasites and insecticide resistant 
mosquitoes and lack of effective vaccine among others (6).  
P. falciparum has a complex life cycle alternate between vertebrate and female Anopheles 
mosquito. During its blood meal, the infected mosquitoes inoculates the transmissive form the 
parasite, the sporozoites, in to human skin. From the skin the sporozoites enter in to the blood 
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circulation or up-taken by the lymphatic system and invade liver (7). After maturation, the parasite 
buds off the hepatocytes and released in to the circulation in the form of merozomes containing 
hundreds of thousands of merozoites that infect erythrocytes (7). The erythrocyte stage also called 
blood stage lifecycle is complex multi-step process that involve repeated invasion, growth, 
replication and egress events (8). To create favourable environment for its survival and growth, 
the parasite remodels the infected erythrocyte (IE). The remodelling events include creation of a 
parasitophorous vacuolar membrane (PVM) that surrounds the parasite and modification of 
antigenic and structural properties of the IE by transporting a protein called  P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) to the surface (8). The clinical symptoms of the SM  
have been linked to the blood stage life cycle (8). 
Even though SM is one of the commonest reasons for admission to hospital and is a major cause 
of hospital death in children aged 1-5 years in endemic areas, it constitutes  only a small subset (1-
2%)  of the infected children as the majority of malaria infections is mild (9). It has been shown  
that  such clinical variations is partly attributable to human genetic factors (10, 11). Thus, a 
comprehensive understanding of the human genetic causes of variation in malaria clinical outcome 
may potentially provide clues to design new intervention strategies such as therapeutics and 
vaccines which can facilitate the global malaria eradication program (12, 13). 
Aiming at shedding more light to the genetic basis of severe P. falciparum malaria,  several 
genome-wide association studies (GWASs) have been conducted in diverse malaria endemic 
populations over the last decade (14–18). The GWASs have replicated some of the well-known 
malaria susceptibility genomic risk loci including sickle cell  (HBB) and ABO blood group loci 
and identified new variants in ATP2B4 and Glycophorin regions (14–18). Due to the single-marker 
testing approach commonly used, single SNP-based GWASs may miss candidate variants with 
weak genetic effects and therefore, combining all effects from multiple variants within a gene and 
deconvoluting the interactions between genes underlying the malaria resistance trait  may  provide 
important insights in to underlying genetics (19). Today, a number of gene-based and pathway-
level statistical analytic methods have recently been developed and successfully implemented in 
complex disease studies (20–23). These methods integrate functional information from advanced 
biological databases including the Genotype-Tissue Expression (GTEx)(24), Encyclopedia of 
DNA Elements (ENCODE) (25), Roadmap Epigenomics Project (26) and chromatin interaction 
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information (27). Owing to the fact that direct functional follow-up of several candidate causal 
variants and genes is expensive, application of such computational method to prioritize genes and 
their respective biological pathways are proven to be useful in complex diseases studies (20). 
Furthermore, gene and gene-set analysis can  improve the study power  by aggregating the joint 
effects of weakly associated markers, a common challenge in a polygenic trait studies (28). 
Here, we implement several gene-set, pathway and network analytic methods on summary 
statistics of severe malaria GWAS from 17,000 individuals meta-analysed across eleven 
populations and systematically predicted plausible genes and pathways. We further performed rare 
variant analysis on raw GWAS dataset (N = ~11,000) of Kenya, Gambia and Malawi populations. 
Finally, we performed population genetic structure analysis of the identified genes in the three 
malaria endemic countries and across global populations. Established over the course of long co-
evolution time, blood stage life cycle of the parasite constitutes the most extensive interplay 
between host and parasite genomes which leads to the clinical symptoms of SM. Therefore, our 
results suggest that severe malaria resistance is polygenic and attributed to multiple genes 
aggregated in pathogenic pathways linked to the erythrocyte stage lifecycle of P. falciparum. 
Results 
Functional mapping and annotations 
 
We applied three functional mapping strategies to the severe malaria GWAS summary statistics 
(N=17,000 samples, ~17 million SNPs) meta-analysed across 11 malaria endemic populations in 
Africa, Asia and Oceania (see Material and Methods).  We identified 19 lead SNPs out of 69 
significant SNPs across 6 genomic loci (Supplementary Data 1-3). The genomic locus was 
defined as the region that contain independent lead SNPs and nominally significant SNPs (p<0.05) 
in linkage dis-equilibrium (LD) block with lead SNPs. An independent significant SNP was 
defined as a genome-wide significant SNP (P-value < 5e-8) within the genomic boundary of LD 
threshold of r2 > 0.6. Lead SNPs were selected from independent significant SNPs at LD threshold 
of r2 > 0.1. SNPs in close proximity (< 250 kb) were considered as a single locus and thus, each 
genomic locus can contain multiple independent significant SNPs and lead SNPs. These SNPs 
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were significantly enriched in ncRNA-intronic, intronic, intergenic and ncRNA-exonic regions 
(Fig1.A). 
 Our functional mapping strategies yielded a total of 57 protein-coding genes (Table 1, 
Supplementary Data 4). These include 29, 23 and 14 genes identified by eQTL mapping, 
chromatin interaction mapping and positional mapping, respectively (Fig1.B). Two genes 
including ATP2B4 and HBD were identified by all the three gene mapping strategies while five 
genes including GYPB, HBG2, TRIM6-TRIM34, OR51F2 and TRIM68 were predicted by two of 
the three mapping strategies (Supplementary Data 4).  
The identified genes were enriched in five cytogenic positions including  11p15 (p=2.65e-18), 
chr9q34 (p=4.63e-9) , chr4p31(p= 4.6e-8), chr1q32 (p=2.6e-7), chr3q26 (p=7.97e-4) (S1 Table).  
We noted that the majority (33%) of the identified genes were clustered on 11p15 (Fig 2). These 
include beta globin gene cluster: HBB, HBD, HBG1, HBG2 and HBE1; Tripartite motif-containing 
(TRIM) family genes including TRIM68, TRIM21; and genes involved in olfactory receptors and 
G protein-coupled signalling (GPCR) such as: CCKR OR51F2 and OR51L (Supplementary 
Table 1). About two third (13/19) of the genes in this locus are in eQTL and chromatin interactions 
(Supplementary Data 4 and Supplementary Fig 1).   
All the implicated genes in chr9q34 locus are located outside the genomic risk locus and were 
identified by eQTL mapping (Supplementary Data 4, Supplementary Fig 2). These include 
surfeit gene cluster such as: SURF2, SURF4, MED22 and SURF6; a metalloprotease gene, 
ADAMTS13; and a gene encoding ORS blood group system coding gene (GBGT1). In the 
remaining enriched cytogenic positions, the known genes including ATP2B4 (chr1q32); FREM3, 
GYPE and GYPB (chr4p31) were replicated. Other notable genes include BTG2 a tumour 
suppressor gene on chr1q32 and B3GALNT1 on chr3q26 (Supplementary Data 4). 
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Fig.1. A) Proportion of malaria resistance GWAS SNPs in different genomic annotation 
categories. B) The number of genes identified by each of the three functional mapping strategies 
including positional mapping, eQTL and chromatin interactions. The intersection sections of the 
circles depict the number overlapped genes between the respective mapping strategies. 
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Fig. 2. Regional plot of severe malaria susceptibility GWAS locus on chromosome 11. Non-
GWAS-tagged SNPs are shown at the top of the plot as rectangles since they do not have a P-
value from the GWAS. Prioritized genes are highlighted in red. eQTLs are plotted per gene 
and coloured based on tissue types. CADD score, RegulomeDB score and eQTLs, SNPs which 








  Table 1. Fifty-seven severe malaria resistance candidate genes identified by eQTL mapping, chromatin interaction mapping  
  and positional mapping strategies implemented in FUMA 
Genes -Ensg Symbols Chr Cytoband Start End Biotype Independent significant SNPs 
ENSG00000160323 ADAMTS13 9 q34.2 136279478 136324508 protein coding rs8176751; rs687621 
ENSG00000197859 ADAMTSL2 9 q34.2 136397286 136440641 protein coding rs8176751 
ENSG00000179674 ARL14 3 q25.33 160394948 160396233 protein coding rs116423146 
ENSG00000058668 ATP2B4 1 q32.1 203595689 203713209 protein coding rs4951370 
ENSG00000169255 B3GALNT1 3 q26.1 160801671 160823172 protein coding rs116423146 
ENSG00000159388 BTG2 1 q32.1 203274619 203278730 protein coding rs4951370 
ENSG00000110148 CCKBR 11 p15.4 6280966 6293357 protein coding rs113892119:rs28576676 
ENSG00000133063 CHIT1 1 q32.1 203181955 203242769 protein coding rs4951370 
ENSG00000113758 DBN1 5 q35.3 176883609 176901402 protein coding rs687621 
ENSG00000122176 FMOD 1 q32.1 203309756 203320617 protein coding rs4951370 
ENSG00000183090 FREM3 4 q31.21 144498455 144621828 protein coding rs201510180 
ENSG00000109458 GAB1 4 q31.21 144257915 144395721 protein coding rs111374053 
ENSG00000148288 GBGT1 9 q34.2 136028340 136039332 protein coding rs687621 
ENSG00000250361 GYPB 4 q31.21 144917257 145061844 protein coding rs201510180 
ENSG00000197465 GYPE 4 q31.21 144792020 144826716 protein coding rs34330779 
ENSG00000244734 HBB 11 p15.4 5246694 5250625 protein coding rs334 
ENSG00000223609 HBD 11 p15.4 5253908 5256600 protein coding rs334; rs4290259; rs79681613; 
rs113892119:rs28576676 
ENSG00000213931 HBE1 11 p15.4 5289582 5526847 protein coding rs145843585 
ENSG00000213934 HBG1 11 p15.4 5269313 5271122 protein coding rs7927066 
ENSG00000196565 HBG2 11 p15.4 5274420 5667019 protein coding rs145843585; rs183322782; 
rs148179286;rs7927066;rs11037724 
ENSG00000203813 HIST1H3H 6 p22 27777842 27778314 protein coding rs8176751 
ENSG00000122188 LAX1 1 q32.1 203734304 203745361 protein coding rs4951370 
ENSG00000148297 MED22 9 q34.2 136205160 136214986 protein coding rs8176751; rs687621 
ENSG00000108960 MMD 17 q22 53469974 53499353 protein coding rs8176751 
ENSG00000167346 MMP26 11 p15.4 4726157 5013659 protein coding rs141862673; rs145429724 
ENSG00000169251 NMD3 3 q26.1 160822484 160971320 protein coding rs116423146 
ENSG00000184881 OR51B2 11 p15.4 5344541 5345582 protein coding rs145843585 
ENSG00000176925 OR51F2 11 p15.4 4842551 4843686 protein coding rs141862673; rs145429724; 
rs113892119:rs28576676 
ENSG00000176798 OR51L1 11 p15.4 5020213 5021160 protein coding rs113892119:rs28576676 
ENSG00000182070 OR52A1 11 p15.4 5172239 5207612 protein coding rs116780407 
ENSG00000228474 OST4 2 p23.3 27293340 27294641 protein coding rs8176751 
ENSG00000142657 PGD 1 p36.22 10458649 10480201 protein coding rs687621 
ENSG00000143850 PLEKHA6 1 q32.1 204187979 204346793 protein coding rs4951370 
ENSG00000163590 PPM1L 3 q25.33 160473390 160796695 protein coding rs116423146 
ENSG00000188783 PRELP 1 q32.1 203444956 203460480 protein coding rs4951370 
ENSG00000170955 PRKCDBP 11 p15.4 6340176 6341877 protein coding rs28576676 
ENSG00000160271 RALGDS 9 q34.2 135973107 136039301 protein coding rs8176751; rs687621 
ENSG00000148300 REXO4 9 q34.2 136271186 136283164 protein coding rs8176751 
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ENSG00000080345 RIF1 2 q23.3 152266397 152364527 protein coding rs8176751 
ENSG00000170153 RNF150 4 q31.21 141780961 142134031 protein coding rs111374053 
ENSG00000136193 SCRN1 7 p14.3 29959719 30029905 protein coding rs687621 
ENSG00000160326 SLC2A6 9 q34.2 136336217 136344259 protein coding rs8176719; rs687621 
ENSG00000196542 SPTSSB 3 q26.1 161062580 161090668 protein coding rs116423146 
ENSG00000148290 SURF1 9 q34.2 136218610 136223552 protein coding rs8176751; rs687621 
ENSG00000148291 SURF2 9 q34.2 136223428 136228045 protein coding rs8176751 
ENSG00000148248 SURF4 9 q34.2 136228325 136242970 protein coding rs8176751 
ENSG00000148296 SURF6 9 q34.2 136197552 136203235 protein coding rs8176751; rs687621 
ENSG00000196628 TCF4 18 q21.2 52889562 53332018 protein coding rs687621 
ENSG00000132109 TRIM21 11 p15.4 4406127 4414926 protein coding rs28576676 
ENSG00000132274 TRIM22 11 p15.4 5710919 5758319 protein coding rs28576676 
ENSG00000258659 TRIM34 11 p15.4 5640994 5665628 protein coding rs183322782; rs148179286 
ENSG00000213186 TRIM59 3 q25.33 160150233 160203561 protein coding rs116423146 
ENSG00000121236 TRIM6 11 p15.4 5617339 5634188 protein coding rs28576676 
ENSG00000258588 TRIM6-
TRIM34 
11 p15.4 5617955 5665628 protein coding rs183322782; rs148179286; 
rs28576676 
ENSG00000167333 TRIM68 11 p15.4 4619902 4629489 protein coding rs10837488; 
rs4290259:rs113892119:rs28576676 
ENSG00000175518 UBQLNL 11 p15.4 5535623 5537935 protein coding rs11037724 




ENSG00000148300 REXO4 9 q34.2 136271186 136283164 protein coding rs8176751 
ENSG00000080345 RIF1 2 q23.3 152266397 152364527 protein coding rs8176751 
ENSG00000170153 RNF150 4 q31.21 141780961 142134031 protein coding rs111374053 
ENSG00000136193 SCRN1 7 p14.3 29959719 30029905 protein coding rs687621 
ENSG00000160326 SLC2A6 9 q34.2 136336217 136344259 protein coding rs8176719; rs687621 
ENSG00000196542 SPTSSB 3 q26.1 161062580 161090668 protein coding rs116423146 
ENSG00000148290 SURF1 9 q34.2 136218610 136223552 protein coding rs8176751; rs687621 
ENSG00000148291 SURF2 9 q34.2 136223428 136228045 protein coding rs8176751 
ENSG00000148248 SURF4 9 q34.2 136228325 136242970 protein coding rs8176751 
ENSG00000148296 SURF6 9 q34.2 136197552 136203235 protein coding rs8176751; rs687621 
ENSG00000196628 TCF4 18 q21.2 52889562 53332018 protein coding rs687621 
ENSG00000132109 TRIM21 11 p15.4 4406127 4414926 protein coding rs28576676 
ENSG00000132274 TRIM22 11 p15.4 5710919 5758319 protein coding rs28576676 
ENSG00000258659 TRIM34 11 p15.4 5640994 5665628 protein coding rs183322782; rs148179286 
ENSG00000213186 TRIM59 3 q25.33 160150233 160203561 protein coding rs116423146 
ENSG00000121236 TRIM6 11 p15.4 5617339 5634188 protein coding rs28576676 
ENSG00000258588 TRIM6-
TRIM34 
11 p15.4 5617955 5665628 protein coding rs183322782; rs148179286; rs28576676 
ENSG00000167333 TRIM68 11 p15.4 4619902 4629489 protein coding rs10837488; 
rs4290259:rs113892119:rs28576676 
ENSG00000175518 UBQLNL 11 p15.4 5535623 5537935 protein coding rs11037724 




Candidate genes identified by gene-based GWAS analysis 
 
Taking the polygenic nature of severe malaria resistance trait in to consideration (11), we applied 
a pathway scoring algorithm(Pascal) (22) method that aggregates  all SNPs within a gene and 
capture polygenic effects at the gene level (see Material and Methods). The Pascal analysis 
replicated 13 genes that were identified by our functional annotation methods in malaria genomic 
risk loci (Supplementary Table 2) and identified 125 additional genes across the genome 
(Supplementary Data 5). The genes with top scores outside genomic risk loci include CSMD1 
(p=1.58e-12) on chr8p23.2 and RBFOX1 (p=9.76e-11) on chr16p13.3. CSMD1 is an important 
regulator of complement activation and inflammation (29, 30) while RBFOX1 encodes for an 
mRNA-splicing factor linked to autism spectrum disorders (31). A previous study in Tanzanian 
population reported association of variants in  RBFOX   gene with  SM (17).  
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Other important genes identified by gene-based GWASs include neural adhesion molecules 
including CNTN4 (p=3.88e-9) on chr3p26.3-p26.2; PCSK5(p=2.88e-11) on chr9q21.13; CDH13 
(p=4.19e-8) on chr16q23.3) and TMEM132 (p=2.18e-8) on chr17q12 (Supplementary Data 5). 
These genes were reported to be linked  to autism spectrum disorders and other 
neurodevelopmental conditions (32). Furthermore, protein kinases including FLT4 (p=9.96e-8) on 
5q35.3; and PTPRT (p=4.92e-7) on chr20q12-q13 and PRKG1 ((p=1.2e-6) on 10q11.2-q21.1 were 
among the genes with top scores (Supplementary Data 5). PTPRT is a tyrosine phosphatase 
receptor involved in STAT3 pathway and was recently reported to be associated with mild malaria 
susceptibility in Benin populations (33). PRKG1 is a cyclic guanosine monophosphate (GMP) 
dependent protein kinase which plays important roles in relaxation of vascular smooth muscle and 
inhibition of platelet aggregation (34). FLT4 acts as a cell-surface receptor for vascular endothelial 
growth factor C (VEGFC) and vascular endothelial growth factor D (VEGFD), and plays an 
essential role  in the development of the vascular network (35). It has been shown that VEGF and  
its receptor-related molecules are expressed in the brain tissues and reported to play protective 
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Gene-based rare variant association 
 
Because rare variants are known to play role in the variation of most complex traits, we applied 
optimal unified sequence kernel association test (SKAT-O), which combines burden and variance-
component analyses (37) to the raw genotype GWAS dataset of Gambia, Kenya and Malawi 
populations (see Material and Methods). The SKAT-O analysis identified a total of six and nine 
nominally significant genes in Gambia and Malawi populations, respectively. These include nine 
long intergenic non-protein coding RNAs (LincRNAs), MIR4282, GLYR1, NDNF, EPB41L2, 
ATP8A1 and WASF3 (Supplementary Table 3). However, none of these genes were significant 
after correction for multiple testing.   
 
Functional networks and subnetworks of severe malaria resistance candidate genes 
 
To investigate the functional interaction between all the candidate malaria resistance candidate 
genes identified in this study, we implemented network analysis (see Materials and Methods). 
Our global network generated 351 functional interactions between 268 genes. Topology analysis 
identified ABO, HBB, HBD, HBE1, ATP2B4 as highly influential connector hub genes influencing 
at least two subnetworks/communities while TRIM21 and OR5F2 constituted independent 
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Fig. 3. Network generated from predominant severe malaria protective candidate genes, 
comprising of 351 interactions between 268 nodes. Topology analysis identified ABO, HBB, HBD, 
HBE1, ATP2B4 as highly influential connector hub genes influencing at least two 
subnetworks/communities while TRIM21 and OR5F2 constituted independent communities. 
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Molecular functions and pathways of candidate severe malaria resistance genes  
 
To test whether the genes predicted  by the three functional mapping strategies overlapped in 
functional gene sets and pathways, we conducted gene enrichment analysis  implemented in 
FUMA (20) using MsigDBc5 (38) gensets as background  (see Material and Methods). The gene 
enrichment analysis identified several shared biological functions linked to erythrocyte-related 
pathways including three gene ontology (GO) cellular components, eight GO molecular functions 
and fourteen GO biological processes (Table 2).  The implicated cellular components include 
haptoglobin-haemoglobin complex (p=7.6e-8), haemoglobin-complex(p=7.63e-8) and cytosolic-
part (p= 6.73e-3). The enriched molecular functions include haptoglobin binding (p=4.87e-8), 
oxygen carrier activity(3.8e-7), oxygen binding (p=4.87e-5) and other activities related to 
haemoglobin functions. The shared biological activities include oxygen transport (p=4.22e-6), gas 
transport (p=4.87e-6), hydrogen peroxide catabolism (p=9.08e-5), protein hetero-oligomerization 
(p=2.86e-3), protein complex-oligomerization (p=4.23e-3), interferon gamma mediated signalling 
pathways (p=3.09e-2) and blood coagulation (p=3.09e-2). 
In addition to genes within severe malaria genomic risk loci, we performed functional analysis and 
pathway analysis for the genes identified by the gene-based GWAS using Database for Annotation, 
Visualization and Integrated Discovery (DAVID) method (39) and Pascal (22), respectively(see 
Material and Methods). The DAVID analysis yielded eight functional categories, the majority of 
which are linked to malaria pathogenesis (Table 3) including GPCR signalling, 
membrane/transmembrane proteins, Na+/K+ transporting ATPases, cell adhesions, haemoglobin 
related functions, calcium signalling and actin binding activities.  
Similarly, Pascal analysis implicated eleven significant pathways the majority of which are linked 
to malaria pathogenesis in RBCs, vasculatures and brain (Fig 4A). These include G protein-
coupled receptor signalling (p=7.88e-15), haemostasis (p=4.52e-10), neuronal system (p=1.25 e-
9), axon guidance (p=5.93e-8), calcium signalling (p=1.10e-7), chemical transmission across 
synapses (p=1.75 e-7), immune system (p=2.61e-6), signalling by Rho GTPase (p=1.45 e-5) and 
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11 5 8.91e-11 7.63e-8 HBB, HBD, HBG1, HBG2, HBE1 
Haemoglobin 
complex 
12 5 1.52e-10 7.63e-8 HBB, HBD, HBG1, HBG2, HBE1 






10 5 4.87e-11 8.02e-8 HBB, HBD, HBG1, HBG2, HBE1 
Oxygen carrier 
activity 
14 5 3.84e-10 3.16e-7 HBB, HBD, HBG1, HBG2, HBE1 
Oxygen binding 36 5 6.87e-8 3.77e-5 HBB, HBD, HBG1, HBG2, HBE1 
Molecular carrier 
activity 
41 5 1.35e-7 5.56e-5 HBB, HBD, HBG1, HBG2, HBE1 
Oxidoreductase 
activity acting on 
peroxide as 
acceptor 
56 5 6.66e-7 2.19e-4 HBB, HBD, HBG1, HBG2, HBE1 
Haemoglobin 
binding 
7 3 8.69e-7 2.38e-4 HBB, HBD, HBE1 
Antioxidant 
activity 
85 5 5.35e-6 1.26e-3 HBB, HBD, HBG1, HBG2, HBE1 
Tetrapyrrole 
binding 
136 5 5.23e-5 1.08e-2 HBB, HBD, HBG1, HBG2, HBE1 
Biological 
Processes 
Oxygen transport 15 5 5.74e-10 4.22e-6 HBB, HBD, HBG1, HBG2, HBE1 




32 5 3.71e-8 9.08e-5 HBB, HBD, HBG1, HBG2, HBE1 
Antibiotic 
catabolic process 
50 5 3.74e-7 6.88e-4 HBB, HBD, HBG1, HBG2, HBE1 
Drug catabolic 
process 




66 5 1.52e-6 1.87e-3 HBB, HBD, HBG1, HBG2, HBE1 
Protein hetero-
oligomerization 




551 10 4.60e-6 4.23e-3 TRIM21, HBB, HBD, HBG1, 




91 5 7.49e-6 6.11e-3 HBB, HBD, HBG1, HBG2, HBE1 
Cellular 
detoxification 
107 5 1.65e-5 1.21e-2 HBB, HBD, HBG1, HBG2, HBE1 
Protein 
trimerization 
54 4 2.00e-5 1.34e-2 TRIM21, TRIM6, TRIM34, 
TRIM22 




70 4 5.60e-5 3.09e-2 TRIM21, TRIM68, TRIM34, 
TRIM22 
Coagulation 335 7 5.89e-5 3.09e-2 HBB, HBD, HBG1, HBG2, HBE1, 
HIST1H3H, ADAMTS13 









         Table 3: Functional categories of genes identified by gene-based GWAS analysis grouped using DAVID method 
Functional group Genes Enrichment 
Score 
GPCR signalling pathways 
and olfactory receptions 
OR51B6, FZD10, TMEM132C, OR51V1, OR51B2, OR52K2, SORCS2, OR56A1, 





and, Na+/K+ transporting 
ATPase 
TSPAN11, VSTM1, TMEM132D, SURF4, NKAIN2, TMEM132C, EVC, SLC35F3 3.07 
Tyrosine phosphatase, 
tyrosine kinase, cell adhesion 
molecule-like 
OPCML, PTPRD, PTPRT, CNTN5, FLT4, NTM, CNTN4, PTPRN2, VSTM1, PTPRS 2.51 
Haemoglobin related 
activities 
HBG2, HBE1, HBB, HBD 2.42 
Sodium leak and Potassium 
channel interacting protein 
KCNIP1, NALCN, KCNIP4, KCTD1 1.14 
zinc finger protein SMYD3, TSHZ2, ZNF385B, ZNF385D 0.61 
Actin binding LIM protein 
family and RAR-related 
orphan receptor A 
RORA, THRB, GLIS3, ABLIM2 0.45 
Calcium/calmodulin-
dependent protein kinase, 
cGMP-dependent kinase and 
fms-related tyrosine kinase 


































Fig. 4. A) Pathway scores obtained from pascal analysis. Significant Pathways at Bonferroni 
corrected P-value ≤ 0.05 are coloured in red. B) Tissue specific gene expression and shared 
biological functions of genes identified by pascal in GTEx v8 30 general tissue types. Input genes 
were tested against each of the precomputed differentially expressed sets using the hypergeometric 
test. Significant enrichment at Bonferroni corrected P-value ≤ 0.05 are coloured in red. 
Population genetic structure of   malaria resistance candidate genes 
 
We noted that the minor allele frequencies (MAF) of the SNPs residing in the identified genes are 
generally higher in the three malaria populations compared to 20 ethnic groups (Supplementary 
Fig 1 and 2). We further observed that the proportion of pathogenic SNPs in a total of eighteen 
genes is much higher in the three malaria endemic populations compared to other populations 
(Supplementary Data 6 and 7). These include TRIM family genes such as TRIM21, TRIM22, 
TRIM68, TRIM6-TRIM34 and TRIM34 in which the pathogenic SNP proportion ranges from 13.3-
25%; olfactory receptors genes such as: OR51B4, OR51B6, OR51B2, OR56A1, OR51L1, OR52K2 
and OR51E2 in which the pathogenic SNP proportion ranges from (27.3 -100%).  
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The principal component analysis based on the SNPs residing in the identified genes effectively 




Fig .5. A)  We clustered the merged malaria GWAS dataset containing only SNPs residing in the 
identified malaria resistance candidate genes (N= 10578 samples, 15,675 SNPs) using smartpca 
software.  The three populations and their case/control status were indicated by different colours 
and symbols. B). We clustered the AGVP dataset containing only SNPs residing in the identified 
malaria resistance candidate genes (N=4932 samples, 93,5549 SNPs) in to sub-regions/populations 
using smartpca software. The populations were indicated by different colours and symbols. 
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In this study, we applied statistical functional analytic method to the largest ever severe malaria 
susceptibility GWAS dataset and identified the well-known malaria resistance loci and a number 
of novel genes that can guide future functional experiments. We noted that severe malaria 
resistance is attributed to multiple genes and pathways linked to malaria pathogenesis during blood 
stage life cycle of the parasite including merozoite invasion, parasite growth, cytoadherence, and 
signal transduction. The genes that were identified by our three mapping strategies might have 
equal importance; genes that were identified by positional mapping may act at protein level 
through structural changes while the genes identified by eQTL and chromatin interactions exert 
their influences  through quantitative changes at gene expression levels (20). 
The fact that the functionally mapped genes are clustered on chromosome 11p15 is consistent with 
our recent work in which we reported the disproportionate concentration of   SNP-heritability on 
chromosome eleven. This might reinforce the need for targeting this chromosome in the future  
severe malaria susceptibility studies (11). We noted that in addition to the sickle trait gene (HBB), 
our mapping strategies identified other members of beta globin gene cluster that cause various 
forms of beta-thalassemia (HBE1, HBD, HBG and HBG2). 
Our network analysis showed that all these genes constituted hub with which several other genes 
are connected; which reaffirm the importance of homeopathies in resistance against severe malaria. 
Beta-thalassemia and other hemoglobinopathies are thought to confer protection against severe 
malaria by suppressing the parasite growth and by mitigating associated pathogenic effects (40).  
The proposed protective mechanisms of hemoglobinopathies against severe malaria has been 
extensively  reviewed elsewhere (40, 41). In addition to the beta globin gene cluster, the Tripartite 
motif (TRM) containing gene family (TRIM68 and TRIM21) identified in this locus are known to 
play critical role in down regulating Toll-like receptors(TLR)- and Rig-like receptors (RLR)-
induced responses and protect from autoimmune and inflammations (42, 43). Mal-adapted 
inflammatory reactions is one of the hall mark pathogenic pathways in severe malaria (44, 45).  
The olfactory receptors super-family genes (CCKR, OR51F2 and OR51L) identified in this locus 
might involve  in G protein-coupled receptors(GPCR) signalling activities which is important in 
blood stage life cycle of P. falciparum (46). However, it is also possible that these genes were 
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detected because of their abundance and close proximity to with globin gene cluster(47). We also 
be noted that the genes in the TRM family and olfactory receptors super-family contain higher 
proportion of pathogenic SNPs in the three-malaria endemic population compared to the global 
populations. The majority of the well-known malaria protective genes have deleterious variants 
and were evolved under balancing selections [42].  
 Our eQTL mapping identified ADAMTS13 gene on chr9q34 outside the malaria genomic risk 
locus which would not have been identified by the conventional SNP mapping approach (20). 
ADAMTS13 is a zinc-containing metalloprotease enzyme that cleaves, von Willebrand factor vWF, 
a large protein derived from endothelial surface and megakaryocytes which plays a crucial role in 
basic haemostasis (48, 49). Following activation of endothelial cells, vWF is directly released in 
to plasma and basement membrane or is stored in Weibel–Palade bodies (WPBs) from where it is 
released by regulated secretion to promote adhesion of platelets at the sites of vascular injury and 
facilitate vascular healing (49). However, abnormal accumulations of vWF caused by  deficiency 
of plasma ADAMTS13 trigger intravascular platelet aggregation and micro thrombosis leading to 
a vascular disease, Thrombotic Thrombocytopenic Purpura (TTP) (48). Indeed, recent works have 
linked the platelet-mediated clumping of infected erythrocytes in microvasculature  during cerebral 
malaria with increased level of VWF in plasma caused by mutations in ADAMTS13 genes (50–
52). 
 In the same genomic locus, our eQTL functional mapping identified surfeit gene cluster, 
metalloprotease genes linked to epithelial adhesions and blood coagulations.  SURF4 gene  has 
been implicated in epithelial cell adhesion trait (53), MED22 gene is  linked to VWF factor/factor 
VIII level measurement (54)  and SURF6 has been implicated in epithelial ovarian cancer (55). 
Our network analysis showed that MED22 forms a central hub to which the rest of surfeit gene 
cluster are connected. This may suggest that the greater importance of MED22 gene compared 
with the other members of the cluster. However, further comprehensive studies are needed to better 
understand the association of these genes with SM resistance. In the remaining genomic risk loci, 
the well-known genes including ATP2B4 (chr1q32), FREM3, GYPE and GYPB (chr4p31) were 
replicated and few additional genes were identified. The glycophorin gene cluster, GYPA and 
GYPB encode the MNS blood group system and are host-erythrocyte receptors for P. falciparum; 
suggesting that polymorphisms in these genes play protective role by interfering with the invasion 
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processes [55]. ATP2B4 variants may impair the parasite lifecycle in erythrocyte by affecting  
intracellular Calcium homeostasis (18, 56).  
Novel genes identified in the loci include BTG2 on chr1q32 and B3GALNT1 on chr3q26. BTG2 is 
a tumour suppressor gene known to be  linked to RBC related traits including MCHC level, RBC 
distribution and reticulocyte count (57). B3GALNT1 encodes globoside blood group system which 
is determined by P antigen (58). Globoside/P antigen is the most abundant neutral glycolipid in 
the erythrocyte membrane and has been recognized as a cellular receptor for parvo-B19 virus (59). 
Individuals lacking this receptor are resistant to parvo-B19 virus and uro-pathogenic E.coli 
infections (59, 60).  Further investigations are needed to establish the link between these genes and 
SM resistance.  
We noted that the mapped genes share cellular components including haptoglobin binding, 
haemoglobin complex and cytosolic part and several overlapped molecular functions and 
biological processes linked with the blood stage life cycle of the parasite. P. falciparum spends 
most of its lifecycle within RBCs, where it undergoes multiple rounds of invasion, growth, 
replication and egress; causing  the signs and symptoms of malaria (44, 61). The majority of the 
classical haemoglobin variants confer protection against severe malaria by restricting invasion 
process and intraerythrocytic growth of the parasite (40). Haptoglobin is an acute phase 
glycoprotein present in human plasma. It forms stable complexes with extracellular haemoglobin 
that is released from lysed RBCs and thereby curtail the haemoglobin-induced oxidative tissue 
damage (62). 
 P. falciparum ingest the host cell cytosol to obtain nutrients and space for growth in the RBCs 
(63). A recent study showed that the host cytosol uptake process is mediated by parasite’s protein 
called VPS45 (64). The fact that the identified candidate genes in this study were enriched in the 
cytosol part of the cellular component might suggest that these genes might arrest the nutrient up-
take of the parasites and thereby confer protection against their pathogenic effects. In addition to 
haemoglobin related functions, some of the candidate genes were enriched in other pathways 
linked to  malaria pathogenesis including  blood coagulation related processes malaria (65, 66) and  
interferon gamma mediated signalling pathways (67, 68). This may suggest that the host genetic 
factors might interfere with parasite development and its pathogenic outcomes at multiple levels 
to confer protection the life-threatening form of malaria.  
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted August 17, 2020. .https://doi.org/10.1101/2020.08.15.20175471doi: medRxiv preprint 
 88 
 21 
Our gene-based GWAS analysis replicated the well-known malaria resistance candidate genes in 
the genomic risk loci and identified several genes across the genome. Genes with top scores encode 
for different malaria relevant functions such as: regulation of inflammation (CSMD1), neural 
adhesion (CNTN4, PCSK5, CDH13, TMEM132), vascular epithelial development (FLT4) and 
protein kinases (PTPRT, PRKG1). Furthermore, functional analysis of the candidate genes yielded 
functional categories linked with the blood stage lifecycle of the parasite and associated 
pathologies. The top enriched functions include GPCR signalling, membrane/transmembrane 
proteins, [Na+/K+] transporting ATPases, Sodium leak and Potassium channel interacting 
proteins, cell adhesions molecules and Calcium/Calmodulin-dependent protein kinases (CDPKs). 
CDPKs have crucial functions in calcium signalling at various stages of the parasite’s life cycle 
and is proposed to be one of the  potential drug targets against malaria (69). It has been shown that 
P. falciparum infection activates host signalling pathway involving protein kinase C (PKC) (70).  
Similarly, host GPCR signalling pathways have been shown to play vital roles in invasion, intra-
erythrocyte parasite development  and egress processes  (71, 72); suggesting the existence of 
substantial interactions between host membrane/transmembrane signalling and parasite signalling 
elements which might mediate the disease severity. Further studies are needed to decouple the 
host-parasite interface of signal transduction and explore the potential target for new therapeutics. 
Sodium leak and Potassium channel interacting proteins, [Na+/K+] transporting ATPases play 
critical role in maintaining electrochemical equilibrium in normal erythrocytes. However, upon 
invasion by trophoblast stage of the parasite, the ion pump-leak balance is perturbed; with  
increased leak rate and decreased pump rate resulting in a remarkable increase in [Na+] and 
decrease in [K+] in the erythrocyte cytosol (73, 74). This results in formation of a new permeability 
pathway (NPP) in the erythrocyte membrane which allow the transport of nutrients and waste 
products necessary for the parasite. The composition and physiological role of NPP has been 
reviewed elsewhere (75, 76).  Studies have shown that both parasites driven proteins encoded by 
clag3.1 and clag3.2 (77, 78) and host benzodiazepine receptor mediate the formation of NPP (79, 
80).  Our result may suggest the existence of multiple host genes that are involved in mediating 
this process. Given that TPP can be a potential target for new therapeutics, further studies are 
needed to investigate the role of host and parasites genetics in mediating the channel and its 
pathophysiology.  
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 In addition to the well-known pathways such as: haemostasis and immune system that play role 
in malaria resistance (13), our analysis identified novel pathways including cell adhesion 
molecules, Rho GTPase activities, tight junction, neuronal system and axon guidance. One of the 
key virulence factors of P. falciparum is  its capacity to  modify  iRBCs  to adhere to the 
endothelium of the vasculature and, thereby, sequester in capillaries and postcapillary venules in 
vital organs leading to severe disease manifestations (61). Adhesion phenotype is mediated by 
expression of P. falciparum erythrocyte membrane protein 1 (PfEMP1) on the iRBCs (81, 82). 
The binding of iRBCs with endothelium involve various adhesion molecules including CD36, 
ICAM-1, E-selectin and chondroitin sulfate A (CSA) that are variably expressed in different 
organs (83–85). The neural adhesion molecules identified in the current study might involve in 
receptor activities and their polymorphisms might play protective roles against SM.  Furthermore, 
adhesion events have been shown to activate Rho kinase signalling pathway which is strongly 
implicated in various vascular diseases (86). The genes that are enriched in these pathways might 
provide protection against severe malaria by weakening the cytoadherence interactions and 
associated pathologies. Other genes that are enriched in neuronal system, axon guidance and tight 
junction might be linked with intra cerebral pathogenesis of SM (87). Furthermore, the candidate 
malaria resistance genes identified by gene-based GWAS were differential expressed in blood 
vessels; suggesting that the majority of the identified genes are likely  counteract P. falciparum 
induced endothelial disfunctions in microvasculature and capillaries (44). 
In conclusion, our functional mapping analysis identified 57 genes located in the known malaria 
genomic loci while our gene-based GWAS analysis identified additional 125 genes across the 
genome which can potentially guide future experimental studies. The identified genes were 
significantly enriched in malaria pathogenic pathways including multiple overlapping pathways in 
erythrocyte-related functions, blood coagulations, ion channels, adhesion molecules, membrane 
signaling elements and neuronal systems. Overall, our results suggest that severe malaria 
resistance trait is attributed to multiple genes that are enriched in overlapping pathways linked to 
severe malaria pathogenesis; highlighting, the possibility of harnessing new malaria therapeutics 
that can simultaneously target multiple malaria protective host molecular pathways. Further 
experimental studies are needed to validate the findings in the current study. 
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Materials and Methods 
 
Description of the study datasets  
We accessed a previous severe malaria GWAS datasets (16)  (N = ~11,000) of three African 
populations including Kenya, Gambia and Malawi from European Phenome Genome Archive 
(EGA) following the standard data access protocols outlined in (88, 89). Children with severe 
malaria cases were recruited on admission to hospital using definitions as per WHO guidelines for 
cerebral malaria (Blantyre coma score < 3 in children or Glasgow coma score < 11 in adults), 
severe malarial anaemia (haemoglobin < 5 g/100 mL or haematocrit < 15%) and other malaria-
related symptoms (90). Control samples  were obtained from representative of the ethnic groups 
of the cases or in some study sites from the local population (89). The samples were genotyped on 
Illumina Omni 2.5Marray and QC filtered as described in (14). In addition to the genotype dataset, 
we obtained a set of  severe malaria susceptibility GWAS summary statistics (N=17,000)  meta-
analysed across eleven population in Africa, Oceania and Asia from (18). The dataset contained 
information on GWASs of individual study populations and their meta-analysis. We additionally 
accessed a merged data set from 1000 Genomes Project and African Genome Variation Project 
(AGVP)(91) of which 20 world-wide ethnic groups (Supplementary Table 4) have been grouped 
following ethno-linguistic information (92).  
 
Functional mapping and annotations  
 
We used the meta-analyzed malaria GWAS summary statistics (N=17,000 samples, 17million 
SNPs) across eleven populations(18) for functional mapping and annotations. We implemented 
FUMA(20), a pipeline that determines genomic risk loci and  prioritize potential causal genes by 
incorporating information from multiple sources including GTEx (93), ENCODE (25), Roadmap 
Epigenomics Project (26) and chromatin interaction information (27). Briefly, a pre-calculated LD 
structure based on 1000 Genome version 3 of the African population was used to determine the 
risk loci and independent significant SNPS from the GWAS summary statistics data. Independent 
significant SNP was defined as a genome-wide significant SNP (P-value < 5e-8) within LD 
threshold of r2 >0.6.  Other nominally significant SNPs (p<0.05) that are in LD (r2 <0.6) with 
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independent significant SNPs were designated as candidate SNPs and included for annotation 
analysis. From identified independent significant SNPs, lead SNPs were selected at LD threshold 
of r2 >0.1. SNPs in close proximity (< 250 k) were considered as a single locus and thus, each 
genomic locus can contain multiple independent significant SNPs and lead SNPs. 
We then implemented three gene mapping strategies including positional mapping, expression 
Quantitative Trait Locus (eQTL) mapping, and chromatin interaction implemented in FUMA(20). 
Positional mapping was performed by ANNOVAR tool (94) using  Ensembl (build 85; 
http://www.ensembl.org/) dataset. A maximum distance of 10kb window size upstream and 
downstream was used to map SNPs to genes. SNPs filtering was carried out based on CADD 
score(95), RegulomeDB score (96) and 15-core chromatin state (97).  
eQTL mapping was performed for genes within 1 Mb of the most significant variant using   
datasets that contain eQTL information related to severe malaria such as brain and blood. These 
include:PsychENCODE(98), GTExv8 (93), BRAINEAC (99), DICE (100), eQTLGen (101) (and 
Blood eQTLbrowser (102) and scRNA_eQTLs(103). Chromatin interaction mapping was 
performed using dataset including Hi-C data of 21 tissues/cell types obtained from GSE87112. 
(104), Hi-C loops from Giusti-Rodriguez et al. 2019 (105) which contains pre-processed enhancer-
promoter and promoter-promoter interactions based on Hi-C data for adult and foetal human brain 
samples(105), Hi-C based data from PsychENCODE (98) which is composed of Enhancer-
Promoter links based on Hi-C and Promoter anchored Hi-C loops and Enhancer-Promoter 
correlations from FANTOM5 (106). We restricted our analysis to tissues related to severe malaria 
pathogenesis. Genes prioritized by any of these three strategies were considered as potential causal 
genes. To gain  insights in to the biological functions of prioritized genes, we performed gene 
enrichment analysis using  an hypergeometric test in which  gene-sets obtained from MsigDB (38) 
and WikiPathways (107) were used as background genes. We further tested differential gene 
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Gene-based genome-wide association analysis  
Considering the polygenic nature of severe malaria susceptibility trait (11), we applied Pascal (22) 
, a gene-based GWAS analysis that can aggregate  all SNPs within a gene and thus, capture modest 
effects.  Briefly, Pascal sum of chi-squared statistics (SOCS) analysis was applied to nominally 
significant GWAS SNPs (p-value < 0.05) and to compute the corresponding gene scores (p-values) 
in 50kb upstream and downstream window. LD information for estimation of correlation structure  
was obtained from African dataset in  1000G phase 3 (108). We further categorized the prioritized 
genes in to different functional groups using DAVID tools (39). Significant genes were  subjected 
to differential gene expression analysis implemented in FUMA software using  54 tissues obtained 
from the GTEx (93). Pathway scores were computed by combining the scores of genes that belong 
to the same gene-set.  The analysis doesn’t require a gene score threshold and incorporates weakly 
associated genes for pathway enrichment.  Gene-fusion parameter was set to 1Mb so that all 
pathway-member genes within 1Mb apart were fused together. Genes in HLA-region and those 
containing more than 3000 SNPs were removed as outlined in Pascal documentations (22).  
 
Gene burden and rare-variants association tests 
 
Given that the GWAS assumption is based on common variant common disease hypothesis, 
GWAS approach always miss potential association signal from rare variants. To examine the 
contribution of rare variants, we applied optimal unified sequence kernel association test (SKAT-
O), which combines burden and variance-component analyses (37) to the  GWAS dataset of 
Gambia, Kenya and Malawi populations. Briefly, we aligned the VCF files including Gambia 
(N=4920 samples, 1.6 million SNPs), Malawi (N=2560 samples, 1.6 million SNPs) and Kenya 
(N=3143 samples, 1.6 million SNPs) to GWAS dataset to 1000 Genome v-3 reference haplotypes 
using Genotype Harmonizer (109) and removed  SNPs with position and strand mismatches and 
phased using SHAPEITv2 (110). We performed imputation using impute 2 (111) and obtained ~ 
20 million from each population. After removal SNPs with low genotype rate and imputation 
accuracy, we retained ~15,000 SNPs in each population. We then  applied SKAT-O test  to the 
quality filtered data following the procedure outlined in  SKAT package (37).   
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We performed a network analysis to investigate the functional interaction between malaria 
resistance candidate genes. Briefly, we obtained functional interaction network from of the 
identified candidate malaria resistance genes using Multiple Association Network Integration 
Algorithm (geneMANIA) tool (112). Using this information, we computed network parameters 
including degree, betweenness and closeness centrality metrics to evaluate the topology of 
nodes(genes) and edges(interactions) in the network using networkX (113) and R igraph packages 
(114).  
Closeness measures the average distance from the node to all other nodes in the network, indicating 
which nodes represent a greater “risk” (maximally close with lowest sum of edge weights) for 
eliciting other nodes. Betweenness measures the number of times that a node lies on the shortest 
path between two other nodes, indicating which nodes serve as a “hub” between other nodes (114). 
The degree of a node is described as the number of direct connections it has with other nodes 
within the network. Low degree nodes usually connect to nodes within their local community 
whereas high degree nodes usually extend to the neighbouring community (114). Using the 
centrality scores, we quantified node centrality to identify hub genes by investigating the 
contribution of the edges and the weight of the edges towards node centrality. The hubs genes 
make strong contributions to the subnetwork and/or global network integrity. Connector hubs and 
provincial hubs refers to nodes that link other nodes across different communities and local 
communities, respectively. 
 
Population genetic structure of malaria-specific resistance candidate genes 
 
We performed the population genetic structure of the identified genes in malaria endemic 
populations (Kenya, Gambia and Malawi) and global populations of 20 ethnic groups obtained 
from African Genome Variation Project (AGVP) (91).  We mapped a total of 14,106,476 SNPs to 
the identified candidate genes using dbSNP database. We  merged the  quality filtered GWAS 
datasets of  the three malaria endemic populations using PLINK software (115) and retained 
dataset that contains the SNPs that are mapped to the identified genes (N= 10578 samples, 15,675 
SNPs).  We performed basic quality control, removed structural variants and ambiguous SNPs 
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using PLINK software (115) as described elsewhere (116).  We retained AGVP dataset containing 
only the SNPs that are mapped to the identified candidate genes (N=4932 samples, 93,5549 SNPs).  
We then partitioned these datasets in to a total 23 different Ethnic groups (20 from AGVP and 3 
from malaria endemic populations) based on population or country labels information.  We 
clustered the merged malaria GWAS dataset and the AGVP dataset containing only SNPs residing 
in the identified genes in to sub-regions/populations using smartpca software (117). For each 
ethnic group, we computed various population genetics analysis including minor allele frequency 
(MAF) at various bins and gene-specific in SNPs MAF by aggregating MAF of all associated 
SNPs within gene from dbSNPs. We finally computed proportion of pathogenic SNPs within the 
candidate genes using ANNOVAR software (94) by computing the number of SNPs reported to 
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Supplementary Fig 1 . Chromatin interactions and eQTLs of severe malaria resistance candidate 
genes on chr 11 risk locus. The most outer layer is the Manhattan plot displaying SNPs with P-
value < 0.05. Candidate SNPs are coloured based on the highest r2 to one of the independent 
significant loci (red: r2 > 0.8, orange: r2 > 0.6). Other SNPs are coloured in grey. The outer circle 
is the chromosome coordinate and genomic risk loci are highlighted in blue. Genes mapped by 
either Hi-C or eQTLs are shown on the inner circle. Genes identified by chromatin interaction and 
eQTLs are coloured orange and green respectively while genes mapped by both are coloured red. 
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Supplementary Fig2. Chromatin interactions and eQTLs of severe malaria resistance candidate 
genes on chr 9 risk locus. The most outer layer is the Manhattan plot displaying SNPs with P-value 
< 0.05. Candidate SNPs are coloured based on the highest r2 to one of the independent significant 
loci (red: r2 > 0.8, orange: r2 > 0.6). Other SNPs are coloured in grey. The outer circle is the 
chromosome coordinate and genomic risk loci are highlighted in blue. Genes mapped by either 
Hi-C or eQTLs are shown on the inner circle. Genes identified by chromatin interaction and eQTLs 
are coloured orange and green respectively while genes mapped by both are coloured red 
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Supplementary  Fig 3. Minor allele frequency bins of SNPs mapped to severe malaria 
resistance candidate genes in three malaria endemic populations (Gambia, Malawi, Kenya) and 
global populations of 20 ethnic groups. Y-axis represent allele frequency, X-axis represent 
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Supplementary Fig 4. Gene specific MAF of SNPs mapped to severe malaria resistance 
candidate genes in three malaria endemic populations (Gambia, Malawi, Kenya) and global 
populations of 20 ethnic groups. Y-axis represent gene specific allele frequency, X-axis represent 
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 Supplementary Table 1. Positional enrichment of genes identified by FUMA method using 
MsigDB genes as background 
 
 
Supplementary Table 2. Candidate malaria resistance genes identified by both functional 





Ensg entrezID HUGO symbol chromosome Cytoband Start end Biotype 
ENSG00000058668 493 ATP2B4 ATP2B4 1 q32.1 203595689 203713209 Protein coding  
ENSG00000148296 6838 SURF6 SURF6 9 q34.2 136197552 136203235 Protein coding  
ENSG00000148297 6837 MED22 MED22 9 q34.2 136205160 136214986 Protein coding  
ENSG00000148290 6834 SURF1 SURF1 9 q34.2 136218610 136223552 Protein coding  
ENSG00000148291 6835 SURF2 SURF2 9 q34.2 136223428 136228045 Protein coding  
ENSG00000148248 6836 SURF4 SURF4 9 q34.2 136228325 136242970 Protein coding  
ENSG00000132109 6737 TRIM21 TRIM21 11 p15.4 4406127 4414926 Protein coding  
ENSG00000176925 119694 OR51F2 OR51F2 11 p15.4 4842551 4843686 Protein coding  
ENSG00000244734 3043 HBB HBB 11 p15.4 5246694 5250625 Protein coding  
ENSG00000223609 3045 HBD HBD 11 p15.4 5253908 5256600 Protein coding  
ENSG00000196565 3048 HBG2 HBG2 11 p15.4 5274420 5667019 Protein coding  
ENSG00000213931 3046 HBE1 HBE1 11 p15.4 5289582 5526847 Protein coding  
ENSG00000184881 79345 OR51B2 OR51B2 11 p15.4 5344541 5345582 Protein coding  
Position N N P-value adjusted P Genes 
chr11p15 297 19 8.86e-21 2.65e-18 TRIM21, TRIM68, MMP26, OR51F2, OR51L1, OR52A1, HBB, HBD, HBG1, HBG2, 
HBE1, OR51B2, UBQLNL, TRIM6, TRIM6-TRIM34, TRIM34, TRIM22, CCKBR, 
PRKCDBP 
chr9q34 214 11 3.10e-11 4.63e-9 RALGDS, GBGT1, SURF6, MED22, SURF1, SURF2, SURF4, REXO4, ADAMTS13, 
SLC2A6, ADAMTSL2 
chr4q31 67 6 4.61e-8 4.60e-6 RNF150, ZNF330, GAB1, FREM3, GYPE, GYPB 
chr1q32 147 7 2.62e-7 1.96e-5 CHIT1, BTG2, FMOD, PRELP, ATP2B4, LAX1, PLEKHA6 
chr3q26 61 3 7.97e-4 4.77e-2 B3GALNT1, NMD3, SPTSSB 
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Supplementary Table 3.  Nominally significant genes obtained from burden and rare variant 





















start end Biotype P.value N.Marker.Rare 
Gambia LOC105377246 4 q13.1 58,976,071 58,984,194 ncRNA 1.72e-4 29 
LOC100507464 8 q11.21 49,496,763 49,512,234 ncRNA 9.68e-05 36 
MIR4282 6 q13 72967687 72967753 lncRNA 4.83e-4 7 
GLYR1 16 P13.3 4803203 4847288 
Protein 
coding 3.72e-4 139 
LINC00520 14 q22.3 55781132 55796731 lncRNA 9.70e-05 19 
LOC105371381 - - - - - 1.84e-4 15 
Malawi 
ATP8A1 4 P13 42408373 42657105 
Protein 
coding 4.91e-4 244 
EPB41L2 6 q23.2 130839347 131063322 
Protein 
coding 3.91e-4 207 
LOC105376161 9 q22.32 95,764,922 95,776,282 ncRNA 1.51e-4 9 
LOC105377731 5 q35.1 173,269,431 173,280,929 ncRNA 3.13e-4 29 
NDNF 4 q27 121035613 121073021 
Protein 
coding 9.53e-05 28 
LINC00676 13 q13.34 109,728,274 109,730,034 lncRNA 3.40e-4 10 
LOC105370198 13 q14.2 48,108,123 48,166,377 ncRNA 4.87e-4 122 
LOC653786 - - - -  4.53e-4 29 
WASF3 13 q12.13 26557683 26688948 
Protein 
coding 2.54e-4 193 
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cus uniqID Lead SNPs Chr Position P-value Start End 
1 
1:203652905:
C:G rs4951370 1 203652905 3.49E-08 203649423 203713887 
2 
3:160396863:
C:T rs116423146 3 160396863 1.64E-08 160362359 160397943 
3 
4:144587704:
A:G rs141274959 4 144587704 4.28E-10 143606326 145500856 
4 
9:129250119:
A:G rs57032711 9 129250119 1.31E-08 129250119 129264823 
5 
9:136132908:T
:TC rs8176719 9 136132908 1.16E-19 136128000 136148231 
6 
11:5248232:A:
T rs334 11 5248232 1.31E-55 3542398 6540324 
 
 
S2 Data. Independent significant SNPs at r2>0.6 identified from severe malaria resistance 
GWASs 
   
Genomic
Locus uniqID rsID Chr Pos P nSNPs 
nGWASS
NPs   
1 1:203652905:C:G rs4951370 1 203652905 3.49E-08 76 64    
2 3:160396863:C:T rs116423146 3 160396863 1.64E-08 17 17    
3 4:144501489:C:T rs111374053 4 144501489 8.90E-10 141 8    
3 4:144587704:A:G rs141274959 4 144587704 4.28E-10 1 1    
3 4:144653717:C:G rs78251788 4 144653717 1.09E-08 16 2    
3 4:144666678:A:C rs149914432 4 144666678 7.79E-09 2 2    
3 4:144747271:C:T rs184497846 4 144747271 5.21E-10 53 34    
3 4:144768545:A:G rs2323342 4 144768545 1.36E-09 20 2    
3 4:144778659:T:TA rs201510180 4 144778659 2.29E-08 202 9    
3 4:144783909:C:T rs181143788 4 144783909 5.34E-09 171 24    
3 4:144921625:G:T rs111843057 4 144921625 1.68E-09 32 15    
3 4:145064514:C:CTT rs373218729 4 145064514 3.09E-09 1 1    
3 4:145104286:C:T rs149988318 4 145104286 1.48E-08 36 6    
3 4:145124084:A:G rs34330779 4 145124084 1.68E-08 1 1    
4 9:129250119:A:G rs57032711 9 129250119 1.31E-08 3 3    
5 9:136131022:C:T rs8176751 9 136131022 6.42E-10 19 17    
5 9:136132908:T:TC rs8176719 9 136132908 1.16E-19 1 1    
5 9:136137065:A:G rs687621 9 136137065 2.68E-09 36 6    
6 11:3589834:C:T rs76727905 11 3589834 1.02E-08 11 6    
6 11:4528855:C:T rs374510430 11 4528855 2.05E-10 7 3    
 110 
6 11:4681473:G:T rs188923516 11 4681473 1.19E-17 6 4    
6 11:4716564:A:G rs181023493 11 4716564 1.95E-12 9 6    
6 11:4721821:C:T rs12286023 11 4721821 2.39E-10 1 1    
6 11:4831481:A:G rs141862673 11 4831481 7.45E-13 72 70    
6 11:4841199:A:G rs145429724 11 4841199 6.33E-11 3 3    
6 11:4856570:C:T rs114980444 11 4856570 1.39E-15 7 7    
6 11:4863120:A:G rs146607281 11 4863120 3.11E-17 17 15    
6 11:4871997:A:G rs148547877 11 4871997 4.06E-09 10 9    
6 11:4907203:C:T rs75265800 11 4907203 2.39E-15 6 6    
6 11:4916348:C:T rs76444902 11 4916348 5.54E-10 9 7    
6 11:4918226:A:G rs184415744 11 4918226 1.44E-13 2 2    
6 11:4953000:A:T rs74052644 11 4953000 5.59E-10 4 4    
6 11:5012800:A:G rs142527103 11 5012800 2.71E-16 21 21    
6 11:5057159:C:T rs16908890 11 5057159 5.75E-09 28 28    
6 11:5067053:C:G rs139248000 11 5067053 6.35E-16 7 7    
6 11:5094696:C:T rs148559893 11 5094696 5.81E-14 20 18    
6 11:5111447:A:G rs147273018 11 5111447 2.86E-17 61 58    
6 11:5118578:T:TA rs201250014 11 5118578 2.45E-17 2 2    
6 11:5150187:A:G rs75366027 11 5150187 3.69E-09 8 8    
6 11:5150751:A:G rs7927066 11 5150751 1.08E-08 5 5    
6 11:5168952:C:T rs6578556 11 5168952 2.32E-08 3 3    
6 11:5178410:G:T rs189023578 11 5178410 2.75E-13 16 16    
6 11:5184567:A:G rs200657212 11 5184567 4.37E-10 1 1    
6 11:5187079:A:G rs7938610 11 5187079 8.80E-12 8 8    
6 11:5187842:C:T rs10837488 11 5187842 8.83E-09 3 3    
6 11:5188027:G:T rs183055323 11 5188027 1.79E-33 15 13    
6 11:5190368:A:G rs116780407 11 5190368 1.49E-11 28 28    
6 11:5192015:C:G rs73396897 11 5192015 2.62E-08 4 4    
6 11:5236954:C:T rs79681613 11 5236954 4.60E-09 9 9    
6 11:5241282:C:G rs4290259 11 5241282 6.79E-12 19 17    
6 11:5243936:C:T rs113850170 11 5243936 1.53E-12 2 2    
6 11:5248232:A:T rs334 11 5248232 1.31E-55 1 1    
6 11:5249011:A:C rs7119261 11 5249011 1.56E-08 1 1    
6 11:5252794:A:G rs12295158 11 5252794 1.02E-08 1 1    
6 11:5273865:C:G rs113892119 11 5273865 1.40E-22 6 3    
6 11:5321510:C:CAGG rs145843585 11 5321510 7.14E-13 10 10    
6 11:5342001:A:G rs11036798 11 5342001 1.13E-13 2 2    
6 11:5407041:A:G rs183322782 11 5407041 1.03E-29 29 14    
6 11:5504744:AAA rs11037724 11 5504744 3.71E-13 36 1    
6 11:5511525:A:G rs147525041 11 5511525 1.03E-10 17 16    
6 11:5523004:C:T rs150299658 11 5523004 1.87E-12 2 1    
6 11:5536537:A:C rs393044 11 5536537 1.74E-08 7 7    
 111 
6 11:5549043:C:T rs116554111 11 5549043 1.06E-14 3 3    
6 11:5622634:A:G rs141046578 11 5622634 1.55E-11 2 1    
6 11:5639076:T:TA rs141872087 11 5639076 2.06E-16 12 2    
6 11:5737256:C:T rs186977392 11 5737256 2.87E-08 1 1    
6 11:5808878:A:C rs148179286 11 5808878 3.74E-12 8 4    
6 11:5829334:A:G rs28576676 11 5829334 8.60E-11 1 1    
6 11:5938210:A:G rs183089109 11 5938210 5.33E-10 7 7    
 
S3 Data. Lead SNPs identified from independent significant SNPs of severe malaria 
resistance GWAS 
GenomicL
ocus uniqID rsID 
chromo
some Position P-value 
nIndSigSNP
s 
1 1:203652905:C:G rs4951370 1 203652905 3.49E-08 1 
2 3:160396863:C:T rs116423146 3 160396863 1.64E-08 1 
3 4:144587704:A:G rs141274959 4 144587704 4.28E-10 3 
3 4:144768545:A:G rs2323342 4 144768545 1.36E-09 6 
3 4:144783909:C:T rs181143788 4 144783909 5.34E-09 2 
3 4:144921625:G:T rs111843057 4 144921625 1.68E-09 2 
3 
4:145064514:C:CT
T rs373218729 4 145064514 3.09E-09 1 
3 4:145104286:C:T rs149988318 4 145104286 1.48E-08 3 
4 9:129250119:A:G rs57032711 9 129250119 1.31E-08 1 
5 9:136132908:T:TC rs8176719 9 136132908 1.16E-19 3 
6 11:3589834:C:T rs76727905 11 3589834 1.02E-08 1 
6 11:4681473:G:T rs188923516 11 4681473 1.19E-17 22 
6 11:4831481:A:G rs141862673 11 4831481 7.45E-13 8 
6 11:5118578:T:TA rs201250014 11 5118578 2.45E-17 9 
6 11:5150187:A:G rs75366027 11 5150187 3.69E-09 15 
6 11:5187079:A:G rs7938610 11 5187079 8.80E-12 8 
6 11:5241282:C:G rs4290259 11 5241282 6.79E-12 4 
6 11:5248232:A:T rs334 11 5248232 1.31E-55 13 



















ENSG00000142657 PGD 1 10458649 10480201 No No rs687621 5 
ENSG00000133063 CHIT1 1 203181955 203242769 NA Yes rs4951370 1 
ENSG00000159388 BTG2 1 203274619 203278730 NA Yes rs4951370 1 
ENSG00000122176 FMOD 1 203309756 203320617 NA Yes rs4951370 1 
ENSG00000188783 PRELP 1 203444956 203460480 NA Yes rs4951370 1 
ENSG00000058668 ATP2B4 1 203595689 203713209 Yes Yes rs4951370 1 
ENSG00000122188 LAX1 1 203734304 203745361 Yes No rs4951370 1 
ENSG00000143850 PLEKHA6 1 204187979 204346793 NA Yes rs4951370 1 
ENSG00000228474 OST4 2 27293340 27294641 Yes No rs8176751 5 
ENSG00000080345 RIF1 2 152266397 152364527 Yes No rs8176751 5 
ENSG00000213186 TRIM59 3 160150233 160203561 NA Yes rs116423146 2 
ENSG00000179674 ARL14 3 160394948 160396233 NA No rs116423146 2 
ENSG00000163590 PPM1L 3 160473390 160796695 NA Yes rs116423146 2 
ENSG00000169255 
B3GALNT
1 3 160801671 160823172 NA Yes rs116423146 2 
ENSG00000169251 NMD3 3 160822484 160971320 NA Yes rs116423146 2 
ENSG00000196542 SPTSSB 3 161062580 161090668 NA Yes rs116423146 2 
ENSG00000170153 RNF150 4 141780961 142134031 NA Yes rs111374053 3 
ENSG00000109445 ZNF330 4 142142041 142155851 NA Yes rs111374053 3 
ENSG00000109458 GAB1 4 144257915 144395721 NA No rs111374053 3 
ENSG00000183090 FREM3 4 144498455 144621828 Yes No rs201510180 3 
ENSG00000197465 GYPE 4 144792020 144826716 Yes No rs34330779 3 
ENSG00000250361 GYPB 4 144917257 145061844 Yes No rs201510180 3 
ENSG00000113758 DBN1 5 176883609 176901402 Yes No rs687621 5 
ENSG00000203813 
HIST1H3
H 6 27777842 27778314 Yes No rs8176751 5 
ENSG00000136193 SCRN1 7 29959719 30029905 Yes No rs687621 5 
ENSG00000160271 RALGDS 9 135973107 136039301 Yes No 
rs8176751;rs6
87621 5 
ENSG00000148288 GBGT1 9 136028340 136039332 Yes No rs687621 5 
ENSG00000148296 SURF6 9 136197552 136203235 Yes No 
rs8176751;rs6
87621 5 
ENSG00000148297 MED22 9 136205160 136214986 Yes No 
rs8176751;rs6
87621 5 
ENSG00000148290 SURF1 9 136218610 136223552 Yes No 
rs8176751;rs6
87621 5 
ENSG00000148291 SURF2 9 136223428 136228045 Yes No rs8176751 5 
ENSG00000148248 SURF4 9 136228325 136242970 Yes No rs8176751 5 
ENSG00000148300 REXO4 9 136271186 136283164 Yes No rs8176751 5 
ENSG00000160323 
ADAMTS
13 9 136279478 136324508 Yes No 
rs8176751;rs6
87621 5 





L2 9 136397286 136440641 Yes No rs8176751 5 
ENSG00000132109 TRIM21 11 4406127 4414926 NA Yes rs28576676 6 



















S5 Data. Severe malaria candidate genes identified by gene-based GWAS analysis using 
Pascal method 





ENSG00000176798 OR51L1 11 5020213 5021160 NA Yes 
rs113892119:r
s28576676 6 
ENSG00000182070 OR52A1 11 5172239 5207612 NA No rs116780407 6 
ENSG00000244734 HBB 11 5246694 5250625 NA No rs334 6 





ENSG00000213934 HBG1 11 5269313 5271122 Yes No rs7927066 6 






ENSG00000213931 HBE1 11 5289582 5526847 NA No rs145843585 6 
ENSG00000184881 OR51B2 11 5344541 5345582 NA No rs145843585 6 
ENSG00000175518 UBQLNL 11 5535623 5537935 Yes No rs11037724 6 
ENSG00000121236 TRIM6 11 5617339 5634188 NA Yes rs28576676 6 
ENSG00000258588 
TRIM6-




ENSG00000258659 TRIM34 11 5640994 5665628 NA No 
rs183322782;r
s148179286 6 
ENSG00000132274 TRIM22 11 5710919 5758319 NA Yes rs28576676 6 





P 11 6340176 6341877 NA Yes rs28576676 6 
ENSG00000108960 MMD 17 53469974 53499353 Yes No rs8176751 5 









an start  End Biotype N of SNPs P-value 
ABLIM2 chr4 - p16.1 7967036 8160559 protein_coding 37 3.80E-09 
ABO chr9 - q34.2 136130562 136150630 protein_coding 169 2.67E-11 
ADAMTS16 chr5 + 
p15.3
2 5140442 5320412 protein_coding 48 1.61E-07 
ARHGAP18 chr6 - 
q22.3
3 129898239 130182692 protein_coding 53 1.00E-08 
ATP2B4 chr1 + q32.1 203595914 203713209 protein_coding 106 4.68E-09 
ATXN7L1 chr7 - q22.3 105245220 105517031 protein_coding 80 3.40E-08 
BACE2 chr21 + q22.2 42539727 42648524 protein_coding 23 3.78E-07 
CACNA1A chr19 - 
p13.1
3 13317255 13617274 protein_coding 41 2.55E-06 
CAMK1D chr10 + p13 12391582 12871733 protein_coding 41 1.87E-06 
CDH13 chr16 + q23.3 82660398 83830215 protein_coding 245 4.19E-08 
CLYBL chr13 + q32.3 100258918 100549388 protein_coding 16 5.83E-07 
CNOT6 chr5 + q35.3 179921416 180005353 protein_coding 33 3.23E-07 
CNTN4 chr3 + p26.3 2140549 3099645 protein_coding 114 3.88E-09 
CNTN5 chr11 + q22.1 98891705 100229616 protein_coding 240 1.28E-06 
CNTNAP2 chr7 + q35 145813452 148118088 protein_coding 158 6.10E-08 
COL27A1 chr9 + q32 116918230 117072975 protein_coding 32 2.72E-06 
CPXM2 chr10 - 
q26.1
3 125465725 125699779 protein_coding 17 2.69E-06 
CRBN chr3 - p26.2 3191316 3221401 protein_coding 25 1.23E-07 
CSMD1 chr8 - p23.2 2792874 4852328 protein_coding 499 1.58E-12 
CTIF chr18 + q21.1 46065426 46389586 protein_coding 22 1.71E-07 
DAB1 chr1 - p32.1 57463578 59012446 protein_coding 136 5.08E-07 
DGKB chr7 - p21.2 14184673 14942550 protein_coding 52 3.87E-09 
DIP2C chr10 - p15.3 320129 735608 protein_coding 104 4.54E-07 
DLGAP1 chr18 - 
p11.3
1 3496029 4455266 protein_coding 72 2.38E-10 
ERICH1-AS1 chr8 + p23.3 687586 1087777 protein_coding 64 2.04E-06 
EVC chr4 + p16.2 5712923 5830772 protein_coding 16 7.56E-07 
FHIT chr3 - p14.2 59735035 61237133 protein_coding 179 1.78E-09 
FLT4 chr5 - q35.3 180028505 180076624 protein_coding 25 9.96E-08 
FRMD4A chr10 - p13 13685705 14504143 protein_coding 136 1.69E-07 
FZD10 chr12 + 
q24.3
3 130647003 130650285 protein_coding 18 1.26E-07 
FZD10-AS1 chr12 - 
q24.3
3 130636137 130646768 lncRNA 18 1.26E-07 
GAS7 chr17 - p13.1 9813925 10101868 protein_coding 19 1.63E-06 
GLIS3 chr9 - p24.2 3824127 4300035 protein_coding 25 1.50E-07 
GPC5 chr13 + q31.3 92050934 93519487 protein_coding 93 1.59E-06 
HBB chr11 - p15.4 5246695 5248301 protein_coding 177 4.92E-10 
 115 
HBBP1 chr11 - p15.4 5263184 5264822 
transcribed_unpro
cessed_pseudoge
ne 108 2.00E-08 
HBD chr11 - p15.4 5254058 5255858 protein_coding 150 8.79E-10 
HBE1 chr11 - p15.4 5289579 5526882 protein_coding 325 9.39E-11 
HBG2 chr11 - p15.4 5269501 5667011 protein_coding 478 1.00E-12 
ICA1 chr7 - p21.3 8152814 8302242 protein_coding 60 4.63E-07 
IL2RA chr10 - p15.1 6052656 6104333 protein_coding 35 1.31E-06 
KAZN chr1 + 
p36.2
1 14925212 15444544 protein_coding 44 2.15E-06 
KCNIP1 chr5 + q35.1 169780880 170163636 protein_coding 42 2.64E-06 
KCNIP4 chr4 - p15.2 20730238 21950374 protein_coding 157 2.31E-06 
KCTD1 chr18 - q11.2 24034873 24237365 protein_coding 17 3.25E-07 
KIF26B chr1 + q44 245318286 245866428 protein_coding 151 2.23E-08 
KIR3DX1 chr19 + 
q13.4
2 55043908 55055195 
transcribed_unpro
cessed_pseudoge
ne 11 1.53E-06 
LINC00260 chr1 + q32.1 203699704 203700979 lncRNA 99 5.36E-09 
LINC00856 chr10 + q22.3 80008381 80311112 lncRNA 16 1.95E-06 
LOC10013425
9 chr2 +  47055002 47086145 lncRNA 13 4.69E-07 
LOC10050758
4 chr6 -  33857287 33864684 lncRNA 7 1.37E-06 
LOC388948 chr2 +  47043806 47049799 lncRNA 12 7.44E-07 
LPP chr3 + q27.3 187871662 188608460 protein_coding 83 5.61E-08 
LRP1B chr2 - q22.2 140988995 142889270 protein_coding 266 9.36E-09 
MAGI2 chr7 - 
q21.1
1 77646373 79082890 protein_coding 52 1.04E-06 
MED22 chr9 - q34.2 136207754 136214972 protein_coding 42 5.65E-08 
MEGF6 chr1 - 
p36.3
2 3404505 3528059 protein_coding 45 6.37E-07 
MIR5188 chr12 + 
q24.3
1 125400092 125400205 miRNA 26 1.10E-06 
MTHFD1L chr6 + q25.1 151186814 151423023 protein_coding 36 4.30E-08 
MTUS2 chr13 + q12.3 29598747 30080084 protein_coding 90 2.56E-06 
MYO16 chr13 + q33.3 109248499 109860355 protein_coding 32 9.38E-07 
NALCN chr13 - q33.1 101706129 102068843 protein_coding 73 1.19E-06 
NAV2 chr11 + p15.1 19372270 20143147 protein_coding 49 2.84E-06 
NKAIN2 chr6 + 
q22.3
1 124125068 125146786 protein_coding 68 6.74E-09 
NMT2 chr10 - p13 15147770 15210695 protein_coding 59 2.57E-06 
NPAS3 chr14 + q13.1 33408458 34273382 protein_coding 56 3.34E-07 
NTM chr11 + q25 131240370 132206716 protein_coding 105 5.67E-07 
OBP2B chr9 - q34.2 136080665 136084628 protein_coding 112 1.37E-11 
OPCML chr11 - q25 132284874 133402403 protein_coding 112 1.46E-07 
OR51B2 chr11 - p15.4 5344527 5345582 protein_coding 69 8.96E-08 
OR51B4 chr11 - p15.4 5322243 5323176 protein_coding 81 4.62E-10 
 116 
OR51B5 chr11 - p15.4 5362112 5526882 protein_coding 241 2.26E-07 
OR51B6 chr11 + p15.4 5372737 5373676 protein_coding 83 1.50E-07 
OR51E2 chr11 - p15.4 4701400 4719076 protein_coding 33 7.15E-07 
OR51F1 chr11 - p15.4 4790208 4791147 Pseudogene 119 8.00E-07 
OR51F2 chr11 + p15.4 4842615 4843644 protein_coding 118 1.99E-06 
OR51T1 chr11 + p15.4 4903048 4904113 protein_coding 37 1.90E-06 
OR51V1 chr11 - p15.4 5220964 5221930 protein_coding 189 4.38E-09 
OR52B4 chr11 - p15.4 4388492 4389616 protein_coding 133 1.56E-06 
OR52K2 chr11 + p15.4 4470524 4471591 protein_coding 129 2.61E-07 
OR52R1 chr11 -  4824662 4825610  119 1.98E-06 
OR56A1 chr11 - p15.4 6047900 6048971 protein_coding 29 2.34E-06 
PARK2 chr6 -  161768589 163148834  230 6.33E-08 
PCSK5 chr9 + 
q21.1
3 78505559 78977255 protein_coding 73 2.88E-11 
PGAP2 chr11 + p15.4 3818953 3847601 protein_coding 15 1.18E-06 
PITPNC1 chr17 + q24.2 65373396 65693379 protein_coding 28 2.20E-07 
PLCB1 chr20 + p12.3 8095099 8865547 protein_coding 147 2.36E-06 
PRKAG2 chr7 - q36.1 151253200 151574316 protein_coding 24 8.63E-07 
PRKG1 chr10 + 
q11.2
3 52750910 54058110 protein_coding 125 1.25E-06 
PTPRD chr9 - p23 8314245 10612723 protein_coding 320 4.72E-07 
PTPRN2 chr7 -  157331749 158380482 Protein coding 102 4.20E-08 
PTPRS chr19 - q36.3 5158505 5340814 protein_coding 35 2.16E-07 
PTPRT chr20 - 
q13.1
1 40701391 41818557 protein_coding 65 4.92E-07 
RBCK1 chr20 + p13 388708 411610 protein_coding 26 9.65E-07 
RBFOX1 chr16 +  6069131 7763340  219 9.76E-11 
RBFOX3 chr17 - q25.3 77085426 77512230 protein_coding 34 9.50E-07 
RBM17 chr10 + p15.1 6130948 6159422 protein_coding 40 5.80E-07 
RIMBP2 chr12 - 
q24.3
3 130880680 131200826 protein_coding 78 3.33E-07 
RORA chr15 - q22.2 60780482 61521502 protein_coding 63 2.28E-07 
RPL7A chr9 + - 136215068 136218280 Protein coding 38 5.81E-08 
RUNX1 chr21 - 
q22.1
2 36160097 37357047 protein_coding 115 5.70E-07 
RYR2 chr1 + q43 237205701 237997288 protein_coding 115 1.74E-08 
RYR3 chr15 + q13.3 33603176 34158303 protein_coding 93 1.04E-07 
SARDH chr9 - q34.2 136528683 136605077 protein_coding 8 2.69E-06 
SCARB1 chr12 - 
q24.3
1 125262173 125365007 protein_coding 33 9.95E-07 
SCGB3A1 chr5 - q35.3 180017104 180018487 protein_coding 24 1.46E-07 
SLC35F3 chr1 + q42.2 234040678 234460262 protein_coding 73 4.50E-08 
SLIT3 chr5 - q35.1 168088737 168728133 protein_coding 30 1.82E-07 
SMYD3 chr1 - q44 245912641 246670644 protein_coding 142 1.79E-06 
 117 
SNORA77 chr1 + q32.1 203698708 203698833 snoRNA 101 5.53E-09 
SNORD24 chr9 + q34.2 136216250 136216325 snoRNA 37 1.07E-07 
SNORD36A chr9 + q34.2 136217310 136217382 snoRNA 37 1.17E-07 
SNORD36B chr9 + q34.2 136216948 136217019 snoRNA 36 2.15E-07 
SNORD36C chr9 + q34.2 136217700 136217767 snoRNA 37 1.17E-07 
SORCS2 chr4 + p16.1 7194373 7744564 protein_coding 111 5.30E-09 
SSUH2 chr3 - p25.3 8661085 8786726 protein_coding 41 3.92E-08 
SURF1 chr9 - q34.2 136218665 136223361 protein_coding 37 1.12E-07 
SURF2 chr9 + q34.2 136223420 136228040 protein_coding 34 1.74E-07 
SURF4 chr9 - q34.2 136228339 136242970 protein_coding 31 8.55E-07 
SURF6 chr9 - q34.2 136197551 136203047 protein_coding 62 6.98E-09 
TBC1D20 chr20 - p13 416123 443187 protein_coding 23 2.81E-06 
TCEB1 chr8 -  74857372 74884522  27 2.61E-06 
TENM3 chr4 + q34.3 183065139 183724177 protein_coding 53 6.16E-08 
THRB chr3 - p24.2 24158644 24536453 protein_coding 65 5.38E-07 
THSD7B chr2 + q22.1 137523114 138435287 protein_coding 77 7.84E-07 
TIAM2 chr6 + q25.2 155153830 155578857 protein_coding 29 2.56E-07 
TMEM132C chr12 + 
q24.3
2 128751947 129192460 protein_coding 62 2.18E-08 
TMEM132D chr12 - 
q24.3
3 129556270 130388212 protein_coding 77 1.17E-06 
TMPRSS6 chr22 - q12.3 37461478 37505603 protein_coding 16 1.25E-06 
TRIM21 chr11 - p15.4 4406126 4414926 protein_coding 133 1.56E-06 
TSHZ2 chr20 + q13.2 51588945 52111869 protein_coding 13 2.42E-06 
TSPAN11 chr12 + 
p11.2
1 31079361 31149537 protein_coding 15 1.03E-06 
UBC chr12 - 
q24.3
1 125396191 125399587 protein_coding 24 1.03E-06 
VRK1 chr14 + q32.2 97263683 97347951 protein_coding 9 2.13E-06 
VSTM1 chr19 - 
q13.4
2 54544079 54567207 protein_coding 14 2.39E-06 
WBSCR17 chr7 +  70597522 71178586  117 4.46E-07 
WWOX chr16 + q23.1 78133326 79246564 protein_coding 177 1.42E-06 
ZNF385B chr2 - q31.3 180306710 180726232 protein_coding 96 2.35E-08 





S6 Data. Proportion of pathogenic SNPs in candidate malaria resistance genes that recorded 
higher scores in three endemic countries (Kenya, Malawi and Gambia) compared to the global 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5. CHAPTER FIVE: CONCLUSIONS AND PERSPECTIVES  
 
5.1. Conclusions 
P. falciparum malaria remains one of the leading public health problems worldwide. The global 
tally of malaria in 2018 was estimated at 228 million cases and 405, 000 deaths worldwide [8]. 
The global malaria eradication efforts have been implemented  in malaria endemic areas using 
conventional strategies including  distribution of long-lasting insecticide treated nets (LLINS), 
indoor residual insecticide spraying, intermittent treatment for pregnant women in high 
transmission settings [11]. This led to the significant decline of malaria burden in many parts of 
the endemic regions [12]. Despite the successes gained, the progress towards global malaria 
elimination is currently challenged by emergence of drug resistant parasites, insecticide resistant 
mosquitoes and lack of effective vaccine [12].  
To overcome these challenges and maintain the current momentum, there is a pressing need of 
new intervention tools including effective drugs and vaccines, rapid and accurate diagnostic tools, 
effective insecticides, improved surveillances and rapid responses among others. A comprehensive 
understanding of the genetic basis of severe malaria resistance can potentially inform the 
development of new vaccines and therapeutics. In attempt to identify the natural human genetic 
factors that confer malaria resistance and determine their corresponding molecular mechanisms, 
multiple studies have been conducted at least for the last half a century. Earlier studies used 
conventional genetic study approaches including candidate gene association studies and linkage 
analysis to identify the genetic variants.  In the last decade, several GWASs have been conducted 
in diverse malaria endemic populations and identified a number of novel variants. However, the 
conventional GWASs cannot pinpoint the causal variants and their biological functions.  
Furthermore, the performances of GWASs is relatively weak in African populations in general and 
in malaria resistance datasets in particular. 
To address these challenges, we applied various alternative statistical genetic analytic approaches 
to the malaria resistance GWAS datasets. We showed that malaria resistance is polygenic trait with 
h2g of ~20% and that the causal variants are overrepresented around protein coding regions of the 
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genome. The reference panel we prepared as part of our analyses can potentially be used for other 
LD-based studies in African populations.  By applying several gene-based, pathway-level and 
network-level functional analyses to severe malaria resistance GWAS summary statistics 
(N=17,000) meta-analyzed across eleven populations in malaria endemic regions in Africa, Asia 
and Oceania, we systematically identified 57 genes located in the known malaria genomic loci and 
additional 125 genes across the genome. We showed that the identified genes were significantly 
enriched in malaria pathogenic pathways including multiple overlapping pathways in erythrocyte-
related functions, blood coagulations, ion channels, adhesion molecules, membrane signaling 
elements and neuronal systems. Furthermore, our population genetic analysis revealed that MAF 
of the SNPs residing in the identified genes are generally higher in the three malaria endemic 
populations compared to global populations. Overall, our results suggest that severe malaria 
resistance trait is attributed to multiple genes that are enriched in pathways linked to severe malaria 
pathogenesis. This highlights the possibility of harnessing new malaria therapeutics that can 
simultaneously target multiple malaria protective host molecular pathways. These findings laid the 
foundations of future experimental studies which can potentially lead to translational medicine 
such as development of vaccine and new therapeutics.  
5.2. Limitations and the way forward 
We noted that the current severe malaria GWAS datasets are comprised of several populations 
each with small sample size; making it difficult to perform population specific analyses including 
GWASs and heritability studies to capture local variations. Moreover, our h2g enrichment study 
was very limited as it requires larger sample sizes to produce reliable estimates at cell and pathways 
levels. The reference panel we prepared as part of our analyses can be further enriched by including 
additional datasets such as H3Africa datasets in the future. The h2g enrichment studies can 
potentially provide clues about the functional groups, tissues, cells and pathways in which the 
causal variants are localized. Thus, powered studies with larger sample size from each study 
population would provide more resolutions to the current findings.   
More powered studies would also enable investigation of epistatic interactions of malaria 
resistance loci at genome-wide scale and genetic correlation between malaria resistance and 
susceptibility/resistance to other infectious diseases. Such studies can potentially provide clues to 
common molecular processes between resistance/susceptibility to infectious diseases and may lead 
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to translation medicine such as multi-purpose vaccine and therapeutics across common infectious 
diseases.  SM is a complex disease with various clinical manifestations including CM, SMA and 
others  which may arise from distinct pathophysiological processes [37,55]. This implies the 
existence of sub-phenotype specific variants that influence the disease outcomes.  However, sub-
phenotype analyses were not presented in the current study owing to the lack of adequate sub-
phenotype information in the MalariaGen datasets. We anticipate that the future studies will 
address these challenges and lead to novel discoveries.  
Our genotype-based rare variant association analysis in the current study was limited because, such 
analyses work best in whole genome dataset. The rare variant and burden analyses enable 
identifications of rare variants that influence malaria resistance trait unlike the conventional 
GWASs which focus on common variant associations.  Future Whole genome-based studies are 
needed to better understand the contribution of rare variants in malaria resistance trait. 
Furthermore, the candidate malaria resistance genes that we identified by our Insilco-functional 
analyses should be substantiated by experimental studies in the future.  
As a concluding remark, besides the GWAS-based studies implemented in our current studies, 
other -omics approaches including whole genome sequencing, copy number variation, whole 
exome and proteomic and epigenome studies have huge potentials to unravel the genetic and 
biological basis of malaria resistance. 	The application of several single ‘-omics’ study will pave 
ways to the possibility of multi-stage and multi-dimensional integrative multi-omics study that 
combines multiple data types from the human host, the parasite, the mosquitoes and the 
environment. The current biotechnological advances and their continuously decreasing cost 
together with the availability of advanced analytical techniques, will eventually lead to feasibility 
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